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The anti-malarial chloroquine (CQ) and derivatives are useful anti-inflammatory agents which 
have been useful in treating patients with rheumatoid arthritis and systemic lupus 
erythromytosus.  Nevertheless derivatives of CQ, such as hydroxychloroquine (HCQ) have 
been made to reduce the toxicity and increase the potency of the drug.  We have approached 
this challenge by synthesizing 13 quinoline based compounds bearing a saturated or 
un-saturated fatty acid side chain (carbon chain length of 3 to 20).   
 
Examination of their immunomodulatory properties in vitro at concentrations up to 50µM 
showed these compounds to have no effect on phytohaemagglutinin- and antigen, tetanus 
toxoid- induced human lymphocyte proliferation and i terferon-γ, interleukin(IL)-2, IL-10 
and lymphotoxin production.  Similarly, there was no effect on the responses induced by the 
B cell mitogen, Staphylococcus aureus. In contrast, at the same concentrations, CQ 
significantly inhibited lymphoproliferation and cytokine production induced by these agents.  
Using bacterial lipopolyssacharide (LPS) as a stimulus for monocytes in the peripheral blood 
mononuclear fraction, we found that cytokine production, tumour necrosis factor alpha 
(TNFα), IL-1β and IL-6 was inhibited by CQ but not the NT compounds.   
 
In contrast the data demonstrated that a number of the NT compounds were effective in 
inhibiting human neutrophil adherence induced by TNF.  However, this activity was not 
related to either the carbon chain length or their saturated versus un-saturated state of the fatty 
acid side chain.  In comparison, both CQ and HCQ had no effect on this response.  The 
compound NT8 which had lauric acid on the side chain of the quinoline structure was the 
X 
 
most active.  Further studies with this compound revealed that it was particularly effective in 
inhibiting TNF-induced neutrophil cytokine (IL-1β and IL-8) production but not TNF-induced 
neutrophil migration inhibition or TNF-induced respiratory burst. CQ and HCQ had no effect 
on all of these responses. At the lower concentrations of NT8 which significantly inhibited 
neutrophil adherence and cytokine production, the compound had no effect on adherence 
induced by phorbol 12-myristate 13-acetate (PMA) and calcium ionophore (A23187). These 
agents are known to by-pass the surface receptors and act on protein kinase C and cause an 
increase in intracellular calcium levels respectively, suggesting that the effects of NT8 are 
upstream in the signalling cascade. Interestingly we found that NT8 caused a significant 
decrease in surface expression of TNF receptor II (TNFRII) but not TNFRI.  This selective 
effect of NT8 on neutrophil functions such as adherence was lost with an increase in 
concentration, where the neutrophil responses to the agonists, complement fragment C5a, 
IL-8, granulocyte macrophage-colony stimulating factor, formyl-Met-Leu-Phe, PMA, A23187 
and arachidonic acid were also inhibited. A similar selectivity was seen for neutrophil 
responses to leukotriene B4. The anti-inflammatory effects of NT8 were confirmed in vivo in a 
mouse model of LPS-induced peritonitis, where both TNF and neutrophils play an important 
role. 
 
The research in this thesis has enabled the developm nt and characterization of a new class of 
quinoline based compounds with anti-inflammation properties distinguishable from those of 
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1.1 General introduction   
 
The immune system through its innate and acquired chara teristics protects the body against 
microbial pathogens (Kaufmann and Steward, 2005).  These responses involve a network of 
different leukocyte types and mediators such as cytokines as well as cell surface receptors.  
In this manner, the immune system is able to mount an effector action which leads to the 
elimination of bacteria or other foreign matter in t ssues and organs.  However, these 
characteristics of the immune system can also induce allergic and autoimmune reactions in the 
body, which are responsible for many debilitating diseases in our community, namely the 
immune system can either act as a friend or a foe to the human body.  The very nature of the 
foreign structure, whether of microbial or auto-antigen origin, dictates the characteristics of 
the inflammatory response displayed (Ferrante et al., 1992).  The onset of the inflammatory 
reaction and its resolution is guided by a balance of positive and negative regulators of both 
the cellular and molecular elements of the immune system.  In simplistic terms, the 
inflammatory response can be classified into the acute or chronic type. 
 
Cells of the immune system can participate in innate immunity. Some of these cells are more 
specialised for this function than others.  In the absence of antibodies and T cells, which can 
recognise antigen specifically, the host defence system is dependent on the recognition of 
patterns of distinct differences of defined molecular structures on the surface of microbial 
pathogens, tumor cells and altered self structures (Chaplin, 2006; Goldsby et al., 2003a).  
These are known as pathogen recognition systems (PRS).  Pattern recognition receptors 
(PRR) on leukocytes such as toll like receptors (TLR) have a spectrum of recognition 
functions.  Engagement of these receptors leads to cellular activation and production of 




For example, killing of tumor cells via pattern recognition is carried out by natural killer (NK) 
cells (large granular lymphocytes) (Goldsby et al., 2003b).  Both macrophages and 
neutrophils have TLRs which recognise microbial structures (Goldsby et al., 2003b; Ferrante, 
2005).  This is a first line recognition system, which when initated activates the leukocytes 
to release a weak range of mediators to either directly deal with microbial pathogens and/or 
promote the infiltration and activation of cells whic  assist in defence against infection.     
 
The classification of inflammatory responses can also be based on the types of cells 
infiltrating infected area; mononuclear infiltrate (T lymphocytes, macrophages and B cells) or 
predominantly polymorphonuclear cells (PMN) (neutrophil, eosinophils and basophils) 
(Goldsby et al., 2003c).  Regulating the characteristic of the cellular infiltration is now 
recognised to occur via different T cell subpopulations which mediate their effect through the 
release of specific cytokine patterns.  Apart from T cells existing as T helper/ inducer cells 
(Th) and T suppressor/cytotoxic (Ts) cell, the Th cells have now been further characterised 
into Th1, Th2 and Th17 (Chaplin, 2006).  The cytokines they release influence the type of 
inflammatory response observed.  Other T cells thatare designated to play a key role in 
regulating the immune response are the regulatory T cells (Treg) (Sakaguchi, 2008).  Again, 
these have a distinct cytokine pattern from the Th cells.  The T cell arm of the immune 
system is essential to the adaptive or acquired immune response.  The diversity of the TCR 
repertoire is generated by combinational rearrangement of a variety of germ-line 
immunoglobulin (Ig) or TCR gene segments (Goldsby et al., 2003c).  T cells respond to 
antigen, presented in association with major histocompatibility complex (MHC) molecules by 




The other component of the adaptive immune response is the B cell, which can be triggered 
by antigen to develop into plasma cells to produce antibodies complimentary to the 
stimulating antigens.  In order for B cells to be activated and mature into antibody-producing 
cells, T cells are required to release several cytokines (Goldsby et al., 2003c).  This T cell 
assistance is also necessary for downstream immunoglobulin class switching.  The 
anti-microbial resistance mediated by adaptive immunity occurs through the production of 
antibodies which neutralise the microbial toxin or promote the phagocytosis of bacteria.  
This represents the humoral immunity of the immune system which is principally a function 
of B cells.   
 
Cell-mediated immunity occurs as a result of the generation of cytotoxic T lymphocytes 
which attack virus infected target cells or by T cells recruiting and activating macrophages for 
microbial killing (Kumaratilake et al., 1992).  Th1 cells play important roles, by releasing 
cytokines such as interferon-γ (IFN-γ) which activate macrophages to promote the killing of 
intracellular bacterial parasites or virus infected cells.  In comparison, protection against 
helminths requires eosinophils, a response best promoted by Th2 cytokines such as interleukin 
4 (IL-4) and IL-5(Coffman et al., 1989; Shin et al., 2009).  However, the interplay between 
the Th1 and Th2 arm of the immunity is quite complex and requires further direction.   
 
Inflammatory reactions may be initiated by autoantigens or allergens.  Autoantigens can 
elicit autoimmune responses involving the cellular and humoral arms of the immune system.  
Antibodies and sensitised T cells promote target destruction through antibody-mediated 
cellular cytotoxicity or cytotoxic T cells which destroy the host cells.  Type 1 diabetes, 
multiple sclerosis, rheumatoid arthritis and systemic erythematosus are all examples in which 
the Th1 response plays a critical role in tissue damage (Kowanko and Ferrante, 1996; Ware 
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and Matthay, 2000).   
 
Although there have been several developments in providing anti-inflammatory therapeutics, 
the search for newer approaches continues.  Present therapies range from those which target 
the immune system non-specifically, such as steroidal and non-steroidal anti-inflammatory 
agents, to those which target a specific cytokine or its receptor e.g. the use of anti-TNF 
antibodies or TNF soluble receptors (Chu et al., 1991; Feldmann and Maini, 2001; Gabay et 
al., 1997).  Other targets include the intracellular signalling pathways such as the 
calcium/calmodulin pathway and the p38 mitogen activ ted protein (MAP) kinase (Cole and 
Kohn, 1994; Mayer and Callahan, 2006).  In some cases, antimicrobial agents have shown 
immunosuppressive properties are used as anti-inflamm tory agents.  This includes 
chloroquine (CQ) and its derivatives.  The interest xtends to various attempts to produce 
derivatives of CQ which may improve the drug action f the compound, such as 
hydroxychloroquine (HCQ).  This literature review will describe the nature and function of 
cells of the innate and acquired immune system, the intercellular signalling mediators and also 
review what is currently known about the use of anti-malarials as anti-inflammatories.  It 
will also cover areas of possible therapies and targe  sites will also be explored.  
   
1.2 Mononuclear phagocytes 
 
In the bone marrow, through haematopoiesis, myloid cells mature into monocytes which are 
released into the blood stream and become a source f tissue resident macrophages and tissue 
infiltrating mononuclear cells during the inflammatory reaction (Figure 1.1) (Goldsby et al., 




Macrophages are distributed in tissues throughout the body, mainly seen in the skin, liver, 
peritoneum, kidney, heart, blood vessels and brain.  These cells can display functional 
characteristics which assist both innate and adaptive immunity.  Macrophages mainly 
achieve their objectives by possessing marked functio al heterogeneity in accordance with 
their role in the tissues in which these reside (Fujiwara and Kobayashi, 2005).  Resident 
tissue macrophages display characteristics and specializ d function relevant to the tissues in 
which they are found, e.g. the kupffer cells of the liv r line the sinusoids and play a major role 
in filtering blood to remove foreign matter (Fujiwara and Kobayashi, 2005) whereas the 
macrophages of the lung phagocytose airborne particles and bacteria which lodge in the lungs.   
 
In the initial stages of an infection, macrophages d pend on PRRs to distinguish self from 
non-self.  They recognise conserved regions on microbial pathogen structures termed 
pathogen-associated microbial patterns (PAMP) which in lude bacterial lipopolysaccharide 
(LPS) (Brown and Gordon, 2005).  The PRR are found in serum, on the surface membrane 
or intracellularly.  Table 1.1 shows selected molecul s of the different types and their 
microbial ligands.  Those free in serum, such as complements, can bind to microbial 
pathogens and promote their phagocytosis (Brown and Gor on, 2005).  Interaction with PRR 
in plasma membrane (such as TLRs) or intracellular (such as nucleotide-binding 
oligomerization domains-NOD) to PAMPs will elicit key responses in macrophages leading to 
phagocytosis, microbicidal activity and the release of cytokines (Brown and Gordon, 2005).  
The nature of this macrophage-microbial pathogen interaction is likely to dictate the 
effectiveness of the adaptive immune response which is important for the destruction of 





The role of macrophages in adaptive immune response is to prime naïve T cells as well as to 
present antigens to primed T cells, like dendritic cells (DCs) (Porcheray et al., 2005).  
Antigen-presentation by macrophages and their DC relativ s leads to the generation of 
functional T cells with different properties relevant to the elimination of microbial pathogens 
(Goldsby et al., 2003a).  The main subsets, CD4+ and CD8+ T cells play quite different roles 
in immunity.  CD4+ T cells are considered helper T cells and are instrumental in producing 
cytokines which enable the development of effector ytotoxic T cells (CD8+ T cells) that 
target and kill cells infected with cytosolic pathogens e.g. viruses (Goldsby et al., 2003c).  
Depending on the environmental stimulus, CD4+ T cells may differentiate into Th1 or Th2 
cell types and can also be influenced by cytokines released from macrophages.  These T cells 
types produce different cytokine patterns which mediat  immunity to different type of 
pathogens.   
 
The anti-microbial activity of macrophages has been well characterized.  Usually 
extracellular microbial pathogens are killed following opsonisation with antibody which not 
only promotes their phagocytosis, but stimulates signals through the Fcγ receptors.  This 
process stimulates a combination of biochemical pathw ys that generates several microbicidal 
substances delivered to the intracellular site where the pathogen is confined; the phagocytic 
vacuole (Goldsby et al., 2003d).  These substances include enzymes, peptides and oxygen 
derived reactive species.  Many of these overlap with those used by the neutrophil and are 
extensively described in section 1.4.  However, themost striking characteristic of the 
macrophage which distinguishes it from the neutrophil is the process of macrophage 
activation.  This is classically described for the killing of the intracellular bacteria, Listeria 
monocytogenes (Sonoda et al., 1997).  These bacteria can live and multiply within 
macrophages but when macrophages are transformed into an activated state the bacteria are 
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killed.  The activation is brought about by Th1 cytokines such as IFN-γ (Sonoda et al., 1997), 
whereas Th2 cytokines including IL-10, IL-12 and TGF- β are considered to deactivate 
macrophage (Fujiwara and Kobayashi, 2005; Kumaratilke and Ferrante, 1992).   
 
Macrophages activate the immune response by secreting a wide range of mediators.  These 
include cytokines, pro-and anti-angiogenic factors, a variety of enzymes, complement 
components and metabolites of arachidonic acid. An area of intensive investigation is the 
cytokines released by macrophages and their role in the cytokine network.  Macrophages are 
major producers of TNF, IL-1, IL-10, IL-12, IFN-α and IL-18 (Brown and Gordon, 2005; 
Fujiwara and Kobayashi, 2005).  These cytokines are critical to many aspects of the cytokine 
network operations in microbial immunity as well as microbial pathogenesis.   
 
Macrophages also promote pathogenic processes associated with infection and autoimmune 
diseases.  Recruitment of macrophages into tissues as a result of persistent microbial 
antigens (tuberculosis) or autoimmune antigens (rheumatoid arthritis) can lead to tissue 
changes and eventually organ failure and death.  They are involved in promoting diseases 
such as rheumatoid arthritis, atherosclerosis, multiple sclerosis (Brown and Gordon, 2005; 
Kaperonis et al., 2006; Ma et al., 2004).  The cytokines produced by these cells play an 
important role in pathogenesis and it is not surprising that anti-TNF therapy has become 
important in the treatment of rheumatoid arthritis (Feldmann and Maini, 2001).     
 
1.3 T lymphocytes 
 
T lymphocytes derived from the bone marrow, undergo further maturation in the thymus 
gland expressing unique α, β T cell receptors on the cell membrane (Figure 1.1).  They can 
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exist in a naïve form and only mature following activation.  The T cell receptor expressed on 
the naïve T lymphocytes is a complex of polypeptides expressing CD3 and either CD4 or 
CD8 receptor (Goldsby et al., 2003c).   
 
However, mature T cells usually express CD28, a receptor for the co-stimulatory B7 
molecules present on B cells and other antigen-presenting cells (APC) and CD45, a 
signal-transduction molecule (Goldsby et al., 2003c).  These T cell receptors can only 
recognize specific antigen that is bound to the cell m mbrane proteins, MHC molecules that 
are further divided into two classes: MHC class I and II (Goldsby et al., 2003d).  T cells that 
express CD4 are usually restricted to recognizing antigen bound to MHC class II molecules 
whereas T cells expressing CD8 are restricted to rec gnition of antigen bound to MHC class I 
molecules (Goldsby et al., 2003c).    
 
1.3.1 Th cells and inflammation 
 
Upon stimulation and under the influence of different nvironmental conditions , naïve T cells 
develop into at least three types of Th cells and T cells with regulatory properties (i.e. the Treg) 
(Figure 1.2) (Sakaguchi, 2008).    There is interplay between these subpopulations to 
promote microbial killing and as well as in allergic and autoimmune diseases (Table 1.2).  
The skewing towards a Th cell type development seem to be controlled by the antigenic 
environment the cells encounter.  These four T cell subtypes can be differentiated by the 
cytokines they produce and transcriptional factors which promote their differentiation from 








Figure 1.1 Hematopoiesis.  The formation and development of the different functional 





   Table 1.1 Microbial pattern recognition molecules. 








Influenza A virus, herpes simplex 





HIV, influenza A virus, S.aureus, 
Neiserria meningitides, Chlamydia 
pneumonia, Candida albicans, 








S.aureus, E.coli, Streptococcus 
pyogenes, N. meningitides, A. 
fumigates, C. albicans, Plasmodium 
falciparum, influenza A virus, LPS 
 Complement C1q 
Antibody-coated microbes, Listeria 
monocytogenes, Legionella 
pneumophila, E.coli, HIV 
  C3 Microbial surfaces 







Candida albicans, P. carinii, 
Mycobacterium tuberculosis, K. 
pneumonia, Lishmania donovani, 
HIV-1, zymosan 










CD14 E.coli, LPS, LTA, peptidoglycan 
  Toll-like 
receptors (1-10) 
LPS, LTA, zymosan, bacterial 
lipoproteins, peptidoglycan, viral 
proteins, fagellin, bacterial DNA 
 Scavenger 
receptors 
SR-A (I and II), 
LOX-1, MARCO 
E.coli, S.aureus, M. tuberculosis, 
Enterococcus faecalis, N. 
meningitides, LPS, LTA, bacterial 
DNA 
 Integrins CR3, CR4 Complement-coated microbes, LPS, 















  Mx GTPase Viral-protein complexes 




T helper cells can also be further subdivided into Th1, Th2 and Th17 (Figure 1.2).  Th1 cells 
produce IFN-γ which is important for cell-mediated immune responses which are required for 
protection against intracellular microbial pathogens, and are regulated by the T-box 
transcription factor (T-bet) and Runt-related transcription factor 3 (Runx3) (Mowat and 
Gardside, 2005; Sakaguchi et al., 2008). Th2, regulated by the trans-acting T cell specific 
transcription factor 3 (GATA-3), are defined by their production of IL-4 and role in humoral 
immunity and response against extracellular pathogens (Mowat and Gardside, 2005; 
Sakaguchi et al., 2008). Th17s are regulated by the orphan receptor transcription factor 
(RORγt) and produce IL-17 (Sakaguchi et al., 2008) (Table 1.2). 
 
Tregs which are formally known as the suppressor T cells, can differentiate directly from the 
thymus without the aid of cytokines into nTregs or fr m naïve T cells under the influences of 
cytokines into iTreg (Figure 1.2) (Sakaguchi et al., 2008).  Tregs are known to control other 
T cells types and suppress either their activation in secondary lymphoid organs or their 
effector functions in peripheral tissues (Packard et al., 2009).  Regulatory T cells are often 
classified as CD4+, CD25+ and forkhead box P3 (FoxP3+) cells with the special emphasise on 
the expression of the transcription factor FoxP3+ which acts as an important regulator for Treg 
development and functions (Figure 1.2) (Sakaguchi et al., 2008).  Upon antigen exposure, 
Tregs become activated and exert antigen specific suppressor functions on the antigen (Table 

























Figure 1.2 Differentiation and maturation of T helper and regulatory T cells.  Cytokines 
and transcription factors that promote the differentiation of naïve T cells into Tregs and T 
helper cells are shown.  The transcription factors T-bet and Runx3, GATA3, or RORγt are 
required for the differentiation of naïve T cells into Th1, Th2 and Th17 cells respectively, 















Production of cytokines which: 
• activates macrophages. 
• promotes the development of cytotoxic T cells. 
• helps B cells to make antibody. 
• induces class and subclass immunoglobulins switching. 
• induces monocyte and neutrophil infiltration. 
• inhibits Th2 responses. 
 
Th2 cell Anti-inflammatory or allergic inflammation 
• Production of cytokines which: 
• promotes basophil and eosinophil infiltration and activation. 
• promotes downstream switch of immunoglobulin class and 
subclass e.g. towards IgE and IgG4. 
• inhibits macrophage functions. 
 
Th17 cell Inflammatory 
• Production of cytokines which promotes inflammation e.g. in 
rheumatoid arthritis. 
• Produces IL-17. 
 
Tregs Imunosuppression/ Anti-inflammatory 
• Compete with antigen-specific naïve T cells for DC. 
• Target dendritic cells including DC maturation, function and 
suppress DC maturation. 








The development of neutrophils from granulocyte-monocyte progenitor is regulated by a 
group of cytokines such as the granulocyte colony-stimulating factors (G-CSF), granulocyte 
macrophage colony-stimulating factors (GM-CSF) and IL-3 (Ferrante, 2005) (Figure 1.1).  
Neutrophils produced by hematopoiesis in the bone marrow are released into the peripheral 
blood and circulate for 7-10 h before migrating into the tissues, where they have a life span of 
only a few days.  These cells are generally the first to arrive at sites of inflammation 
(Goldsby et al., 2003c).   
 
1.4.1 Neutrophil adhesion-selectins and integrins 
 
Adhesion molecules on leukocytes facilitate their attachment to the endothelium and to tissue 
structures over which they migrate (Schmid-Schonbein, 2006) (Figure 1.3).  The two general 
classes of adhesion molecules involved are the integri s and selectins that are either 
pre-expressed in both the plasma membrane and cytoplasmic granules, or may be newly 
synthesized upon stimulation of the cells (Schmid-Schonbein, 2006)    
 
Initial attachment of leukocytes to endothelial membranes is facilitated by selectins P-, E- L 
(Schmid-Schonbein, 2006).  These selectins are either stored in granules (P-selectins) or 
pre-expressed (E and L-selectin) and can be translocated rapidly to the cell surface in 
response to several inflammatory stimuli (Ulbrich et al., 2003).  The adhesive function of all 
selectins requires specialized counter-receptors and the interactions between P-selectin 
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glycoprotein ligand 1 (PSGL-1) and P-selectin is reponsible for a major part of leukocyte 
rolling during inflammation (Ulbrich et al., 2003).  Neutrophil capture and rolling can be 
mediated by P-selectin binding PSGL-1 and activated by IL-8 (Figure 1.3).    L-selectin 
located on neutrophil microvilli, interacts with PSGL-1 on endothelium to promote leukocytes 
capture to the endothelium (Ulbrich et al., 2003; Burg and Pillinger, 2001). 
 
In contrast, firm adhesion and spreading of cells on the endothelium is facilitated by integrins, 
a family of heterodimers, and tyrosine kinase receptors (Schmid-Schonbein, 2006).  These 
molecules exists as dimers that contain an α and β subunit (Ulbrich et al., 2003).  Integrins 
are activated rapidly from a low-affinity to a high-affinity state following ligand binding and 
cell activation.  The integrins used by leukocytes share a common β2-chain (CD18) and four 
different α-chains (CD11a, CD11b, CD11c, CD11d) with CD11b/CD18 being one of the 
important integrins in the inflammatory reaction expressed on neutrophils, monocytes and 
macrophages (Schmid-Schonbein, 2006).  Firm adhesion of the neutrophil to endothelial 
cells is confirmed when the integrins binds to the intracellular cell adhesion molecules (ICAM) 
or the vascular cell adhesion molecules (VCAM) found on the endothelium cells (Ulbrich et 
al., 2003).   
 
1.4.2 Neutrophil extravasations and transmigration 
 
After firm adhesion via integrins, neutrophils transmigrate either between or directly through 
endothelial cells to arrive at extravascular sites of infection (Figure 1.3) (Witko-Sarsat e  al., 
2000).  Platelet endothelial cell adhesion molecule-1 (PECAM-1), a cell adhesion molecule 
of the Ig superfamily plays a role in transmigration (Witko-Sarsat et al., 2000).  PECAM-1 is 
expressed both on the neutrophil surface and at the endothelial cell junction to mediate 
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neutrophil extravasativia PECAM-1/PECAM-1 homophilic interaction (Witko-Sarsat et al., 
2000).   
 
Neutrophil emigration from the vascular space and migration through the tissues are 
consequences of a regulated process involving the sequential release and 
compartmentalization of a wide variety of inflammatory mediators (Denson et al., 1995).  
Early influx of neutrophils into an area of injury is predominantly mediated by IFN-γ, 
complement 5a (C5a) and leukotriene B4 (LTB4).  IL-8 and IL-6 appear in a second wave of 
mediator activity, followed by IL-1β, GM-CSF, and TNF-α.  In contrast, the concentration of 
IL-1α, IL-2 and IL-4 remains unchanged (Denson et al., 1995).  When neutrophils are 
exposed to a uniform concentration of chemoattractants, the speed or frequency of migration 
increases (Witko-Sarsat et al., 2000).  When the concentration of chemoattractants differs 
across the cell by as little as 0.1-1.0 %, ligand-li ked receptors distribute asymmetrically,  
leading to a polarised response that causes directional movement, resulting in the net 





Once the neutrophils arrive at the site of infection as explained above, they then proceed to 
phagocytose microbial pathogens.  This process may be described in the following steps.  
Once receptors on the cell surface recognize and bi to the pathogen; signals are generated 
that induce actin polymerization under the membrane t the site of contact.  Then actin-rich 
membrane extensions extend over the particle, the membranes fuse behind the particle, 
pulling it in toward the centre of the cell.  Finally the phagolysosome matures via a series of 
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membrane fusion and fission events to become a phagolysosome  (Figure 1.4) (Aderem, 
2003).  The phagolysosome is an acidic, hydrolytic compartment in which the pathogen is 
killed and digested (Aderem, 2003). 
 
Neutrophils, like macrophages internalize opsonised particles bound via the Fc or 
complement receptors.  While the internalization of c mplement opsonised particle involves 
a ‘sinking in process’, the Fc receptor promote the formation of pseudopods that surround the 
particle, termed phagosome (Lee t al., 2003).   
 
1.4.4 Fc receptors 
 
Neutrophil phagocytosis depends upon direct contact with bacteria or other targets that have 
been opsonised by antibody and/or complement involving two different receptor classes, Fc 
receptors and complement receptors (Witko-Sarsat et l., 2000).  The main function of the 
Fc receptors is to recognize the Fc domain of IgG antibody providing a crucial linkage 
between the phagocytic effector cells and the lymphocytes that secrete antibody, as the 
macrophage/monocyte, neutrophil, and NK cell Fc-γRs confer the element of specific 
recognition on the effector cells (Table 1.3).  There are three types of the Fc-γ receptors, 
namely Fc-γRI (CD64), Fc-γRIIA (CD32) and Fc-γRIIIB (CD16) (Ulbrich et al., 2003).  
Fc-γRIII has no transmembrane portion but crosslinking Fc-γRIII enhances Fc-γRII-mediated 
phagocytosis by increasing actin filament assembly and by promoting of oxidants which 
























Figure 1.3 Overview of steps involved during an inflammatory condition.  Tissue 
damage leads to the recruitment of leukocytes from the blood to the site of infection mediated 



























Figure 1.4 Steps involved in the phagocytosis of microorganisms. Adapted from Goldsby 
et al., (2003d).  
 
 
Microorganisms are ingested, 
forming a phagosome 
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1.4.5 Receptors for complement (CR)  
 
The activation of the complement cascade either through the classical, alternative or 
mannose-binding lectin (MBL) pathways causes proteoly ic cleavage of these proteins, 
resulting in several ligands for receptors on leukocytes. These ligands may be divided into 
two categories: (a) soluble ligands, which cause chemotactic movement of leukocytes to sites 
of complement activation; and (b) surface-bound ligands, which function as opsonins.  
Activation of complement leads to the enzymatic cleavage of C3 and the deposition of C3b or 
C3bi on the microbial surface (Table 1.3) (Denson et al., 1995).  Complement-dependent 
neutrophil phagocytosis is mediated by complement rceptor 3 (CR3) acting primarily on 
C3bi due to its high affinity for this component (Burg and Pillinger, 2001).   CR1 and CR4 
are also found to be important for recognition of bacteria by neutrophils. Phosphorylation of 
CR1 can trigger the “inside-out” signalling that acivates CR3 binding capacity (Witko-Sarsat 
et al., 2000) and CR4 directly binds to C3bi (Ferrante, 2005).  However, binding of 
neutrophil CR3 to particles exclusively coated with C3bi is not sufficient to promote 
phagocytosis, and needs to be assisted by activation of other pathways e.g. using PMA or 
formyl-peptides (Brown, 1986).  A complex service of signalling pathways activated during 
engulfment of opsonised targets lead to the fusion of protease-rich granules with the 
phagosome and the triggering of oxidative burst (Witko-Sarsat et al., 2000; Ferrante, 2005).     
 
1.4.6 Neutrophil degranulation 
 
Neutrophil-derived microbicidal molecules are packed in granules that are released upon cell 
activation.  Degranulation of vesicles into phagolys somes or directly into extracellular 
space is a key process in the microbicidal activity of the cell.  During phagocytosis, the 
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cytoplasmic granules approach the membrane of the developing phagocytic vacuole and 
plasma membrane where they fuse with either the membrane delivering granule contents to 
the phagocytic vacuole or with plasma membrane resulting in the extracellular secretion of 
granule proteins (Denson et al., 1995) (Figure 1.4).  There are two major granules, the 
azurophil (primary) and the specific type (secondary) (Segal, 2005).  Azurophil granules, 
contains largely proteins and peptides directed toward microbial killing and digestion, 
whereas the specific granules contain unsaturated lactoferrin and stores for cell surface 
receptor and components which limit free radical reactions (Segal, 2005).   Azurophil 
granules are characterized by the presence of myeloperoxidase and membrane-bound CD63.  
The specific granules contain lactoferrin and membrane-bound CD66b (Lee t al., 2003).   
 
 
A third type of granule has also been described, the tertiary granules which lack CD66 but 
contain gelatinase.  A fourth group known as the secretory vesicles contain albumin and 
express alkaline phosphatase and CD35(Lee et al., 2003).  Degranulation involves the 
release of a wide range of anti-microbial enzymes into the phagosome.  Such enzymes 
include myeloperoxidase, acid hydrolase and lysosomal proteases (Witko-Sarsat et al., 2000) 
The neutrophil uses a range of anti-microbial peptides and proteins to aid in the destruction of 
microorganisms. This includes the defensins, proteinase 3 (PR3), elastase, phospholipase A2 
(PLA2) and metalloproteinase.  Defensins are small cationic, antibiotic peptides that contain 
six cysteines in disulfide linkage and are major comp nents of the azurophilic granules (Burg 
and Pillinger, 2001; Witko-Sarsat e  al., 2000).  They act by inducing microbial membrane 
permeabilization and can regulate inflammatory process through binding of protease 




































Fc domain of IgG 
FcγRIIA (CD32) Fc domain of IgG 
FcγRIIIB (CD16) Fc domain of IgG 
FcαR (CD89) Fc domain of IgA 
CR1(CD35) C3b 
CR3 (CD11b/CD18) C3bi 
CR4 (CD11c/CD18) C3bi 
Adapted from Ferrante (2005). 
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Proteinase 3 can be found in both azurophilic and secretory granules and is often found on the 
membrane surface of secretory granules (Burg and Pillinger, 2001; Segal, 2005).  The 
membrane bound PR3 is bioactive and insensitive to proteinase inhibitor and has been shown 
to enhance cleavage and activation of TNF and IL-1β (Burg and Pillinger, 2001).  Elastase is 
another serine protease and similar to PR3 is capable of cleaving insoluble elastin and matrix 
proteins such as fibronectin, laminin and collagen (Witko-Sarsat et al., 2000).  
Phospholipase A2 (PLA2) is a neutrophil granule protein that has very potent bactericidal 
activity against S.aureus (Burg and Pillinger, 2001).  Lastly, metalloproteinases are 
calcium-requiring enzymes that function at neutral pH and are released in inactive proenzyme 
forms.  These enzymes are required for neutrophil migration (Burg and Pillinger, 2001).   
 
1.4.7 Neutrophil nicotinamide adenine nucleotide phosphate (NADP) H oxidases and 
reactive oxygen species 
 
The killing of the microorganism involves the stimulation of the oxidative respiratory burst 
system, leading to the reduction of oxygen to superoxide anion, involving the NADPH 
oxidase, as well as the generation of hydrogen peroxide (Djaldetti et al., 2002; Segal, 2005).  
The phagocyte NADPH oxidase is an essential component of the human cellular immune 
response which is required for microbial killing and belongs to the family of the NADPH 
oxidase (NOX) proteins (Lee t al., 2003).  However, oxidants generated by this system can 
also contribute to non-specific tissue damage associated with a variety of inflammatory 
diseases (Quinn, 2004).  Because of the potential for tissue damage, the assembly of the 
NADPH oxidase from its components is highly regulated and involves several control points 




Activation of the oxidase requires the assembly of at least five proteins with 
membrane-associated flavocytochrome b, which appear to contain all of the required redox 
components but cannot on their own catalyze the reaction (Quinn, 2004).  While a fraction 
of the intrinsic components of the oxidase are present at the plasma (vacuole) membrane at 
the time of phagocytosis, most are delivered through f sion from intracellular storage sites in 
second granules (Borregaard and Cowland, 1997).      
 
The activation of respiratory burst, leads to the activ tion of the NADPH oxidase, an 
enzymatic complex composed of cytosolic (p40phox, p47phox, and p67phox) and membrane 
proteins (p22phox and gp91phox), which constitute a heterodimeric flavohemoprotein known as 
cytochrome b558 (Witko-Sarsat et al., 2000).  Cytochrome b558 is distributed between the 
plasma membrane and the membrane of specific granules and upon incorporation into the 
wall of the phagocytic vacuole, electrons are being released into the cytoplasm during the 
oxidation of NADPH to NADP+ which counteracts cytosolic acidification (Figure 1.5) (Segal, 
2005; Behe and Segal, 2007).  Stimulation of neutrophils, p47phox, p67phox and p40phox, as 
well as a low molecular weight guanosine 5’-triphosphate (GTP)-binding protein, are 
translocated to assemble with the cytochrome b558 (p22
phox and gp91phox) in the membrane and 
form a complete and active NADPH oxidase (Roos et al., 2003).  During the respiratory 
burst, the oxidase mediates the translocation of electrons across the membrane lipid bilayer so 
as to reduce the oxygen present extracellularly (Lee et al., 2003; Behe and Segal, 2007).  
Moreover, cations are being translocated in response to the electrical potential change by H+ 
and/or K+ influxes which help in granule secretion by increasing the ionic strength of the 





This enzymatic complex is thus able to generate suproxide anion (O2
¯ ), which can dismutate 
into H2O2 (Witko-Sarsat et al., 2000; Ferrante et al., 1992; Dahlgren and Karlsson, 1999).  
There are three intermediates in the reduction of O2, namely O2
¯ , H2O2 and the hydroxyl 
radical (OH·) (Figure 1.5) (Witko-Sarsat et al., 2000; Behe and Segal, 2007).  The 
involvement of O2
¯ , H2O2 and OH
· in tissue damage has been studied extensively especially 
with the role of oxygen reactive species in tissue damage in rheumatoid arthritis (Felson et al., 
1990; Mirshafiey and Mohsenzadegan, 2008; Moots, 2003; Rynes, 1993). 
 
1.4.8 The H2O2-Myeloperoxidase-Halide system 
 
The generation of superoxide anion via the activation of NADPH oxidase is the starting 
material for the production of a vast assortment of reactive oxygen intermediates, including 
halogenated oxidants generated through the myeloperoxidase (MPO) pathway (Witko-Sarsat 
et al., 2000).  MPO is a heme protein present in azurophil granules of neutrophils which is 
released upon cell activation into the phagolysosome r into the extracellular space (Dahlgren 
and Karlsson, 1999).  MPO amplifies the toxic potential of H2O2 by producing reactive 
intermediates such as hypochlorous acid (HOCl) which can oxidise various molecules 
including amino acids, nucleotides, and hemoproteins (Witko-Sarsat et al., 2000; Denson et 
al., 1995; Burg and Pillinger, 2001).  The MPO system is known to be responsible for the 
formation of tyrosyl radical and chloramination productions, the generation of tyrosine 
peroxide, reactive aldehydes, and the oxidation of serum proteins and lipoproteins 
(Witko-Sarsat et al., 2000).  The system has been shown to be important in microbial killing.  
MPO-deficient neutrophils show a slow rate of bacteria killing within the first hours but 




However recent studies from Segal’s group have challenged the importance of MPO in 
microbial killing suggesting other mechanisms are involved including elastase and that the 
MPO system is unlikely to play a significant role in this killing (Reeves et al., 2002; Segal, 
2005).  Studies using proteases knock-out mouse models such as elastase and cathepsin G or 
both enzymes showed that elastase is especially important in the killing of Gram-negative 
bacteria whereas cathepsin G is less important (Belaaouaj et al., 1998; MacIvor et al., 1999; 
Reeves et al., 2002; Tkalcevic et al., 2000).  However, both enzymes are required to mediat  
the killing of microorganisms and the lack of both enzymes resulted in a defect in the killing 
of bacteria whilst displaying normal respiratory burst (MacIvor et al., 1999; Reeves et al., 
2002).  This further supported the idea that both NADPH oxidase acitivy as well as protease 
enzymes are required for effective microbial killing (Segal, 2005).                
 
1.4.9 Neutrophil Priming 
 
Some inflammatory mediators prime neutrophils for enhanced anti-microbial function 
(Ferrante, 2005).  A broad array of inflammatory mediators, including chemotactic factors, 
endotoxin, cytokines, and certain lipids, can prime th  neutrophil, and the primed state exists 
with respect to each of the major aspects of neutrophil function (Ferrante, 2005; Denson et al., 
1995).  Primed neutrophils generate enhanced levels of reactive oxidants and have higher 
levels of degranulation and greater phagocytic activity (Ferrante et al., 1993; Ferrante t al., 
1994).  For example, the expression of cell-surface molecules, such as CR3 and cytochrome 
b, is very low in neutrophils found in blood, but this expression is rapidly up-regulated during 
priming e.g. by N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP), GM-CSF (Edwards, 






















Figure 1.5 Generation of reactive oxygen species by neutrophils. Neutrophils undergoing 
phagocytosis generate reactive oxygen species so as t id in the removal of the bacteria 







Moreover, the priming effect of GM-CSF further confirmed by its effect of enhanced 
neutrophil respiratory burst partially involves the phosphorylation of p47phox (Dang et al., 
1999).  This effect is only observed with GM-CSF but not with fMLP or PMA.  The 
priming effect of TNF has also been studied and it primes neutrophil mediated cartilage 
damage depending on the cell-cartilage contact (Kowanko and Ferrante, 1996).  Moreover, 
neutrophils primed with TNF and later challenged with PGE2 were found to show reduced 
superoxide production measured via chemiluminescence (Li et al., 1996).  However, when 
challenged with fMLP, an enhanced response occurred (Zhang et al., 1992; Ferrante et al., 
1992) and this similar result was also observed in TNF primed neutrophil response towards 
fMLP so to enhance oxidative burst (Elbim et al., 1994).  Other groups have also found that 
the priming of neutrophils by TNF occurs through its p55 receptor inducing the 
phosphorylation of p47phox, a key element of the NADPH oxidase (Dewas et al., 2003). 
 
1.5 Chemoattractant receptors  
 
Chemokines are small heparin binding proteins that direct the migration of circulating 
leukocytes to sites of inflammation, and function via activating specific G protein-coupled 
receptors (Lukacs and Harrison, 2007).  There are more than 50 human chemokines 
described.  These can be divided into three major families based on their structure and 
functional characteristics.   
 
First and foremost is the CC chemokines which attract mononuclear cells found at sites of 
chronic inflammation (Charo and Taubman, 2004; Lukacs nd Harrison, 2007).  The most 
characterised one is MCP-1 (CCL2), an agonist for mnocytes, T cells and basophils that 
plays a role in the recruitment of these cells (Uguccioni et al., 1995; Mackay, 1996; Weber t 
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al., 1996).  Other members of the family include proteins regulated on activation, normal T 
cell expressed and secreted (RANTES or CCL-5), macrophage inflammatory protein-1α 
(MIP-1α) (CCL3), and MIP-1β (CCL4) which are involved in the recruitment of monocytes, 
activation of T cells and mediate neutrophil migration (Charo and Taubman, 2004; Didier et 
al., 1999; Ramos et al., 2005).  The second family of chemokines is the CXC family 
including IL-8 (CXCL8), which is an attractant for neutrophils, usually stored in granules of 
resting neutrophils and increases significantly upon stimulation (Pellme t al., 2006).  IL-8 is 
involved in acute pulmonary inflammation and known to activate monocytes (Charo and 
Taubman, 2004; Baggiolini et al., 1997).  The third family is represented by the CX3  
family with one member, fractalkine (FK)(CX3CL1) (Charo and Taubman, 2004).  
Fractalkine is a type 1 transmembrane protein that acts as a cell-adhesion receptor to arrest 
cells under physiological flow conditions (Haskell t al., 1999).  
 
Other cellular mediators include chemoattractants that are activated and released at the site of 
infection such as fMLP, C5a and LTB4.  They also act as key factors in neutrophil migrat on 
and activation (Burg and Pillinger, 2001).  Each chemoattractant has its own specific 
seven-transmembrane domain, heterotrimeric G protein coupled receptors (Burg and Pillinger, 
2001; Karlsson and Dahlgren, 2002), e.g the activation mediated by fMLP via formyl peptide 
receptor (FPR) (Bylund et al., 2003), C5a via C5a receptor (Karlsson and Dahlgren, 2002) 
and LTB4 via LTB4 receptor (Schultz et al., 1991).  The engagement of the receptors result in 
G protein activation followed by the dissociation of the α from the βγ G protein subunits 
which are important for phospholipase C, phosphatidylinositol-3 kinase (PI-3 kinase) and 
adenyl cyclase activation (Burg and Pillinger, 2001; Bylund et al., 2003) .  Phospholipase C 
can then hydrolyse membrane phospholipids resulting i  the formation of inositol 
trisphosphate (IP3) and diacylglycerol (DAG) and the release of arachidonic acid (AA) (Burg 
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and Pillinger, 2001).  IP3 also induces Ca2+ release from intracellular stores (Bylund et al., 
2003), which in conjunction with DAG lead to PKC activation. (Burg and Pillinger, 2001).      
 
1.6 Cytokines and cytokine receptors 
 
Cytokines are inflammatory mediators produced during flammation and are produced 
following the stimulation of cells by a wide range of agents including LPS, cytokines, 
phagocytic particles, microorganisms, chemotactic fa tors, LTB4, PAF, prostaglandin E2 
(PGE2) and complement C5a (Ethuin and Chollet-Martin, 2005).  They are produced mainly 
by lymphocytes and macrophages.  While neutrophils ave been shown to produce low 
amounts of cytokines, they can still modulate T andB cells as well as APC function.  Some 
of the well studied cytokines includes TNF-α, IL-1, IL-6, IL-12, IFN-α, IL-4, IL-8, TGF-β, 
G-CSF, M-CSF, MCP-1 and MIP-2 (Ferrante, 2005).  These cytokines act via well 
characterised cell surface receptors to induce a response to inflammation.  The production of 
various cytokines by neutrophils depends on the stimulus the cell encounters such as bacteria, 
fungi, viruses, fMLP, LTB4 PAF, C5a and cytokines themselves can also stimulate neutrophils 
(Ferrante, 2005).  While the release of IL-8 is know  to be important in neutrophil migration 
as well as recruiting T lymphocytes and basophils to the site of infection, MIP-1 is also 
known for its potent chemotactic properties for monocytes and T lymphocytes (Ferrante, 
2005). 
 
Neutrophils produce the pryogenic cytokines TNF andIL-1 and this may be one way in which 
the cells play a role in pathogenesis.  TNF is produce  by a number of cell types and is a 
potent mediator of host response to injury, inflammation, immunity and repair.  Cellular 
responses such as adherence, superoxide production, phagocytosis, degranulation and efflux 
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of chloride ions are usually initiated following interaction of either or both TNFRI (55 kDa) 
and TNFRII (75 kDa) with the cytokine (Gasparini et al., 2003; Ethuin and Chollet-Martin, 
2005).  TNF receptors are made up of 10 different transmembrane glycoproteins with 
cytokine-rich repeats in the extracellular region (Gruss, 1996).  It is understood that the 
expression of these receptors decreases via shedding when neutrophils are exposed to 
inducing agents such as TNF, fMLP, PMA, A23187 endotoxin and GM-CSF (Dri et al., 2000).  
Moreover, TNF is also found to enhance neutrophil adhesion molecule VCAM-1 which is in 
turn regulated by mitogen activated protein kinases (MAPKs) and NF-κB signalling 
molecules (Lee et al., 2008).  Under resting conditions, the amount of TNF expressed is 
minimal, however following cellular activation, the l vel of mRNA increases as well as the 
expression of TNF.       
 
 
IL-1 is known to be produced in various cell types.  The IL-1 family consists of 11 members 
of which IL-1α, IL-1β and IL-1 receptor antagonists (IL-1Ra) are the most investigated 
molecules.  IL-1, unlike other cytokines exerts its effect both at the receptor level and 
intracellularly upon binding to IL-1 receptors (Dinarello, 2009).  Other important actions of 
IL-1 are the induction of the production of prostaglandin E2, activation of collagenase, and 
phospholipase A2 as well as enhancing adherence of neutrophils, monocytes and lymphocytes 
(Ferrante et al., 2005).  It is also known to prime neutrophils for an increase in antimicrobial 
activity and the production of IL-1Rα can regulate the effect of IL-1 on neutrophils (Ferrante, 





1.7 Inflammation and fatty acids  
 
The immunomodulatory properties of short, medium and long carbon chain fatty acids have 
been widely reported.  They modulate neutrophils, monocytes and lymphocytes responses by 
either inhibiting or stimulating the production of cytokines, chemokines, growth factors, 
reactive oxygen species and antibodies at non-toxic concentrations (Martins de Lima et al., 
2007; Calder, 1993; Calder et al., 2002).  Studies on the toxicity of these fatty acids on 
Jurkat (T lymphocytes) and Raji (B lymphocytes) cell lines have found that carbon chain 
length and number of double bonds plays an important ole in cytotoxicity (Lima et al., 2002).  
An increase in the number of carbons and double bonds resulted in a increased toxicity (Table 
1.4) (Lima et al., 2002).  This finding was in contrast to those with J774 cells (macrophage 
cell line) where a difference in double bond did not result in a concentration dependent 
cytotoxicity (Table 1.4) (Martins de Lima et al., 2006). This illustrates that the effects of these 
fatty acids may differ substaintially depending on cell and tissue type.   
 
Martins de Lima et al., (2006) have also found that high concentrations of fatty acids can 
mediate macrophage cell death, mainly due to necrosis.  The mechanism of this was thought 
to be through the changes in cell mitochondrial transmembrane potential and intracellular 
neutral lipid accumulation (Martins de Lima et al., 2006).  One of the major action of these 
fatty acids is by activating directly or indirectly intracellular signalling molecules including 
protein kinase C, mitogen activated protein kinase, phospholipase A2 and phosphatidyinositol 
3 (Ferrante et al., 2005).  Fatty acids, in particular long chain fatty acids, inhibit T 
lymphocytes both in vitro and in vivo (Calder, 1993). The ability of long chain fatty acids to 
down-regulate Th1 cell cytokine production in chronic inflammation has also been reported 




The importance of fatty acid chain length was also found in the ability of fatty acids to alter 
neutrophil function (Ferrante t al., 2005).  Several studies have reported that fatty cids, 
depending on their chain length, can mediate neutrophil cell death through reactive oxygen 
species (Miller et al., 2005; Tedelind et al., 2007; Wanten et al., 2000b).  This similar effect 
was also observed on human neutrophil migration (Wanten et al., 2000b).  Short chain fatty 
acids such as acetate, propionate, butyrate were found to inhibit LPS-induced TNF-α 
production but not IL-8 in neutrophils and inhibit the activation of the NF-κB pathway 
(Tedelind et al., 2007).  Furthermore, butyrate was also found to increase ICAM-1 and 
E-selectin expression but not on VCAM-1 and HLA-DR at a concentration of 2.5 to 5 mM 
(Miller  et al., 2005).  Short chain fatty acids (6 carbons to 10 carbons) were found to have no 
effect on oxygen radical production by neutrophils compared to the stimulatory effect of 
medium-long chain fatty acids (12 carbons to 20 carbons) at a concentration of 1 mM 
(Wanten et al., 2002; Ferrante t al., 2005).   Studies on other longer chain fatty acids such 
as palmitic acid, stearic acid, oleic acid (OA), linoleic acid, arachidonic acid (AA), 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been found to stimulate 
nitric oxide production at low concentrations of 1-10 µM and inhibit at higher concentrations 
(50-200 µM) (de Lima et al., 2006).  
 
Omega 3 polyunsaturated fatty acids are used as anti-inflammatory supplements, especially in 
patients with rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and in 
cardiovascular diseases (Calder et al., 2002; Simopoulos, 2002).  Some of the benefits from 
such supplements are due to DHA and EPA decreasing the levels of highly inflammatory 
eiconoids derived from AA and may be useful to lower the usage of anti-inflammatory drugs 
(Simopoulos, 2002).   
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1.8 Anti-malarials as anti-inflammatory agents 
 
Developing appropriate anti-inflammatory agents remains a major challenge.  Presently 
available agents have targeted mainly enzymes, G proteins coupled receptors, nuclear 
hormone receptors, cytokines, cytokine receptors and cell adhesion molecules and 
co-stimulatory molecules (Simmons, 2006).  A summary of the specific anti-inflammatory 
targets is presented in Table 1.5.   
 
Although a wide range of anti-inflammatory agents have been developed, the quest for 
effective drugs to treat chronic inflammatory conditions continues.  Due to the broad usage 
of the present therapies, they are highly toxic andssociated with significant side effects 
(Norman and Hickey, 2005).   
Current treatments for inflammatory diseases have lrge y focused on trying to interrupt the 
synthesis of mediators that drive the host’s respone during injury.  These include 
non-steroidal anti-inflammatory agents, steroids, glucocorticoids and anti-histamines (Gaestel 
et al., 2009; Gilroy et al., 2004).   
 
More recently, treatments for chronic inflammatory diseases have been based on the inhibition 
of mediators that promote acute inflammation (Gilroy et al., 2004; Ulbrich et al., 2003) as 
well as the development of small molecular inhibitors f protein kinases in both acute and 







Table 1.4 Maximum concentration of fatty acid tolerat d by human cell lines, Jurkat 
(T-lymphocyte), Raji (B-lymphocyte) and J774 (macrophages).  
Adapted from Lima et al., (2002) and Martins de Lima et al., (2006).  Abbreviation- ND- 

















Butyric C4:0 800 µM 700 µM ND 
Caproic C6:0 >1 mM >1 mM ND 
Caprylic C8:0 >1 mM >1 mM ND 
Capric C10:0 400 µM 400 µM ND 
Lauric C12:0 200 µM 200 µM ND 
Myristic C14:0 150 µM 150 µM ND 
Palmitic C16:0 50 µM 100 µM 70 µM 
Palmitoleic C16:1 100 µM 100 µM ND 
Stearic C18:0 50 µM 50 µM 70 µM 
Oleic C18:1 250 µM 250 µM 100 µM 
Elaidic C18:1 300 µM 400 µM ND 
Vacenic C18:2 200 µM 150 µM ND 
Linoleic C18:2 100 µM 100 µM 150 µM 
γLinolenic C18:3 50 µM 50 µM ND 
Arachidonic C20:4 50 µM 25 µM 150 µM 
Eicosapentaenoic C20:5 50 µM 25 µM 150 µM 
Docosahexaenoic C22:6 50 µM 25 µM 150 µM 
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However, the limitation of these therapies are evidnt since they also inhibit essential 
physiological processes, resulting in side effects or even leaving the patient susceptible to 
opportunistic infection (Gilroy et al., 2004).   
 
The usage of anti-malarials as immunosuppressive antimicrobial agents dates back to 
centuries with case studies reporting the effects of these anti-malarials in the 1940s 
(Meyer-Rohn, 1972; Randrianarivelojosia et al., 2009).  These have been widely used for 
therapeutic purposes in inflammatory diseases and also serve as a tool for examination of 
mechanisms of immunological functions (Thong and Ferrante, 1978, 1980).  Of the various 
anti-malarial drugs developed, those with a 4-aminoquinoline structure such as amodiaquine, 
primaquine, quinine, mefloquine, CQ and HCQ have ben found to have anti-inflammatory 
properties.  However only CQ and HCQ have been successful in the treatment of rheumatic 
conditions (Jones and Jayson, 1984).  Summaries of the effects of 4-aminoquinoline base 
compounds on leukocytes responses can be found in Table 1.6.  While the different 
compounds exert their effects differently, it is evident that quinine, melfoquine, CQ and HCQ 
showed the most promising effects as an anti-inflamm tory agent and only CQ and HCQ were 












































Cytokines and cytokines receptors 
 
TNF-α and TNFRII 
 IL-1β and IL-1RA 





LFA and CD11a 
CD2 and LFA-3 
VLA-4 and CD49d 
 
Cell interaction molecules 
(adhesion and co-stimulatory molecules) 
CTLA4 and Ig 
  
Adapted from Simmons (2006) with modifications. Abbreviations-IMPDH- 
inosine monophosphate dehydrogenase, LFA-leukocyte functional antigen, 
VLA-very late antigen and CTLA- cytotoxic T lymphocyte-associated antigen. 
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(Ferrante et al., 
1986; Labro and 
Babin-Chevaye, 
1988; Kharazmi et 
al., 1983) 




√ √ √ √ √ (Ferrante et al., 
1986; Hurst et al., 
1987; Neal et al., 
1987; Kharazmi et 




Degranulation X ND ND ND √/X (Neal et al., 1987; 
Bates and Ferrante, 
1988; Ferrante t 
al., 1986) 
MPO activity √ ND ND √ ND (Labro and 
Babin-Chevaye, 
1988; Ferrante t 
al., 1986) 
Phagocytosis √ ND X ND √ (Labro and 
Babin-Chevaye, 
1988; Jones and 
Jayson, 1984) 
Abbreviation: ND-not done, √-inhibition observed, X-no inhibition 
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1.8.1 Chloroquine  
 
CQ is a 4-aminoquinoline anti-malarial that contains a 7-chloroquinoline-substituted ring 
system with a flexible pentadiamino side chain (Figure 1.6A). These compounds can be 
readily synthesised, are inexpensive to produce, and re generally well tolerated with 
acceptable toxicity profiles for treatment of acute infections (O'Neill et al., 1998).  The 
medication is available in tablets of 125 mg or 250 mg as chloroquine phosphate and is 
known to have potent blood schizonticide activity, effective against the erythrocytic forms of 
all strains of Plasmodia, and has also been useful in the treatment of rheumatoid arthritis, 
systemic lupus erythematosus and various dermatological diseases (Adams et al., 1983; 
Isaacson et al., 1982).  Moreover the anti-HIV1 effect of CQ has al o been reported where it 
suppresses HIV-1 replication in T cell lines (Tsai et al., 1990).   
 
CQ is a weak base which tends to accumulate down the pH gradient so that its presence in the 
parasite is 10,000 times greater than in the red blood cell (O'Neill et al., 1998).  The weak 
base effects of CQ on parasite vesicular pH and/or its ability to concentrate in the parasite, 
facilitates the killing of Plasmodium and limiting undesirable side effects (Schlesinger et al., 
1988).  The action of CQ is limited to the stages of the parasite that are actively involved in 
haemoglobin degradation (O'Neill et al., 1998).  Moreover, it has been found that although 
CQ highly concentrates within acidic compartments, it  site of action is extralysosomal 





1.8.1.1 Effects of CQ on neutrophils  
 
The effects of CQ on neutrophil functions have been xtensivly documented.  It has been 
reported by Raghoebar et al., (1986) that neutrophils accumulate CQ to a greater extent than 
mononuclear cells due to the large numbers of acidic organelles present in neutrophils, 
reaching a steady state after 60 min at 37 °C (Raghoebar et al., 1986).  In vitro treatment of 
neutrophils with high concentrations (194 µM) of CQ did not result in cell death (French et al., 
1987; Labro and Babin-Chevaye, 1988) but exerted a concentration dependant inhibitory 
effect on neutrophil chemotaxis (Kharazmi et al., 1983; Ferrante t al., 1986)  (Table 1.6).  
The ability of CQ to inhibit neutrophil functions was further confirmed by showing that it 
inhibited phagocytosis of zymosan particles (Jones and Jayson, 1984; Labro and 
Babin-Chevaye, 1988) as well as superoxide production induced by fMLP and PMA (Hurst et 
al., 1987).  
 
One study examining the inhibitory effect of CQ on superoxide production induced by  
opsonised zymosan, found that it does not act on Mo-1 expression (an epitope on CR3) 
suggesting that it does not inhibit surface receptors expression (Hurst et al., 1988).  With 
further findings suggesting that it inhibits PMA induced superoxide production in neutrophils 
(Hurst et al., 1988).  Therefore, it has been proposed that chloroquine inhibits activation of 
the PKC signalling pathway by either competing for the membrane phospholipid regulatory 
site of PKC, thereby reducing availability of this essential cofactor or it impairs the 
recruitment of components of the NADPH oxidase from specific granules to the cell 





1.8.1.2 Effect of CQ on monocytes/macrophages 
 
CQ markedly inhibits LPS-induced synthesis and release of pro-inflammatory cytokines such 
as TNF-α, IL-1β, and IL-6 in human macrophages (Karres t al., 1998).  This 
down-regulatory effect on cytokine production occurs at the transcriptional level and may be 
caused by disturbance of the signalling through the weak base property of CQ (Karres t al., 
1998). Another finding suggested that the effect of CQ on TNF production in RAW 264.7 
murine macrophages occurred at the pro-TNF level, inhib ting the maturation of pro-TNF into 
the mature 17 kDA TNF, namely at the post-translational step (Jeong and Jue, 1997).  In the 
same study, it was found that treating macrophages with CQ (150 µM) at -2, 0 and 2 h before 
or after LPS challenge resulted in an inhibition on TNF (Jeong and Jue, 1997).  The 
mechanism of the inhibitory effect of CQ on IL-1β and IL-6 production in macrophages 
stimulated with LPS is different from that of TNF in that it reduces the levels of IL-1β and 
IL-6 mRNA by decreasing their stability (i.e. accelerating its decay) (Jang et al., 2006). 
 
Apart from the inhibitory effect of CQ seen on cytokine production, Ziegler and Unanue, 
(1982) suggested that CQ also altered macrophage antigen-handling events as observed by its 
inhibition of Listeria uptake by macrophages treated with CQ 30 min prior to Listeria 
encounter.  A lesser effect was seen if CQ was added post bacterial interaction.  CQ was 
also found to inhibit calcium release from macrophage intracellular stores by blocking inositol 
trisphosphate (IP3) from binding to its receptor (Misra et al., 1997).  In purified mouse 
macrophages treatment with CQ inhibited the release of arachidonic acid and generation of 
the eicosanoid PGE2 production induced following stimulation with PMA (Bondeson and 




1.8.1.3 Effect of CQ on lymphocyte responses 
 
The effect of CQ on lymphocyte proliferation has been previously investigated.  The drugs 
inhibit both antigen-(tetanus toxoid-TT or paraphenyl ediamine-PPD) and 
mitogen-(phytohaemagglutinin-PHA) induced lymphocyte proliferation in a dose dependent 
manner with EC50 values of 6.9, 11.6 and 20.8 µM respectively (Hugosson et al., 2002) .  
The greater inhibitory activity of CQ on TT is likely to be due to an effect on APCs and the 
requirement to process antigen through the lysosomal pathway, a target for CQ due to the 
lysosomotropic effects of the drug (Hugosson et al., 2002).  Moreover, its weak base 
properties are likely to contribute to the inhibition of T cell proliferation and IL-2 production 
(Landewe et al., 1995).        
 
Morphological studies of the effects of CQ on lymphocytes suggested that it induces a dose 
dependent increase of autophagosomes, affecting the lysosomal function which contributes to 
the immunosuppressive properties of CQ (Jones and Jyson, 1984).  As a lysosomotropic 
agent, it also affects lysosomal acidification, resulting in a decrease of the invariant chain 
dissociation from the MHC II molecule (Blum and Cresswell, 1988).  The inhibition of 
endosomal antigen processing of exogenous proteins by CQ is thought to be due to the raising 






































1.8.2 Hydroxychloroquine  
 
HCQ is an amphiphilic drug prepared via beta hydroxylation of chloroquine (i.e. introduction 
of a hydroxyl group into one of the N-ethyl groups of chloroquine) (Figure 1.6B) (O'Neill et 
al., 1998).  The hydroxyl function group is thought to reduce the toxicity by introducing a 
readily available functionality that could undergo luccoronidation and thus detoxification 
and excretion (O'Neill et al., 1998).  HCQ has been proven to be three times less toxic than 
chloroquine in animal models of gross toxicity and achieves higher blood levels after a single 
oral dose (O'Neill et al., 1998).  This drug is used in the treatment of malari , rheumatoid 
arthritis, and systemic lupus erythematosus, and is on the market under the name of Plaquenil 
(Sanofi Pharmaceuticals, New York) (Marquardt and Albertson, 2001).  The drug is available 
as tablets of 200 mg of HCQ phosphate each containig 155 mg of HCQ.    
 
1.8.2.1 Effect of HCQ on neutrophils 
 
Although not as extensively studied as chloroquine, HCQ has been shown to affect leukocyte 
function.  Hurst et al., (1987) found that there was a dose dependent inhibition of 
fMLP-stimulated neutrophil superoxide production byHCQ.  It caused no effect on 
fMLP-receptor binding and was proposed that HCQ inhibits fMLP stimulated hydrolysis of 
phosphioinositides thus inhibiting the production of NADPH which is important for 
superoxide production (Table 1.6).  The drug inhibited neutrophil superoxide production 
induced by opsonised zymosan particles as well as th t induced by PMA and fluoride, with 
maximum of 40 to 50 % inhibition at 100 µM (Hurst et al., 1988).  HCQ has no effect on the 
expression of CR3 on neutrophil surfaces, similar to CQ.     
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1.8.2.2 Effect of HCQ on monocytes/macrophages and T lymphocytes 
 
HCQ is found to cause inhibition of IL-1α and IL-6 in monocytes stimulated by LPS at a 
post-transcriptional level by either inhibiting the translation of the two cytokines or by 
altering the enzymes involved in the process (Sperber et al., 1993).  In contrast, it has no 
effect on TNF production by monocytes and no effect on IL-2, IL-4 and IFN-γ production in 
T cells (Sperber et al., 1993).  HCQ was also found to inhibit the release of arachidonate 
induced by zymosan in murine macrophages suggesting an effect on phospholipase C, similar 
to the effects of CQ (Bondeson and Sundler, 1998).   
 
1.8.3 Clinical use of anti-malarials in inflammatory diseases 
 
CQ and HCQ are widely used in the treatment of rheumatoid arthritis and systemic lupus 
erythematosus (Chen et al., 2005).  The mechanisms of action of these two drugs has been 
linked to their ability to alkalinise macrophage lysosomes (Poole and Ohkuma, 1981), 
stabilise lysosomal membranes, inhibit receptor recycling, inhibit phospholipase A2 
(Bondeson and Sundler, 1998) and inhibit leukotriene formation from human and guinea pig 
lung tissue (Kench et al., 1985).  While the above studies investigated the mechanisms by 
which these drugs exert their inhibitory effects, some results have been contradictory and 






1.8.3.1 Drug metabolism and toxicity of CQ and HCQ 
 
CQ is highly lipophilic with a diacidic base and accumulates within the acidic compartments 
of the cell leading to an increase in lysosomal pH,hence, it exerts toxic effects at high doses 
(O'Neill et al., 1998). The drug diffuses through the plasma membrane and preferentially 
concentrates in acidic cytoplasmic vesicles which influence cell endocytosis, exocytosis, 
phagocytosis, antigen presentation and iron metabolism (Chen et al., 2005).  Also, oral 
administration of therapeutic doses of CQ may cause psychosis, delirium, personality changes, 
and depression.  There is ganglio-side storage of CQ in the nervous tissue (Chen t al., 2005).  
Clinical symptoms of chloroquine toxicity range from reversible cardiac muscle damage to 
irreversible retinopathy (Jaeger t al., 1987).  The toxicity associated with CQ occurs not 
only because of its accumulation but due to its long-half life and high plasma concentrations 
(O'Neill et al., 1998).  It has been estimated that retinal toxicity occurs in approximately 10 
to 20 % of patients who receive CQ therapy and up to 3 % of patients who receive HCQ 
therapy (Finbloom et al., 1985).  Cases of CQ overdoses usually result in serious rapid 
symptoms seen within 30 min and death within 1 to 3 h of ingestion due to cardiac arrest 
(Marquardt and Albertson, 2001). Oral administration f CQ usually results in a rapid 
absorption from the gastrointestinal tract to the blood with a high bioavailability of between 
80 and 90 % (Chen et al., 2005). The metabolic degradation of CQ investigated by others has 
confirmed that CQ undergoes degradation and oxidizat on and only a small fraction of the 
drug is secreted as carboxylic acid (McChesney et al., 1966).  The metabolic degradation of 






HCQ has been reported as a drug with a low margin of safety and a mortality rate in overdose 
studies from adults ranging from 10-30 % with symptoms observed between 30 min to 4.5 h 
after ingestion (Marquardt and Albertson, 2001).  Some clinical symptoms reported include 
drowsiness, dizziness and visual disturbances to seizures, apnea, arrhythmias, and 
hypotension (Marquardt and Albertson, 2001).  The drug mainly accumulates in tissues, 
especially the liver and has a half-life of approximately 8 weeks (Temprano et al., 2005).  
The biotransformation of HCQ differs from CQ only in that it produces two first-stage 
metabolites instead of one (McChesney, 1983).     
 
Extracellularly, CQ/HCQ are present in a protonated form and are incapable of crossing the 
plasma membrane (Savarino et al., 2003).  However, their non-protonated portion canenter 
the intracellular compartment and become protonated, therefore enabling accumulation within 
acidic organelles such as the endosome, golgi vesicles, and the lysosomes (Savarino et al., 
2003).   
 
Studies in human volunteers revealed differences in excretion of CQ and HCQ, while three 
times as much CQ (18 %) appeared in urine compared with faeces (8 %),  three times more 
HCQ was found in faeces (24 %) than urine (6 %) (O'Neill et al., 1998).  This reflects the 
differences in metabolism between CQ and HCQ (O'Neill  et al., 1998).  Results from 
previous research on the effects of these two drugs have concluded that 400 mg of HCQ is 
safer than 250 mg of CQ (Rynes, 1997), but despite the influences of both CQ and HCQ, 
































1.9 Aims and hypothesis 
 
Our group has previously been interested in the anti-inflammatory properties of quinoline 
compounds commonly used as anti-malarial agents.  This includes quinine, chloroquine, 
mefloquine and primaquine.  One of the activities of these compounds was found to inhibit 
neutrophil function, a component of acute inflammation and also chronic inflammation 
(Benna et al., 1991).  While patients with certain inflammatory disorders such as rheumatoid 
arthritis have been shown to benefit from the CQ derivative, HCQ, it has remained of limited 
use in the treatment of these diseases.  Scherbel t al., (1958) reported that the use of CQ and 
HCQ resulted in neuromuscular reactions; blurring of vision, throbbing and unilateral 
headaches; gastrointestinal reactions; nausea, anorexia, vomiting, bloating, abdominal cramps, 
heartburn and loss in weight and dermatologic reactions; dryness of the skin, itching, urticaria, 
morbilliform eruptions, increased pigmentation and graying or bleaching of the hair.  
Moreover, neuromyotoxicity (Stein et al., 2000), cardiac toxicity (Veinot et al., 1998), 
retinopathy (Browning, 2002) and fetal abnormalities (Temprano et al., 2005) have also been 




By adding a fatty acid to the side chain of the quinoline group, structural elements are 
generated which lead to the development of anti-inflammatory agents with selectivity for 
immune cells activation pathway targets.  Furthermore activity of the newly synthesised 











To synthesise a series of quinoline based compounds bearing fatty acids of different carbon 
length on the side chain (NT compound). 
To examine the effects of the NT compounds on neutrophil functions of adherence, 
chemotaxis, respiratory burst and cytokine production. 
To study the effects of the compounds on lymphocyte and macrophage responses. 
To compare their activity with that of CQ and HCQ. 
To examine whether any effects are related to responses induced by specific cell agonists. 
To try to understand the bases for any effects caused by the NT compounds. 
To determine whether key NT compounds have in vivo efficacy in inflammatory mouse 

































2.1 Reagents, biochemicals and antibodies 
 
Ficoll 400, percoll and lymphoprep were obtained from Pharmacia Biotech (Uppsala, 
Sweden).  Lucigenin and dimethyl sulphoxide (DMSO) were from Merck KGaA (Darmstadt, 
Germany).  Modified-Wright Giemsa were obtained from Hema-Tek Stain Pak (Bayer, 
USA), and mounting medium from Surgipath (Victoria, Australia). Roswell Park Memorial 
Institute (RPMI-1640), hanks balanced salt solution (HBSS) and foetal bovine serum (FBS) 
and L-glutamine were from JRH Biosciences (Lenexa, KS, USA).  Lauric acid (LA), 
chloroquine (CQ), hydroxychloroquine (HCQ), arachidonic acid (AA), leukotriene B4 (LTB4), 
A23187, interleukin 8 (IL-8), complement 5a (C5a), HEPES, pyridoxal phosphate (PyrP), 
palmitoyl co-enzyme A (PCoA), L-serine, bis-nitrophenyl phosphate (NBPP), magnesium 
(Mg2+), ATP, β-mercaptoethanol, trypan blue, folin and ciocalteau’s phenol reagent, fMLP, 
PMA, sodium diatrizoate, formaldehyde and rose bengal were from Sigma, Aldrich Pty. Ltd, 
(Sydney, Australia).  Angiografin was obtained from Schering AG (Berlin, Germany).    
GM-CSF and TNF-α were purchased from Prospec-Tany Technogene Ltd., (Rehovot, Israel).  
Ammonia solution was from AJAX chemical (NSW, Australia).  Penicillin/streptomycin was 
from Commonwealth Serum Laboratories (CSL) (Victoria, Australia).  Isoton II and bovine 
serum albumin (BSA) were purchased from Beckman Coulter (Fullerton, CA).  
Phytohaemagglutinin (PHA) was purchased from Murex Diagnostics (Dartford, U.K).  
Tetanus Toxoid was from Calbiochem (Darmstadt, Germany). Anti-CD3 and anti-CD28 
antibodies were purchased from eBioscience (San Diego, CA).  Anti-mouse IgG1, (HRP 
conjugated) and PE-labelled mouse anti-human CD11b anti ody were from Becton Dickinson 
(San Jose, CA).  Anti-mouse IgG1 (FITC), FITC-labelled mouse anti-human anti-CD120a 
and anti-CD120b were purchased from Monosan (Uden, N therland).  Fatty acid chlorides 
were purchased from Nu Chek Prep (Elysan, Minnesota). 
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2.2 Chemical experimental sections 
 
Experimental sections described in 2.2, 2.3 and 2.4 were carried out by the organic chemist, 
Dr. Neil Trout.  Melting points were determined on a Buchi melting point apparatus in sealed 
glass capillaries and are uncorrected.  Nuclear magnetic resonance (NMR) spectra were 
recorded on a Varian Gemini-300 MHz spectrometer (Palo Alto, CA). The probe temperature 
of the instrument was 295 ± 2 K. All 1H and 13C NMR spectra were recorded in deuterated 
chloroform (CDCl3) as solvent at 300 and 75 MHz, respectively, with chloroform (CHCl3) 
(7.26 ppm) for 1H and CDCl3 (77.0 ppm) for 
13C as the internal reference. Analytical 
thin-layer chromatography (TLC) was performed on silica gel plates and visualized with 
ultraviolet (UV) absorbance.  Solvents and reagents were obtained from commercial sources 
and were used without purification, unless noted.  Reactions were carried out under an inert 
atmosphere of nitrogen.  Elemental analysis and compound purity were determined via 
NMR performed by Monash University, Melbourne, Australia.  
 
2.3 Synthesis of base structure 4-amino-7-chloroquinoline (NT0)  
 
Methods were followed as described previously (Vippagunta et al., 1999).  A mixture of 4, 
7-dichloroquinoline (10 g, 0.05 mmol) and phenol (80 g, 0.85 mol) were heated and stirred 
together up to 145 °C under N2 when anhydrous ammonia gas was bubbled into the solution 
for 10 min. The ammonia was stopped and the resulting mixture heated further to 180 °C 
(internal temperature), then the ammonia was re-administered for 2 h. After this time, the 
mixture was cooled slowly to room temperature to which ether and water were added. The 
ether mixture was washed with 15 % sodim hydroxide ( NaOH) solution (2 x 50 ml) followed 
by water. The ether extracts were dried and evaporated to dryness to yield the crude amine.  
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The residue was re-dissolved in diethyl ether (250 ml) and washed with 2 M hydrochloride 
(HCl) solution (2 x 100 ml). The aqueous layer was then basified with 15 % NaOH solution 
and then re-extracted with ether, dried and removed in vacuo to afford the pure-amine as an 
off-white solid (5.20 g, 58 %), mp 147-148 °C, (148.5-149.5 ºC). The compound was 
characterised by 1H and 13C NMR and all spectra agreed with those previously published 
(Vippagunta et al., 1999). It was used without further purification. 
 
2.4 Synthesis of 4-amino-7-chloroquinoline-fatty acid conjugates (NT1-13) 
 
To the above solution of amine in dry distilled tetrahydrofuran (THF) (4 ml) containing a 
spatula amount of oven dried K2CO3 or 1 equivalent of DBU under N2 at 0 °C was added the 
appropriate fatty acid chloride drop wise (2 equivalents).  In order to generate a variety of 
compounds of interest, different commercially available fatty acid chlorides were added to the 
above solution.  These are detailed in Table 2.1.   After 5 min, the mixture was allowed to 
warm up to room temperature and refluxed for 48 h under N2. The reaction was then 
quenched with the slow addition of water and the mixture extracted with CH2Cl2. The organic 
extracts were washed with NaHCO3 solution, dried, filtered and removed by rotary 
evaporation to yield the crude product. The residue was chromatographed on silica gel eluting 
with 10-40 % ethyl acetate in hexane. Appropriate fractions were taken and visualised on thin 
layer chromatography (TLC) plates under UV light for identification. The fractions were 






2.5 Preparation of NT compounds 
 
The dry compound was dissolved in chloroform (1 ml) and then transferred into a 
pre-weighed glass tube.  This was then dried under nitrogen and the final weight was 
determined.  A stock solution was then prepared in chloroform including an ethanol working 
stock of 20 mM.  All stocks were then gased briefly with nitrogen, the lid was sealed with 
parafilm and stored in 4 °C.  The compound was further diluted either with RPMI or HBSS 
prior to experiments to ensure so that the final concentration of ethanol in the solution did not 
exceed 0.1 %.    
 
2.6 Preparation of lauric acid 
 
Chloroform stocks and an ethanol working stock of lauric acid were prepared.   All stocks 
were gased with nitrogen and the lid sealed with parafilm and stored in 4 °C.  A further 
dilution from the ethanol stock was performed either with RPMI or HBSS prior to adding to 
cells, to ensure the final concentration of ethanol i  the solution did not exceed 0.1 %.    
 
2.7 Preparation of CQ and HCQ 
 
Working stocks of CQ and HCQ were prepared as previously described (Weber t al., 2002).  
Briefly, CQ and HCQ stocks were prepared in HBSS, the lid sealed with parafilm, and stored 



























NT2 100 mg, 0.56 mmol  Stearoyl chloride 200 µl 
NT3 120 mg, 0.67 mmol Undecenoyl chloride 250 µl 
NT4 100 mg, 0.56 mmol Hexanoyl chloride  
(caproyl chloride) 
200 µl 
NT5 100 mg, 0.56 mmol Butyroyl chloride 
(tetranoyl chloride) 
200 µl 
NT6 120 mg, 0.67 mmol Octadecenoyl chloride (85%) 
(oleoyl chloride) 
250 µl 
NT7 115 mg, 0.65 mmol Propanoyl chloride 200 µl 
NT 110 mg, 0.62 mmol Dodecanoyl chloride  
(lauroyl chloride) 
200 µl 
NT9 120 mg, 0.67 mmol Nonadecanoyl chloride 200 µl 
NT10 150 mg, 0.84 mmol Pivalolyl chloride 250 µl 
NT11 120 mg, 0.67 mmol Pentanoyl chloride 
(valeroyl chloride) 
200 µl 
NT12 120 mg, 0.67 mmol Nonaoyl chloride 200 µl 
NT13 100 mg, 0.56 mmol 11-eicosenoyl chloride 250 µl 





Male BALB/c mice aged between 6-8 weeks with an aver g  weight of 20-25 g were 
purchased from Adelaide University Animal House, Adelaide and Animal Resource Center, 
Perth.  The animals were housed in the Women’s and Children’s Hospital’s animal house.  
The study was approved by the CYWCH Animal Ethics Committee and the University of 
Adelaide Animal Ethics Committee.   
 
2.9 Isolation of human peripheral blood mononuclear cells and neutrophils.  
 
Human mononuclear leukocytes and neutrophils were pu ified from blood of healthy donors 
by the rapid single step method as previously described (Ferrante et al., 1982).  Briefly, 6 ml 
of peripheral blood was layered onto 4 ml of Hypaque-ficoll medium containing 8 % Ficoll 
400 and adjusted to a density of 1.114 by the addition of sodium diatrozoate and angiograffin.  
The preparation was then centrifuged at 600 g for 35 min to allow leukocytes to separate.  
PBMCs were harvested from the top band and neutrophils from the lower band.  The cells 
were washed three times in RPMI-1640 for PBMCs and in HBSS for neutrophils.  The cells 
were of > 98 % purity and > 99 % viability as judge by their ability to exclude trypan blue.   
 
2.10 Preparation of TNF-rich medium (TNF-RM) 
 
TNF-RM was prepared as previously described (Bates e  al., 1991).  Briefly, PBMCs (20 
mls of 4 x 107) in RPMI-1640 supplemented with L-glutamine (200 mM), penicillin (100 
U/ml) and streptomycin (100 µg/ml) were mixed in a culture flask (Greiner Bio-One, 
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Germany) with (20 mls of 2 x 108) Staphylococcus aureus (S. aureus NCTC 6571, Oxford 
strain) in RPMI-1640 supplemented with 5 % of human heat inactivated AB serum.  The 
cells were then incubated at 37 °C with 5 % CO2 for 24 h and the resultant TNF-RM was 
obtained by centrifugation at 2600 g for 10 min, filter ng through 0.20 µm pore filter 
(Sartorius Stedium Biotech, Goettinger, Germany) and liquoted for storage at -70 °C until 
further usage.  The amount of TNF in this preparation was 39 ng/ml.      
 
2.11 Neutrophil function assays 
 
A limitated number of key neutrophil functional responses were used to assess the 
immunomdulatory properties of the compounds, these promote neutrophil accumulation at 
infection sites (adherence and chemotaxis) and micribal killing/tissue damage (generation of 
oxygen derive reactive species and cytokine production). These assays have been widely used 
in our Laboratory and have both been standardized and published previously. They represent 
internationally widely accepted assays for determining eutrophil functional responses.  
 
2.11.1 Adherence assay 
 
The adherence assay was carried out as described previously (Bates et al., 1993).  Briefly, a 
96 well flat bottom microtiter plate (Greiner Bio-One, Germany) was coated with 250 µl of 10 
% autologous plasma for 30 min at 37 °C/ 5 % CO2  followed by washing three times with 
HBSS.  To 100 µl neutrophils (5 x 105 cells), was added the stimulus (20 µl) and HBSS to 
give a final volume of 200 µl and cells.  Then the cells were allowed to adhere for either 30 
min at 37 °C/ 5 % CO2 and unbound cells were removed by washing the wells twice with 
87 
 
HBSS (200 µl).  The adhered cells were then stained with 0.25 % Rose Bengal (w/v), a dye 
that rapidly stains predominantly the cell nucleus, for 5 min at room temperature (Feenstra 
and Tseng, 1992).   Excess dye was then removed by washing three times with HBSS.  The 
dye was then released by adding 100 µl 50% ethanol in PBS.  Cell adhesion was determined 
by the amount of dye present in each well.  This is done by reading the plate at an 
absorbance of 570 nm using a Dynatech MR5000 plate re der.  Parallel wells were run in the 
absence of neutrophils and results are expressed aft r subtraction of absorbance values from 




Neutrophil chemotaxis was measured using the under-aga ose method as described previously 
(Ferrante et al., 1980).  Briefly, equal volumes of agarose (1 %, w/v) and double strength 
RPMI-1640 supplemented with 10 % heat-inactivated FCS were mixed and allowed to set in 
60 mm culture dish (Geriner Bio-One, Germany) and sets of 3 wells were made.  Then 5 µl 
aliquots of fMLP (0.4 µM), neutrophils (2 x 105), and 0.1 % DMSO (v/v) were added to the 
outer, central and inner wells, respectively.  The dish was then incubated at 37 °C for 90 min 
in a humidified atmosphere of 5 % CO2 in air.  Neutrophil migration was measured from the
edge of the central well to the cells leading front migrating towards either the fMLP 
(chemotaxis) or DMSO (random migration) containing well under an inverted Leitz 





2.11.3 Chemiluminescence assay 
 
Neutrophil superoxide production was assayed by measuring lucigenin (9, 9’-bis 
N-methyl-acridinium nitrate)-dependent chemiluminescence assay (Hii et al., 1999) via a 
luminometer (Autolumat Plus LB 953, Berthold Australia, Bundoora, Australia).  This assay 
had been shown privously to measure superoxide producti n (Dahlgren et al., 1985; 
Gyllenhammar, 1987; Alves et al., 2003).   To 100 µl (1 x 106) neutrophils was added the 
stimulus (100 µl), lucigenin (500 µl of 250 µM) and HBSS to a total volume of 1 ml.  The 
cells were placed in a luminometer and the resulting chemiluminescence measured.  Results 
are expressed as peak chemiluminescence produced, unl ss specified otherwise.   
 
2.12 Analysis of cytokine and chemokine gene expression by quantitative real-time PCR 
2.12.1 Preparation of samples for RNA isolation 
 
Neutrophils (1 ml of 1 x 107) were pretreated with various concentrations of the compound (1 
ml) for 1 h and then stimulated with 2 ml TNF (100 U) in the presence of autologous plasma 
(200 µl) for 30 minutes at 37 °C/ 5 % CO2.  After stimulation, samples were pelleted and 
stored at -70 °C until RNA isolation.   
 
2.12.2 Isolation of RNA 
 
Total RNA was extracted from 1 x 107 neutrophils using the RNeasy Mini Kit according to 
the manufacturer's instructions (Qiagen, Australia). The neutrophil samples were lysed and 
homogenized in 600 µl RLT buffer supplement with β-mercaptoethanol (10 µl/ml) to which 
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ethanol (600 µl of 70 %) was then added.  The lysate (700 µl each time) was then loaded 
onto the RNease Mini spin column, spun for 15 sec at ≥ 8000 g.  The RNA was washed once 
in RW1 buffer (700 µl-15 sec), twice with RPE (500 µl-15 sec followed by 2 min) and 
transferred into a new collection tube to which RNase free water (30 µl) was added.  The 
purified RNA was then eluted by centrifugation for 1 min at > 8000 g and stored at –70 °C 
until required for cDNA synthesis. Purity of the RNA samples was assessed by determining 
the optical density at 260 nm and 280 nm expressed as a ratio via UV/VIS SP8001 
Spectrometer (Metertech, Taiwan). 
 
2.12.3 Synthesis of cDNA (Reverse Transcription) 
 
Single-stranded cDNA was synthesised from total RNA isolated earlier using iScript cDNA 
Synthesis Kit according to the manufacturer’s instructions (BioRad, NSW, Australia). A 
master mixed was prepared containing iScript Reaction Mix (4 µl) which contains a unique 
blend of oligo(dT) and random hexamer primers, iScript Reverse Transcriptase which is 
RNase H+ (1 µl), RNA (1 µg) and RNA free distilled water up to a final volume of 20 µl.  
cDNA was synthesized under the following conditions: 25 °C for 5 min, 42 °C for 30 min and 
85 °C for 5 min.   
 
Firstly, oligo(dT) primer containing additional sequences at the 3’end anneals to the mRNA.  
Reverse transcriptase then extends from the annealed oligo(dT) primer along the mRNA 
template until it reaches the 5’ end where the enzyme’s terminal transferase activity attaches 
several additional nucleotides onto the newly synthesized strand of cDNA, ie. copying of the 
mRNA sequence into the cDNA sequence.  This resulted in a single-strand cDNA that can 
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then be converted into double-strand cDNA for construction of cDNA libraries  
 
2.12.4 Quantitative real-time PCR 
 
Real time PCR was performed in the iCycler iQ™ 96 well PCR plate using iQ™ Sybr® 
Green Supermix (BioRad, NSW, Australia) according to the manufacturer’s directions.  
Primers for cytokines were initially designed using I vitrogen Oligo Perfect Designer website 
and then synthesized by Invitrogen (Carlsbad, CA, USA) (Table 2.2).  The synthesised 
cDNA was then amplified in duplicate in a PCR 96 well plate (Bio-Rad, CA, USA).  Each 
well contained iQ SYBR Green supermix (10 µl), cDNA (1 µl) and each specific primer pair 
or the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (500 nM).  
The amplification conditions used were as follow:  95 °C for 5 min, followed by 40 cycles of 
95 °C for 30 s, 60 °C for 30 s and 72 °C s for 30 s and hold at 4 °C. A standard curve was also 
performed in each run for the cDNA of the diluted control.  All standard curves and data 
were analysed using Bio-Rad iQ5 Standard Edition V2.0.148.060623 (Bio-Rad, CA, USA).  
Fold change values were calculated in which ΔCt = the Ct for cytokine gene minus the Ct of 
the housekeeping gene, GAPDH: ΔΔCt = the ΔCt of stimulated cells at different concentration 













Forward primer (5’ to 3’) 
 




GAG TCA ACG GAT TTG GTC GT 
 
GAC AAG CTT CCC GTT CTC AG 
IL-1β TCA TTG CTC AAG TGT CTG AAG C TCC TGG AAG GAG CAC TTC AT 
IL-8 TCT GTG TGA AGG TGC AGT TTT G AAT TTC TGT GTT GGC GCA GT 
 
 
2.13 Regulation of 3-ketosphinganine synthase  
2.13.1 Microsomal isolation 
 
Microsomal isolation was performed as described previously (Williams et al., 1984). Briefly, 
mice were first euthanized and liver (1-2 g) was removed and stored in ice-cold buffered 
sucrose (1 g/ml) containing sucrose (0.25 M), Tris-HCl buffer (10 mM-pH 7.5) and EDTA (1 
mM).  Mouse liver was then washed 2-3 times with buffered sucrose, minced, and 
homogenized.  The homogenized solution was then centrifuged at 7300 g for 10 min at 4 °C.  
Supernatant was collected and spun further at 100,00  g for 60 min at 4 °C.  The resultant 
supernatant was removed and the pellet containing crude microsomes was re-suspended in 
buffered sucrose (1 g/ml).  Microsomes were then stored at -70 °C and protein concentration 





2.13.2 Lowry’s protein determination 
 
The amount of protein from microsomal isolation was measured via Lowry’s protein 
determination. Protein standards were prepared fresh for each assay, by serially diluting 1 
mg/ml BSA with H2O, resulting in 6 standards (0 µg, 3.125 µg, 6.25 µg, 12.5 µg, 25 µg, and 
50 µg). Unknown samples were diluted 10x before being assayed. All standards and known 
samples were assayed in 50 µl aliquots. To start the reaction, 150 µl of solution 1 [Lowry’s 
solution (2 % Na2CO3, 1 % SDS, 0.4 % NaOH, 0.16 % Na/K tartrate): CuSO2, 100:1] was 
added to all tubes and left to stand at room temperature for 15min. Then 15 µl of solution 2 
(H2O:Folin and Ciocalteau’s Phenol Reagent, 1:1) was added. After 10 min at room 
temperature, 180 µl from each tube was transferred to a 96 well plate and the optical density 
(OD) measured at 540 nm in a plate reader. The OD of the protein standards was used to 
create a standard curve from which the protein concentration of the unknown samples was 
determined. 
 
2.13.3 Serine palmitoyl transferase (SPT) assay 
 
The enzyme substrate assay was performed as described previously (Holleran et al., 1990; 
Williams et al., 1984).  Briefly, a reaction mix containing pyridoxal phosphate (PyrP) (50 
µM), palmitoyl-coenzyme A (PCoA) (150 µM), [G-3H] L-serine (1.0 mM-sp act 
45,000-50,000 dpm/nmol) and microsomal protein (50-20  µg) was added to the assay buffer 
(HEPES- 100 mM-pH 8.3 at 20 °C, DTT-5.0 mM and EDTA-2.5 mM- pH 7.4) containing 
either Mg2+ (1mM), ATP (1mM), NBPP (1mM), NT8 (100 µM) or diluent up to a final 
volume of 100 µl.  The assay mix was then incubated for 10 min at 37 °C in a water bath 
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with gentle shaking to initiate the reaction.  Ice cold NH4OH (0.5 M-200 µl) was added to 
terminate the reaction, followed by the addition of chloroform-methanol solution (1:2) (15 
ml), sphingosine base (25 µg) and NH4OH (0.5 M-2 ml).  The organic phase was then 
obtained by centrifugation for 10 min at 600 g and washing twice with deionized water (2 ml), 
made basic with NH4OH.  The enzymatic activity was then quantitated from the organic 
phase (500 µl) using a Beckman LS-1800 scintillation counter and results were expressed as 
pmoles of 3-keto-sphinganine (3KDS) formed per min per mg of protein.  Total SPT activity 




Whole mononuclear cells or T lymphocytes (50 µl of 5 x 105) were stimulated with various 
stimuli at 37 ºC / 5 % CO2 for either 2 or 5 days in a 96-well U-bottom plate (Linbro; Flow 
Laboratories, Virginia, USA).  Six hours prior to harvesting 1 µCi [methyl-3H] thymidine (25 
Ci/mmol; Amersham Life Sciences, Buckinghamshire, England) diluted in RPMI-1640 
supplemented with 5 % human AB serum was added to each well.  Supernatants (200 µl) 
were removed and stored in -70 °C for cytokine determination.  Cells were then harvested 
onto glass fibre filters (Wallac, Turku, Finland) using a FilterMate Harvester (PerkinElmer, 
Victoria, Australia) and allowed to air dry before 3.5 ml of scintillation cocktail was added.  
The amount of radioactivity present was then measured sing Wallac MicroBeta JET counter 





2.15 Cytokine determination 
 
IFN-γ, IL-1, IL2, IL-6, IL-10, lymphotoxin and TNF-α levels were determined using the 
cytometric bead array (BD Cytometric Bead Array Flex Sets System; BD Biosciences, San 
Diego, CA) according to the manufacturer’s instructions.  Briefly, 50 µl of capture bead 
suspension and 50 µl were added to an equal amount of sample or standard dilution of 1:1, 1:4, 
1:64, 1:256 and 1:1024 in a 96 well U-bottom plate.  It was then incubated for 1 h at room 
temperature in the dark and in some cases the sample was diluted 1:20 with diluent if 
necessary.  The phycoerythrin (PE) detection reagent (50 µl) was added to the wells and 
incubated in the dark at room temperature for a further 2 h.  Subsequently, samples were 
washed and centrifuged at 200 g at room temperature for 5 min.  The supernatant was 
discarded and 150 µl of wash buffer was added. Samples were analysed on a BD FACSArray 
bioanalyser (BD Biosciences, CA, USA) (Figure 2.1).  Quality control beads were used prior 
to reading the samples to ensure the instrument was standardised. Examples of the standard 
curves are shown in Figure 2.2, 2.3. 
 
2.16 Flow cytometry  
2.16.1 CR3 up regulation and expression 
 
The presence and up-regulation of the complement receptor (CR3) in neutrophils treated with 
NT8 was determined by flow cytometry.  In the FACS tubes (Evergreen Scientific, Los 
Angeles, USA), neutrophils (100 µl of 1 x 106) were incubated with TNF-RM for 1 h in 37 °C 






























Figure 2.2 Examples of standard curves for human IL-1, IL-6, lymphotoxin and TNF-α 
production. Standard curves were generated for IL-1, IL-6, lymphotoxin and TNF-α using 
















Figure 2.3 Examples of standard curves for human IFN-γ, IL-2 and IL-10 production. 









The pellet was re-suspended in 200 µl of Isoton II supplement with 0.1 % (w/v) BSA, and 2 µl 
of IgG1 isotype control or 2 µl of PE-labelled anti-CD11b antibody was added.  Tubes were 
then incubated on ice for 30 min in the dark and excess antibodies were then removed by 
washing twice with Isoton II.  Cells were then fixed with formaldehyde 0.1 % and stored in 
the dark at 4 °C until analysed by a flow cytometer (FACScan, Becton Dickinson, CA, USA).    
 
2.16.2 CD120a/CD120b expression 
 
The effect of NT8 on surface receptor TNFRI and TNFRII was measured by flow cytometry.  
Neutrophils (100 µl of 1 x 106) were treated with NT8 for 1 h and then incubated with 
anti-CD120a, anti-CD120b or isotype control anti-mouse IgG1 for 30 min in dark.  Cells 
were then washed, pelleted and incubate further with 2 µl of anti-mouse fluorescein 
isothiocyanate (FITC) for 30 min in dark at 4 °C.  Excess antibodies were removed by 
washing twice with Isoton II and fixed with formaldehyde 0.1 % and then stored in the dark 4 
°C until analysis via the flow cytometer.        
 
2.17 Lipopolysaccharide-induced peritoneal inflammation 
 
Male BALB/c mice were housed under a 12 h light-dark cycle in cages with unlimited access 
to food and water in a temperature controlled room f r at least 5 days prior to usage.  
LPS-induced peritoneal inflammation was carried out as previously described (Ferrante et al., 
2006). Briefly, mice were injected intraperitoneally (ip) with different doses of NT8 for 
various times before or after LPS challenge.    PBS was injected as control and after 24 h, 
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the animals were euthanized and peritoneal cavity washout was performed.  The cavity was 
first injected with 2 ml of HBSS and after mixing, 1 ml of the exudates was collected.  The 
number of leukocytes was then determined by a combination of performing a cell count in a 
haemocytometer and differential count on Giemsa stained smears of the cell exudates.   
 
Slides of cellular infiltrates were prepared by centrifugation of the cells collected from the 
washout (vehicle- 200 µl or LPS challenged-100 µl) and fixed with a drop of methanol 




All data were presented as the mean ± standard error of the mean (SEM) unless stated 
otherwise.  Statistical significance was assessed using analysis of variance (ANOVA).   
Values were considered statistically significant when p<0.05.  All statistical analyses were 
performed using Graphpad Instat software or Graphpad Prism software. For any issues 
regarding statistics which were beyond the experience of the Department stataticians from the 





































For the past decades, there has been a major interest in using anti-malarials such as 
chloroquine and hydroxychloroquine as anti-inflammatory agents.  Clinically, the use of 
these drugs in rheumatoid arthritis and lupus erythmatosus patients can be traced back to the 
mid 1950s  (Page, 1951; Scherbel et al., 1957; Morand et al., 1992).  Even with its 
popularity and demand, there is still a need for the development of new drugs, mainly, due to 
the emergence of CQ resistance strains of malarial parasites and side effects reported from 
patients taking these drugs (Blair et al., 2006; Dittrich et al., 2005; Djimde et al., 2001; Stein 
et al., 2000; Veinot et al., 1998; Scherbel et al., 1958).   
 
A major effort has been made in the synthesis of new compounds with greater anti-malarial or 
anti-inflammatory properties.  The main approach is by either altering the side chain that is 
linked to the 4-amino-7-chloroquinoline ring structre or by altering the ring structure itself 
so to reduce its cytotoxicity (Ridley et al., 1996; Madrid et al., 2004; Solomon et al., 2007).  
HCQ, a CQ derivative different from CQ only by an additional hydroxyl group, has been 
found to be less toxic due to the fact that a lower dosage is required during treatment, 
indicating that it is a more effective compound compared to CQ (Mackenzie, 1983).   
 
Both CQ and HCQ tend to accumulate quickly in the acidic compartments reaching a steady 
state after 60 min at 37 °C due to the fact that they are weak bases (Raghoebar et al., 1986).  
The accumulation of the two compounds leads to an increase in pH within intracellular 
vacuoles, altering the behavior of lysosomes and interfering with the vesicle fusion process so 
that cells do not undergo normal pinocytosis, exoplasmosis and phagolysosomal fusion 
(Gonzalez-Noriega et al., 1980; Tietze et al., 1980).  Moreover, the quinoline ring structure 
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allows CQ to pass through the lipid bilayer into the cell, and once inside the cell protonation 
occurs allowing the diprotonated form to pass back through the lipid layer (Naisbitt et al., 
1997). 
 
It has also been well studied that CQ and HCQ can form a π- π stacking interaction with the 
porphryin system of FE(III)FPIX complex so that the complex is no longer toxic to the 
parasite in the presence of protein (Egan, 2005; Fitch, 1983; Stocks et al., 2002).  In addition 
to that, they have also been found to exhibit an inhib tory effect on some key neutrophil 
functions such as a adherence, respiratory burst, phagocytosis and cytokine production 
(Ferrante et al., 1986; Hurst et al., 1987, 1988; Jones and Jayson, 1984; Karres et al., 1998) as 
well as the antigen processing and presentation processes in macrophages and dendritic cells 
as discussed in detail in Chapter 1 (Fox, 1993).    
 
In an attempt to improve the therapeutic potential of quinoline based drugs we aimed to 
synthesize a group of novel quinoline-fatty acid based compounds (Scheme 3.1). The 
employment of a fatty acid side chain, is expected to makes the compound more soluble and 
facilitate their uptake by cells.  After a series of chemical syntheses and analyses, as 
mentioned in Chapter 2.2-4, 13 compounds were succesfully generated.  All these 
compounds contained fatty acid side chains of different lengths/ saturated and unsaturated 
(Figure 3.1-3.14).  It is expected that these compounds will lead to some unique biological 








All the NT compounds were synthesized from the starting 4-amino-7-chloroquinoline. 
Different fatty chains (length and saturation) were attached to the amine through a coupling 
reaction with the appropriate fatty acid chloride resulting in 13 quinoline fatty acid conjugates, 
(Figures 3.1-14). All the compounds were fully characterized by 1H, 13C NMR, GCMS and 
high resolution MS with purities greater than 98 %. In general, the coupling reaction worked 
well but yields were not optimized as the desired conjugate was easily purified by column 
chromatography thus eluting ahead of the starting amine. The conjugates synthesised were all 
stable at room temperature and there was no evidence of oxidation which was seen with 
greater unsaturation of the fatty chain (not presented). Overall the NMR data showed that all 



















































Figure 3.1 Chemical structure of the synthesised NT0 compound.  Synthesis of NT0 was 
followed as previously published (Vippagunta et al., 1999).  An initial confirmation of the 
yielded product was by TLC and later by 1H and 13C NMR. The chemical name assigned for 
this compound was 4-amino-7-chloroquinoline.  Yield: 58 %; melting point: 147-148 °C; 
molecular weight: 179.6262.  
 
NMR Data 
The compound was characterised by 1H and 13C NMR and all spectra agreed with those 
previously published (Vippagunta et al., 1999). It was used without further purification.   
 
















Figure 3.2 Chemical structure of the synthesized NT1 compound.  The crude product 
was obtained by adding decanoyl chloride to the solution of 4-amino-7-chloroquinoline as 
previously described above in section 2.3.  An initial confirmation of the yielded product 
was by TLC and later by 1H and 13C NMR.  The chemical name assigned for this compound 




1H NMR (CHCl3-7.26 ppm): δ 8.76 (1H, d), 8.45 (1H, NH-bs), 8.2 (1H, d), 8.05 (1H, d), 7.85 
(1H, d), 7.45 (1H, dd), 2.55 (t), 1.80 (m), 1.30 (bs), 0.85 (bt).  
 
13C NMR (CDCl3-77 ppm): 172.45 (CO), 151.71, 148.73, 141.16, 135.55, 128.71, 127.21, 
121.31, 118.64, 111.61 (9 aromatics, 1 carbonyl = 10 C), 37.82, 33.83, 31.78, 29.38, 29.32, 
29.19, 25.41, 22.60, 14.04 (9 aliphatic carbons).  
 












Figure 3.3 Chemical structure of the synthesized NT2 compound.  The crude product 
was obtained by adding stearoyl chloride to the solution of 4-amino-7-chloroquinoline as 
previously described above in section 1.3.  An initial confirmation of the yielded product 
was by TLC and later by 1H and 13C NMR.  The chemical name assigned for this compound 
was 4-steramido-7-chloroquinoline.  Yield: 14 %; melting point: 94-95 °C; molecular weight: 
446.0882.   
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.70 (1H, bs, NH), 8.40 (1H, s), 8.20 (1H, d), 7.95 (1H, s), 
7.75 (1H, d), 7.40 (1H, dd), 2.55 (t), 1.75 (m), 1.25 (bs), 0.89 (bt).  
 
13C NMR (CDCl3-77 ppm): 172.25 (CO), 151.69, 148.60, 141.08, 135.60, 128.70, 127.27, 
121.00, 118.44, 111.39 (9 aromatics, 1 carbonyl = 10 C), 37.90, 31.89, 29.66, 29.62, 29.58, 
29.44, 29.32, 29.21, 25.40, 22.65, 14.08 (1 aliphatc resonances for 17 carbons). 
  












Figure 3.4 Chemical structure of the synthesized NT3 compound.  The crude product 
was obtained by adding undecenoyl chloride to the solution of 4-amino-7-chloroquinoline as 
previously described above in section 1.3.  An initial confirmation of the yielded product 
was by TLC and later by 1H and 13C NMR.  The chemical name assigned for this compound 
was 4-undecenamido-7-chloroquinoline. Yield: 28 %; melting point: 87-88 °C; molecular 
weight: 345.8862.  
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.78 (1H, d), 8.26 (1H, bs), 8.17 (1H, d), 8.05 (1H, d), 7.76 
(1H, d), 7.41 (1H, dd), 5.79 (1H, m), 5.01-4.91 (2H, m), 2.55 (2H, t), 2.00 (2H, m), 1.78 (2H, 
m), 1.36 (10H, m).   
 
13C NMR (CDCl3-77 ppm): 172.20 (CO), 152.11, 149.14, 140.62, 139.0 , 135.33, 129.13, 
127.16, 120.91, 118.61, 114.15, 111.66 (9 aromatics, 1 carbonyl, 2 alkene = 12 C), 37.82, 
33.69, 29.22, 29.22, 29.15, 28.97, 28.79, 25.37 (8 aliphatic carbons).  
 











Figure 3.5 Chemical structure of the synthesized NT4 compound.  The crude product 
was obtained by adding hexanoyl chloride (caproyl chloride) to the solution of 
4-amino-7-chloroquinoline as previously described above in section 1.3.  An initial 
confirmation of the yielded product was by TLC and later by 1H and 13C NMR..  The 
chemical name assigned for this compound was 4-hexanamido-7-chloroquinoline.  Yield: 39 
%; melting point: 119-120 °C; molecular weight: 277.7692.   
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.72 (1H, bd), 8.55 (1H, bs), 8.12 (1H, d), 8.00 (1H, d), 7.80 
(1H, d), 7.38 (1H, dd), 2.50 (2H, t), 1.75 (2H, m), 1.31 (2H, m), 0.89 (3H, bt).   
 
13C NMR (CDCl3-77 ppm): 172.48 (CO), 151.87, 148.99, 140.91, 135.42, 128.84, 127.14, 
121.29, 118.80, 111.91 (9 aromatics, 1 carbonyl = 10C), 37.70, 31.30, 25.08, 22.32, 13.83 (5 
aliphatic carbons).  
 












Figure 3.6 Chemical structure of the synthesized NT5 compound.  The crude product 
was obtained by adding butyroyl chloride (tetranoyl chloride) to the solution of 
4-amino-7-chloroquinoline as previously described above in section 1.3.  An initial 
confirmation of the yielded product was by TLC and later by 1H and 13C NMR.. The chemical 
name assigned for this compound was 4-butanamido-7-chloroquinoline. Yield 46 %; melting 
point: 126-127 °C; molecular weight: 249.7161.  
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.70 (2H, bd), 8.10 (1H, d), 7.95 (1H, d), 7.82 (1H, d), 7.35 
(1H, dd), 2.52 (2H, t), 1.78 (2H, sext), 1.00 (3H, t).  
 
13C NMR (CDCl3-77 ppm): 172.44 (CO), 151.58, 148.69, 141.22, 135.5 , 128.50, 127.14, 
121.55, 118.83, 111.92 (9 aromatics, 1 carbonyl = 10 C), 39.50, 18.85, 13.63.  
 













Figure 3.7 Chemical structure of the synthesized NT6 compound.  The crude product 
was obtained by adding octadecenoyl chloride (85 %) (oleoyl chloride) to the solution of 
4-amino-7-chloroquinoline as previously described above in section 1.3.  An initial 
confirmation of the yielded product was by TLC and later by 1H and 13C NMR. The chemical 
name assigned for this compound was 4-octadec-9-en-amido-7-chloroquinoline.  Yield: 23 
%, oil; molecular weight: 444.0723. 
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.80 (1H, d), 8.25 (1H, d), 8.20 (1H, bs), 8.08 (1H, s), 7.80 
(1H, d), 5.35 (2H, m), 7.48, 2.58 (2H, t), 2.05 (m), 1.81 (m), 1.30 (bs), 0.90 (3H, bt).   
 
13C NMR (CDCl3-77 ppm): 172.12 (CO), 151.93, 148.85, 140.91, 135.54, 130.06, 129.60, 
128.97, 127.29, 120.91, 118.47, 111.41 (9 aromatics, 1 carbonyl, 2 alkene = 12 C), 37.93, 
31.87, 29.73, 29.66, 29.48, 29.28, 29.23, 29.17, 29.07, 27.20, 27.12, 25.38, 22.64, 14.07. 
 












Figure 3.8 Chemical structure of the synthesized NT7 compound.  The crude product 
was obtained by adding propanoyl chloride to the solution of 4-amino-7-chloroquinoline as 
previously described above in section 1.3.  An initial confirmation of the yielded product 
was by TLC and later by 1H and 13C NMR. The chemical name assigned for this compound 
was 4-propanamido-7-chloroquinoline.  Yield: 53 %; melting point: 140-141 °C; molecular 
weight: 235.0638.   
 
NRM Data 
1H NMR (CHCl3-7.26 ppm): δ 8.78 (1H, d), 8.20 (1H, bs), 8.05 (1H, d), 7.78 (1H, d), 7.45 
(1H, dd), 2.59 (2H, q), 1.32 (3H, t).   
 
13C NMR (CDCl3-77 ppm): 172.67 (CO), 152.17, 149.11, 140.64, 135.39, 129.19, 127.24, 
120.76, 118.50, 111.45 (9 aromatics, 1 carbonyl = 10 C), 30.94, 9.39.  
 













Figure 3.9 Chemical structure of the synthesized NT8 compound.  The crude product 
was obtained by adding dodecanoyl chloride (lauroyl chloride) to the solution of 
4-amino-7-chloroquinoline as previously described above in section 1.3.  An initial 
confirmation of the yielded product was by TLC and later by 1H and 13C NMR. The chemical 
name assigned for this compound was 4-dodecanamido-7-chloroquinoline. Yield: 25 %; 
melting point: 78-79 °C; molecular weight: 361.9287.  
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.65 (2H, bs), 8.15 (1H, d), 7.90 (1H, s), 7.75 (1H, d), 7.30 
(1H, dd), 2.55 (t), 1.78 (m), 2.58 (2H, t), 1.30 (bs), 0.90 (t).   
 
13C NMR (CDCl3-77 ppm): 172.64 (CO), 151.03, 147.91, 141.61, 135.70, 127.81, 127.11, 
121.47, 118.38, 111.48 (9 aromatics, 1 carbonyl = 10 C), 37.69, 31.86, 29.63, 29.58, 29.47, 
29.39, 29.36, 29.29, 29.25, 25.42, 24.21, 22.64, 14.06.  
 












Figure 3.10 Chemical structure of the synthesized NT9 compound.  The crude product 
was obtained by adding nonadecanoyl chloride to the solution of 4-amino-7-chloroquinoline 
as previously described above in section 1.3.  An initial confirmation of the yielded product 
was by TLC and later by 1H and 13C NMR. The chemical name assigned for this compound 
was 4-nonadecanamido-7-chloroquinoline.  Yield: 16 %; melting point: 120-121 °C; 
molecular weight: 460.1148.   
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.78 (1H, bs), 8.22 (2H, bs), 8.06 (1H, s), 7.80 (1H, d), 7.45 
(1H, dd), 2.60 (t), 1.80 (dt), 1.30 (bs), 0.90 (bt).   
 
13C NMR (CDCl3-77 ppm): 172.18 (CO), 152.00, 149.00, 140.82, 135.48, 129.07, 127.27, 
120.91, 118.49, 111.50 (9 aromatics, 1 carbonyl = 10 C), 37.93, 31.89, 29.66, 29.62, 29.57, 
29.44, 29.32, 29.21, 25.41, 22.65, 14.08 (18 aliphat c c rbons).  
 












Figure 3.11 Chemical structure of the synthesized NT10 compound.  The crude product 
was obtained by adding pivalolyl chloride to the soluti n of 4-amino-7-chloroquinoline as 
previously described above in section 1.3.  An initial confirmation of the yielded product 
was by TLC and later by 1H and 13C NMR. The chemical name assigned for this compound 
was 4-pivalamido-7-chloroquinoline. Yield: 27 %; melting point: 150-151 °C; molecular 
weight: 263.7426.   
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.80 (1H, bs), 8.25 (2H, m), 8.07 (1H, s), 7.65 (1H, bd), 7.50 
(1H, d), 1.44 (9H, s).   
 
13C NMR (CDCl3-77 ppm): 177.00, 151.89, 148.75, 140.84, 135.47, 129.14, 127.41, 120.36, 
118.76, 111.31 (9 aromatics, 1 carbonyl = 10 C), 40.52, 27.56 (5 aliphatic carbons, 4 in the 
tert-butyl group at 27.56).  
 












Figure 3.12 Chemical structure of the synthesized NT11 compound.  The crude product 
was obtained by adding pentanoyl chloride (valeroyl chloride) to the solution of 
4-amino-7-chloroquinoline as previously described above in section 1.3.  An initial 
confirmation of the yielded product was by TLC and later by 1H and 13C NMR. The chemical 
name assigned for this compound was 4-pentaamido-7-chloroquinoline. Yield: 28 %; melting 
point: 139-140 °C; molecular weight: 263.7426. 
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.78 (1H, bs), 8.40 (1H, bs), 8.19 (1H, d), 8.03 (1H, bs), 7.82 
(1H, dd), 2.56 (2H, t), 1.76 (2H, pt), 1.41 (2H, st), 0.95 (3H, s).   
 
13C NMR (CDCl3-77 ppm): 172.38 (CO), 151.66, 148.68, 141.11, 135.56, 128.65, 127.22, 
121.26, 118.65, 111.68 (9 aromatics, 1 carbonyl = 10 C), 37.54, 27.43, 22.30, 13.74 (4 
aliphatic carbons).  
 












Figure 3.13 Chemical structure of the synthesized NT12 compound.  The crude product 
was obtained by adding nonanoyl chloride (pelargonoyl chloride) to the solution of 
4-amino-7-chloroquinoline as previously described above in section 1.3.  Nonanoyl chloride 
was prepared from the treatment of nonanoic acid with SOCl2 at 60 °C for 15 h.  An initial 
confirmation of the yielded product was by TLC and later by 1H and 13C NMR. The chemical 
name assigned for this compound was 4-nonanamido-7-chloroquinoline.  Yield: 28 %; 
melting point: 100-101 °C; molecular weight: 319.8490.  
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.74 (1H, bs), 8.58 (1H, bs), 8.18 (1H, d), 8.00 (1H, bs), 7.85 
(1H, d), 7.39 (1H, dd), 2.55 2H, t), 1.75 (2H, quin), 1.30 (1H, bs), 0.88 (3H, s).   
 
13C NMR (CDCl3-77 ppm): 172.50 (CO), 151.59, 148.66, 141.24, 135.61, 128.59, 127.22, 
121.40, 118.72, 111.75 (9 aromatics, 1 carbonyl = 10 C), 37.81, 31.73, 29.26, 29.19, 29.07, 
25.41, 22.56, 14.02 (8 aliphatic carbons).  
 











Figure 3.14 Chemical structure of the synthesized NT13 compound.  The crude product 
was obtained by adding 11-eicosenoyl chloride to the solution of 4-amino-7-chloroquinoline 
as previously described above in section 1.3.  An initial confirmation of the yielded product 
was by TLC and later by 1H and 13C NMR.  The chemical name assigned for this compound 
was 4-eicos-11-en-amido-7-chloroquinoline. Yield: 30 %; melting point: 28-29 °C; molecular 
weight: 472.1255.   
 
NMR Data 
1H NMR (CHCl3-7.26 ppm): δ 8.75 (1H, bd), 8.38 (1H, bs), 8.19 (1H, d), 8.05 (1H, bs), 7.80 
(1H, d), 7.40 (1H, d), 5.35 (2H, bm), 2.55 (2H, t), 2.00 (3H bm), 1.76 (2H, quin), 1.31 (25H, 
bs), 0.95 (3H, s).   
 
13C NMR (CDCl3-77 ppm): 172.27 (CO), 151.93, 148.98, 140.87, 135.47, 129.93, 129.73, 
128.97, 127.20, 121.07, 118.64, 111.67 (9 aromatics, 1 carbonyl, 2alkene = 12 C), 37.85, 
31.85, 29.72, 29.47, 29.40, 29.32, 29.27, 29.22, 27.17, 25.41, 22.63, 14.06 (12 aliphatic 
resonances for 17 carbons).  
 
























































































Figure 3.5.1 NMR data for NT4. 
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Figure 3.8.1 NMR data for NT7. 
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Figure 3.13.1 NMR data for NT12. 
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An aromatic base quinoline structure (NT0) with a 7-chloro group has been synthesized 
according to Vippagunta et al., (1999).  From that base structure, thirteen different NT 
compounds have been synthesised each bearing a different fatty acid side chain attached to 
the NH2 group at C4 of the aromatic ring.  All fatty acid chains posse different lengths and 
degrees of saturation.  Thirteen compounds with different carbon chain length of 3 to 20 
carbons were prepared in a yield ranging from 14-58 %.  They can be further subdivided into 
the saturated group: NT1, 2, 4, 5, 7, 8, 9, 10, 11 and 12 and the unsaturated group: NT 3, 6 
and 13.  Of all the 13 compound synthesised, only one compound displayed an oil 
appearance (NT6), which is different to the other compound that exists as powder form.  
Finally, it is also observed that compounds with a longer side chain tend to be less soluble 










































Neutrophil migration and accumulation at inflammatory foci is upregulated by their ability to 
adhere to the endothelium as discussed in Chapter 1.4.1-2.  The process involves receptor 
ligand interaction.  An initial loose-rolling adhesion of the neutrophils to the receptors on the 
endothelial cells involves the L-selectins on the leukocytes and the E- and P-selectins on the 
endothelial cell (Ferrante, 2005).  This then results in the activation of the ICAM on the 
endothelial cell as well as the integrins (CD11a, CD11b and CD11c/CD18) on neutrophils 
thereby promoting firm adhesion (Witko-Sarsat et al., 2000; Ferrante, 2005).   Neutrophil 
adherence is also known to involve other receptors such as the Fc receptors, and the adenosine 
receptors depending on the stimulus they encounter (Witko-Sarsat et al., 2000; Lantz et al., 
1994; Cronstein et al., 1992).  Interestingly, Cronstein et al., (1992) found that engagement 
of adenosine A1 receptors promoted neutrophil adherence to the endothelium whereas the 
engagement of A2 receptors resulted in the inhibition of neutrophil adherence to fibrinogen 
coated surfaces. As you have an interest in integrins eg CR3, CD11b/CD18, you should 
mention and reference these. 
          
During inflammation inflammatory mediators are generat d which bind to neutrophils and 
regulate their ability to adhere to the endothelium. These include cytokines such as TNF and 
GM-CSF and eicosanoids such as LTB4 (refs)         
 
Previous studies have demonstrated that a series of quinoline based compounds including 
quinine, quinacrine, CQ, pryimethamine and melfoquine inhibited neutrophil adherence 
(Ferrante et al., 1986).  The aim of the present studies was to examine the effects of adding a 
fatty acid to the side chain of the quinoline structure on neutrophil adherence with particular 
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emphasis on the role of the structure of the fatty cid used.   
 
4.2 The effect of NT compounds on adherence induced by TNF rich medium 
(TNF-RM)  
 
To enable us to gain an understanding of the activity conferred by altering the fatty acid side 
chain on the quinoline group, we examined all 13 comp unds for their ability to alter the 
adherence of stimulated neutrophil activity.  A previously established strong inducer of 
neutrophil adherence was used, medium derived from S.aureus stimulated PBMC cultures 
which has high TNF activity (TNF-RM) (Bates t al., 1991).   
  
Neutrophils (5 x 105/ml) were pre-treated with NT compounds, CQ or HCQ for 1 h and then 
stimulated with TNF-RM.  After 30 min, the ability of neutrophils to adhere to plasma 
coated plastic surfaces was determined. The compounds were examined at three 
concentrations, 5, 20 and 50 µM.  The results showed that the compounds varied in their 
ability to inhibit neutrophil adherence (Figure 4.1-16, Table 4.1).  NT1, NT3 and NT8 were 
the most active.  Interestingly neither CQ nor HCQ were active at these concentrations.  At 
the 50 µM concentration significant inhibition was seen with NT2, NT5, NT7, NT10 NT11 
and NT12 (Table 4.2).   
 
Under the concentrations tested, the cells showed a viability of > 99 % as judged by their 
ability to exclude trypan blue dye and the finding that these have no inhibitory effects at 50 
µM for all compounds on basal neutrophil adherence (Table 4.3).  The most effective was 
NT8, a compound with a quinoline base attached to a12 carbon (lauric acid) side chain, 
inhibiting at 20 µM, followed by NT1, a compound with a 10 carbon fatty chain inhibiting at 
137 
 
20-50 µM, and NT3, containing an 11 carbon unsaturated fatty chain which inhibited at 20-50 
µM. Interestingly, all these three compounds consist of a medium length fatty acid side chain 
of 10-12 carbons which has been shown previously with structurally similar 
4-aminoquinolines tends to be an effective anti-malari l agent (Krogstad et al., 1988; Ridley 
et al., 1996).  
 
Of all the compounds tested, only NT1, NT3 and NT8 exert a concentration dependent 
inhibitory effect on adherence reaching a 62, 59 and 85 % inhibition respectively at 50 µM 


































Figure 4.1 Effect of NT0 (C9H8ClN2) on neutrohil adherence.  Neutrophils (5 x 10
6/ml) 
were pre-treated with varying concentrations of NT0 and then stimulated by adding 20 µl of 
TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose Bengal and 
reading the plates at OD 570 nm.  The data are present d as ± SEM of 4 experiments, each 
conducted with neutrophils from a different donor.  The basal and stimulated OD 570 nm 





















Figure 4.2 Effect of NT1 (C19H26ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT1 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.    The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 
stimulated OD 570 nm values ± SEM were 0.08 ± 0.00 and 0.41 ± 0.08 respectively.  
Significance of difference between control and NT1 treated cells: *p<0.01 (Tukey-Kramer 





















Figure 4.3 Effect of NT2 (C27H42ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT2 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 
stimulated OD 570 nm values ± SEM were 0.08 ± 0.01 and 0.44 ± 0.10 respectively.  
Significance of difference between control and NT2 treated cells: *p<0.01(Tukey-Kramer 



















Figure 4.4 Effect of NT3 (C20H26ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT3 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 
stimulated OD 570 nm values ± SEM were 0.09 ± 0.01 and 0.33 ± 0.11 respectively.  
Significance of difference between control and NT3 (20 µM) treated cells: *p<0.01; between 




















Figure 4.5 Effect of NT4 (C15H18ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT4 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 
stimulated OD 570 nm values ± SEM were 0.08 ± 0.01 and 0.40 ± 0.11 respectively.   
Significance of difference between control and NT4 (50 µM) treated cells: *p<0.01 




















Figure 4.6 Effect of NT5 (C13H14ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT5 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 
stimulated OD 570 nm values ± SEM were 0.09 ± 0.00 and 0.42 ± 0.10 respectively.  
Significance of difference between control and NT5 (50 µM) treated cells: *p<0.05 




















Figure 4.7 Effect of NT6 (C27H40ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT6 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 





















Figure 4.8 Effect of NT7 (C12H12ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT7 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 
stimulated OD 570 nm values ± SEM were 0.09 ± 0.01 and 0.34 ± 0.10 respectively.  
Significance of difference between control and NT7 (50 µM) treated cells: *p<0.05 





















Figure 4.9 Effect of NT8 (C21H30ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT8 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The data are presented 
as ± SEM of 4 experiments.  The basal and stimulated OD 570 nm values ± SEM were 0.07 
± 0.01 and 0.41 ± 0.10 respectively.  Significance of difference between control and NT8 (20 
µM) treated cells: *p<0.01; between control and NT8 (50 µM) treated cells: **p<0.001 



















Figure 4.10 Effect of NT9 (C28H44ClN2O) on neutropihl adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT9 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 






















Figure 4.11 Effect of NT10 (C14H16ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of N10 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 
stimulated OD 570 nm values ± SEM were 0.09 ± 0.01 and 0.39 ± 0.15 respectively.  
Significance of difference between control and NT10 (50 µM) treated cells: *p<0.001 




















Figure 4.12 Effect of NT11 (C14H16ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT11 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 
stimulated OD 570 nm values ± SEM were 0.09 ± 0.08 and 0.46 ± 0.13 respectively.  
Significance of difference between control and NT11 (50 µM) treated cells: * p<0.05 




















Figure 4.13 Effect of NT12 (C18H24ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT12 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 
stimulated OD 570 nm values ± SEM were 0.09 ± 0.01 and 0.28 ± 0.09 respectively.  
Significance of difference between control and N12 (50 µM) treated cells: *p<0.01 





















Figure 4.14 Effect of NT13 (C29H44ClN2O) on neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT13 and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 





















Figure 4.15 Effect of CQ (C18H26ClN3·2H3PO4)on neutrophil adherence.  Neutrophils (5 
x 106/ml) were pre-treated with varying concentrations of CQ and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 























Figure 4.16 Effect of HCQ (C18H26ClN3O·H2SO4) on adherence assay.  Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of HCQ and then stimulated by adding 
20 µl of TNF-RM (39 ng/ml).  Adherence was measured by staining the cells with Rose 
Bengal and reading the plates at OD 570 nm.  The data are presented as ± SEM of 4 
experiments, each conducted with neutrophils from a different donor.  The basal and 







The IC50 values calculated for each compound were based on the minimal 
concentration required to reach a 50 percent inhibition from Figure 4.1-16.  The 
values generated were based on adherence stimulated with TNF-RM from 4 
experiments, each conducted with neutrophils from a different donor. 
Table 4.1 Summary effects of 4-amino-7-chloroquinoline based compounds on neutrophil 
adherence assay as shown by IC50 comparisons.   
Compounds 
 



























The percentage inhibition calculated for each compound (50 µM) was based on the 
values generated from adherence assay stimulated wih TNF-RM from 4 experiments, 
each conducted with neutrophils from a different donor. 
 
Table 4.2 Summary of the inhibitory effects of 4-amino-7-chloroquinoline based compounds 





























The percentage of control calculated for each compound (50 µM) was based on the 
basal adhesion values of compound treated cells divided by basal adhesion values of 
vehicle.  Data obtained from 4 experiments, each conducted with neutrophils from a 
different donor. 
 
Table 4.3 Summary of the effects of 4-amino-7-chloroquinoline based compounds on 
neutrophil basal adherence at 50 µM concentration.   
Compounds 
 
% of control basal values ± SEM 
0 
 
128 ± 6.15 
1 106 ± 1.56 
2 106 ± 7.49 
3 130 ± 18.53 
4 129 ± 12.96 
5 120 ± 13.92 
6 107 ± 2.46 
7 111 ± 3.92 
8 104 ± 3.24 
9 123 ± 17.73 
10 106 ± 4.78 
11 100 ± 3.89 
12 107 ± 8.99 
13 98 ± 8.45 
CQ 106 ± 4.58 






4.3 Comparison effects of NT8 to NT0 and lauric acid. 
 
Since NT8 is a compound comprised of a 4-amino-7-chloroquinoline base (NT0) attached to a 
lauric acid side chain (12 carbon fatty acid), these two base compounds were also examined 
for effects on the neutrophil adherence response.  Short, medium and long chain fatty acids 
of different degree of unsaturation have been found to have a range of effects on neutrophil 
functions (Naccache t al., 1984; Wanten et al., 2002).  Naccache t al., (1984) found that 
lauric acid stimulated rabbit neutrophil aggregation induced by fMLP.  Moreover Wanten et
al., (2002) found that medium chain saturated fatty acids including lauric acid, induced 
oxygen radical production in neutrophils and that a mixture of long chain/medium chain 
triglyceride or pure medium chain triglycerides enha cesd neutrophil β2 integin expression, 
adhesion and degranulation.   
 
The neutrophils were treated with either NT8, lauric acid or NT8 and after (?) were stimulated 
with the TNF-RM. The adhesion response was measured. Ther results showed that at 
concentrations up to 50 µM, NT8 but neither the base compound NT0 nor lauric acid 
inhibited the neutrophil adherence response. Thus tee inhibitory effects of NT8 are a unique 
property of this compound (Figure 4.17).  
 
4.4 Effect of NT8 on TNF induced neutrophil adherence 
 
In another set of studies, recombinant TNF was used to stimulate neutrophil adherence. 
Similarly, the inhibitory effect of NT8 was also observed when TNF was used as a stimulus 



















Figure 4.17 Comparison of effects of NT8, NT0 and lauric acid on TNF-RM stimulated  
neutrophil adherence.  Neutrophils (5 x 106/ml) were pre-treated as above with 20 µM of 
NT8, NT0 or lauric acid and then tested for adherence i  response to TNF-RM.  The data are 
expressed as % of the control responses and presented as mean ± SEM of 3 experiments, each 
conducted with neutrophils from a different donor.  Significance of difference between 
control and TNF-RM + NT8: *p<0.05; between control and TNF-RM + NT8: *p<0.05 


















Figure 4.18 Effect of NT8 on TNF-mediated neutrophil adherence.    Neutrophils (5 x 
106/ml) were pre-treated with varying concentrations of NT8 and then stimulated by adding 
20 µl of recombinant TNF (100 U/ml).    Adherence was measured by staining the cells 
with Rose Bengal and reading the plates at OD 570 nm.  Results represent the mean data ± 
SEM of 3 experiments, each conducted with neutrophils from a different donor.  The basal 
and stimulated OD 570 nm values ± SEM were 0.08 ± 0.01 and 0.27 ± 0.05 respectively.  
Significance of difference between control and NT8 (20 µM) treated cells; between control 





4.5  Summary 
 
We have now demonstrated that these new quinoline compounds have biological effects.  
Exposure of neutrophils to these compounds resulted in a decrease in the ability of neutrophils 
to respond to TNF-induced adherence.  The type of fatty acid added to the quinoline side 
chain made a significant difference to this activity, which ranged from no effect to a highly 
significant effect over a concentration range of 5-50 µM (Table 4.1).  The most effective of 
the 13 compounds were NT1, NT3 and NT8.  Since NT8 had the greatest inhibitory effect, 
further studies were conducted with the compound.   
 
The data demonstrated that the activity of NT8 was due to the new structure synthesised as 
neither of the individual components, NT0 or lauric a id showed inhibitory activity.  The 
inhibitory effects were seen when TNF-RM was used as the stimulator as well as recombinant 
TNF.  However, the effects of NT8 on neutrophils stimulated with recombinant TNF were 
more pronounced.  This suggested that NT8 may have preference for TNF-induced 
responses.  Under the different concentrations usedin the experiments, the cells maintained 





















5.0 CHAPTER 5 INHIBITORY EFFECTS OF NT8 ON TNF-INDUCED 
NEUTROPHIL RESPIRATORY BURST , MIGRATION INHIBITION AND 














Having established that NT8 was the most effective compound in inhibiting neutrophil 
adhesion (Chapter 4), we sought to gain a better understanding of the effects of NT8 on other 
neutrophil functions relevant to the inflammatory response, the oxygen-dependent respiratory 
burst, migration inhibition and cytokine production.  Previous studies using quinoline 
derived inhibitors have found that primaquine and quinacrine inhibited the fMLP induced 
superoxide production at a concentration rage of 50-250 µM (Neal et al., 1987).  
Chloroquine, under the same condition, was only affective at 1 mM (Neal et al., 1987).  
Moreover Hurst et al., (1988) reported that both CQ and HCQ showed an inhibitory effect on 
zymosan-, PMA- and fluoride-induced superoxide generation in neutrophil at 100 µM.  The 
inhibitory effect of CQ was extended to chemotaxis.  Kharazmi et al., (1983) found that CQ 
inhibited chemotaxis at concentrations attained in clinical situations.   
 
Neutrophils are also known to produce cytokines that are important in activating other cell 
types.  A wide range of cytokines such as IL-1, TNF, IFN-γ, IL-8, etc, have been shown to be 
produced by neutrophils. In this manner, neutrophils may also control the adaptive immune 
response. Because of the importance of TNF in the inflammatory mediator network, it was the 
aim of this studt to examine the effects of NT8 on TNF-induced respiratory burst, cell 







5.2 Effect of NT8 on the oxygen-dependent respiratory burst 
 
It is widely accepted that the respiratory burst can be measured by the lucigenin-dependent 
chemiluminescence assay which measures reactive oxygen species (ROS), in particular 
superoxide (Alves et al., 2003).  This assay method was used to examine the ffects of NT8 
on the respiratory burst in neutrophils as described n Chapter 2.11.3.   
 
The cells were pre-treated with either 20 or 50 µM of NT8 for 1 h and then stimulated with 
TNF-RM.  The resultant chemiluminescence produced was measured.  The data presented 
in Figure 5.1 and 5.2 show that TNF-RM induced a marked respiratory burst (6 fold increase 
in chemiluminescence).  NT8 had no direct effect on he response but inhibited the ability of 
TNF-RM to induce a response, by approximately 50 % at 50 µM concentration.  No effect 
was seen at 20 µM.  The kinetics of the chemiluminescence response is presented in Figure 
5.2.  The data demonstrates that NT8 caused both a delay in response and a reduction in 
peak rate of chemiluminescence production at 50 µM.   
         
5.3 The effects of NT0 and lauric acid on the neutrophil respiratory burst 
 
To see if the activity seen at 50 µM of NT8 was due to the unique structure of the generated 
molecule, the effects of the individual components, NT0 and lauric acid on neutrophil 
respiratory burst was examined.  The data showed that w ile neutrophils treated with NT8 
were not significantly depressed in their response to TNF-RM, neither NT0 nor lauric acid 














Figure 5.1 Effect of NT8 on the oxygen-dependent respiratory burst induced by 
TNF-RM.  Neutrophils (5 x 106/ml) were pre-treated with either 20 µM (□) or 50 µM (■) 
NT8 for 1 h and then stimulated by adding 100 µl of TNF-RM (39 ng/ml).  The resultant 
chemiluminescence was then measured.  The data represent initial peak rates of 
chemiluminescence and are presented as the mean ± SEM of 3 experiments, each conducted 
with neutrophils from a different donor.  Significance of difference between control and 
TNF-RM treated cells:  **p<0.01 and between stimulated and stimulated cells pretreated 





















Figure 5.2 Effect of NT8 on the kinetics of TNF-RM induced change in 
chemiluminescence.  The results are a representative experiment of data presented in Figure 
5.1.  Neutrophils + diluents (■), neutrophils + TNF-RM (▲), neutrophils + NT8 (Δ) and 























Figure 5.3 Effect of NT0 and lauric acid on the neutropil respiratory burst.  Neutrophils 
(5 x 106/ml) were pre-treated with 50 µM of NT8, NT0 or lauric acid for 1 h and then 
stimulated by adding 100 µl of TNF-RM (39 ng/ml) and the resultant chemiluminescence 
measured.  The data represent initial peak rates of chemiluminescence and are presented as 
the mean ± SEM of 3 experiments, each conducted with neutrophils from a different donor.  
Significance of difference between TNF-RM and TNF-RM + NT8 treated group: *p<0.05 






5.4 The effect of NT8 on the respiratory burst induced by recombinant TNF 
 
While the TNF-RM represents a medium culture that mimics cytokine combination most 
likely to be found in bacteria-induced inflammation, the modulatory effects of NT8 can be 
better defined using TNF.  In these experiments the neutrophils were pre-treated with 20 or 
50 µM of NT8 and then stimulated with recombinant TNF.  The results showed that TNF 
caused direct stimulation of the neutrophil respiratory burst of approximately 4 fold above the 
base activity (Figure 5.4, 5.5).  At 50 µM but not 20 µM, NT8 caused significant suppression 
of this response (Figure 5.4, 5.5).  Examination of kinetics of chemiluminescence produced 
showed that NT8 caused a delay in response and a decreas d peak initial rate (Figure 5.5).   
 
5.5 The effects of CQ and HCQ on the neutrophil respiratory burst response   
 
Since the basis for the use of NT8 compound is its relationship to CQ and HCQ as 
anti-inflammatory agents, we examined the effects of these agents on the neutrophil 
respiratory burst (chemiluminescence).  The results showed that neither CQ nor HCQ at 50 
µM significantly inhibited the TNF-induced neutrophil respiratory burst (Figure 5.6).  The 
kinetics of the responses are shown in Figure 5.7.  The kinetics of rates of 
chemiluminescence produced were also not affected by either CQ or HCQ. 























Figure 5.4 Effect of NT8 on TNF-induced chemiluminescence. Neutrophils (5 x 106/ml) 
were pre-treated with either 20 or 50 µM NT8 for 1 h and then stimulated by adding 100 µl of 
recombinant TNF (100 U/ml).  The resultant chemilumnescence was measured.  The data 
represent initial peak rates of chemiluminescence and are presented as the mean ± SEM of 3 
experiments, each conducted with neutrophils from a different donor.  Significance of 
difference between control and TNF treated cells:  **p<0.001 and between stimulated and 
























Figure 5.5 Effect of NT8 on the kinetics of TNF-induced change in chemiluminescence. 
The results are a representative experiment of data presented in Figure 5.4.  Neutrophils + 
diluents (■), neutrophils + TNF (▲), neutrophils + NT8 (Δ) and neutrophils + TNF + NT8 























Figure 5.6 Effect of CQ and HCQ on TNF-induced neurophil respiratory burst.  
Neutrophils (5 x 106/ml) were pre-treated with 50 µM of either CQ or HCQ for 1 h and then 
treated with 100 µl of TNF (100 U/ml).  The resultant chemiluminescence production was 
measured in a luminometer.  The data represent initial peak rates of chemiluminescence and 
are presented as the mean ± SEM of 4 experiments, each conducted with neutrophils from a 
























Figure 5.7 Effect of CQ and HCQ on the kinetics of TNF-induced change in 
chemiluminescence. The results are a representative experiment of data presented in Figure 
5.6.  Neutrophils + diluents (■), neutrophils + TNF (▲), neutrophil + CQ (□), neutrophil + 





5.6 Effect of NT8 on neutrophil random movement 
 
In our experiment, random migration was assessed using the agarose method described in 
Chapter 2.11.2.   Neutrophils were allowed to migrate across the agarose supplemented with 
heat inactived fetal calf serum.  Our results showed that treating neutrophils with either 20 or 
50 µM NT8 had no significant effect on random migration (Figure 5.8).  The base 
compounds NT0 and lauric acid as well as CQ showed no inhibitorys effect at 50 µM. 
 
5.7 Effect of NT8 on the neutrophil migration inhibiton induced by TNF 
 
Another major function of TNF is its ability to inhibit neutrophil migration (Ferrante et al., 
1988) which presumably represents a mean by which cells are retained at the inflammatory 
foci.  The effect of NT8 on TNF-induced migration inh bition was examined.  Neutrophils 
were treated with TNF (300 U) for 30 min and then examined for migration.  TNF inhibited 
random migration (Figure 5.9).  NT8 had no effect on the ability of TNF to induce migration 
inhibition at both 20 and 50 µM (Figure 5.9, 5.10).  TNF also inhibits the fMLP-induced 
chemotactic migration of neutrophils.  The effect of NT8 on this response was examined.  
The neutrophils were pre-treated with NT8 and then with TNF for 30 min prior to 
examination of chemtactic migration in response to fMLP.   The results showed that NT8 
had no significant effect on the ability of TNF to inhibit neutrophil migration induced by 
fMLP (Figure 5.9, 5.10).   
 
These results suggested that the cell migration inhibition properties of TNF were not affected 
by NT8.  Again demonstrating some selective effects of NT8 on the TNF-induced adherence 
response of neutrophils. 
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Figure 5.8 Comparison of effect of NT0, lauric acid and NT8 on neutrophil random 
migration.  Neutrophils (5 x 106/ml) were pre-treated with either lauric acid, NT0, NT8 or 
CQ at 50 µM for 1 h and then tested for random migration.  Data are expressed as the mean 
























Figure 5.9 Effect of NT8 on TNF-induced inhibition of neutrophil random migration.   
Neutrophils (5 x 106/ml) were pre-treated with NT8 at 20 or 50 µM for 1 h and then 
stimulated by adding 160 µl of TNF (300 U/ml) for 30 min.  The random migration was then 
measured.  Data are expressed as % of control migration ± SEM of 3 experiments, each 
conducted with neutrophils from a different donor.  Significance of difference between 
control and TNF treated groups with and without the NT8 treatment: *p<0.05 (Tukey-Kramer 





















Figure 5.10 Effect of NT8 on TNF-induced inhibition of neutrophil chemotaxis.  
Neutrophils (5 x 106/ml) were pre-treated with NT8 at 20 or 50 µM for 1 h and then 
stimulated by adding 160 µl TNF (300 U/ml) for 30 min.  Migration in response to fMLP 
was then measured.  Data are expressed as mean ± SEM of 3 experiments, each conducted 
with neutrophils from a different donor.  Significance of difference between control and TNF 






5.8 Effect of NT8 on TNF-induced IL-1β and IL-8 production by neutrophils 
 
Cytokines play an important role as mediators of various inflammatory conditions.  There is 
little known however about the effects of chloroquine on neutrophil cytokine production.  
Previous reports have examined the effects of CQ on LPS induced production of cytokines in 
PBMCs.  The agents inhibited TNF-α, IL-1β and IL-6 production (Karres et al., 1998; Picot 
et al., 1993; Weber and Levitz, 2000).  Since our previous results showed that NT8 inhibits 
TNF induced adherence and chemiluminescence, the effects of NT8 on neutrophil function 
was extended to cytokine production.   
 
Neutrophils were pre-treated with NT8 and then stimulated with TNF.  After 2 h, the amount 
of IL-1β and IL-8 mRNA was measured using the methods describ d in Chapter 2.12.  The 
results showed that NT8 inhibited the production of b th IL-1β and IL-8 at 20 and 50 µM of 
the compound (Figure5.11, 5.12).  The individual comp unds NT0 and lauric acid did not 
suppress IL-1β and IL-8 mRNA production (Figure 5.13, 5.14). 
 
5.9 Effect of CQ on TNF-induced IL-1β and IL-8 production in neutrophils 
 
The effects of CQ on neutrophil cytokine production have not been previously investigated; 
therefore we also examined the effects.  Results showed that CQ did not cause a significant 






















Figure 5.11 Effect of NT8 on TNF-induced IL-1β mRNA in neutrophils.  Neutrophils (5 
x 106/ml) were pre-treated with either 20 or 50 µM of NT8 and then stimulated with TNF for 
1 h.  Levels of IL-1β were determined by quantitative real-time PCR.  The housekeeping 
gene GAPDH was used to normalize the samples.  Dataare expressed as amount of mRNA 
produced ± SEM from 3 experiments.  Significance of difference between control and TNF 
treated cells and between stimulated and stimulated cells pretreated with NT8: *p<0.05, 






















Figure 5.12 Effect of NT8 on TNF-induced IL-8 mRNA in neutrophils.  Neutrophils (5 x 
106/ml) were pre-treated with 20 or 50 µM of NT8 and then stimulated with TNF for 1 h.  
Levels of IL-8 were determined by quantitative real-time PCR.  The housekeeping gene 
GAPDH was used to normalize the samples.  Data are expressed as amount of mRNA 
produced ± SEM from 3 experiments.  Significance of difference between control and TNF 
treated cells and between stimulated and stimulated cells pretreated with NT8: *p<0.05 





















Figure 5.13 Effect of NT0 and LA on TNF-induced IL-1β mRNA in neutrophils.  
Neutrophils (5 x 106/ml) were pre-treated with either lauric acid or NT0 (50 µM) and then 
stimulated with TNF for 1 h.  Levels of IL-1β were determined by quantitative real-time 
PCR.  The housekeeping gene GAPDH was used to normalize the samples.  Data are 
expressed as amount of mRNA produced ± SEM from 3 experiments.  Significance of 






















Figure 5.14 Effect of LA or NT0 on TNF-induced IL-8 mRNA in neutrophils.  
Neutrophils (5 x 106/ml) were pre-treated with either lauric acid or NT0 (50 µM) and then 
stimulated with TNF for 1 h.  Levels of IL-8 were dtermined by quantitative real-time PCR.  
The housekeeping gene GAPDH was used to normalize the samples.  Data are expressed as 
amount of mRNA produced ± SEM from 3 experiments.  Significance of difference between 





















Figure 5.15 Effect of CQ on TNF-induced IL-1β mRNA in neutrophils.  Neutrophils (5 x 
106/ml) in RPMI-1640 supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 
µg/ml streptomycin, 2 % AB serum were pre-treated with CQ (50 µM) and then stimulated 
with TNF for 1 h.  Levels of IL-1β were determined by quantitative real-time PCR.  The 
housekeeping gene GAPDH was used to normalize the samples.  Data are expressed as 
amount of mRNA produced ± SEM from 3 experiments.  Significance of difference between 





















Figure 5.16 Effect of CQ on TNF-induced IL-8 mRNA in neutrophils.  Neutrophils (5 x 
106/ml) in RPMI-1640 supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 
µg/ml streptomycin, 2 % AB serum were pre-treated with CQ (50 µM) and then stimulated 
with TNF for 1 h.  Levels of IL-8 were determined by quantitative real-time PCR.  The 
housekeeping gene GAPDH was used to normalize the samples.  Data are expressed as 
amount of mRNA produced ± SEM from 3 experiments.  Significance of difference between 







NT8 significantly inhibited the TNF or TNF-RM induced respiratory burst in neutrophils.  
However, this was evident only at 50 µM NT8.  At the same concentration neither NT0 nor 
lauric acid had any effect.  It is also interestingly that CQ and HCQ had no effect on this 
neutrophil function at 50 µM.   
 
Results also showed that NT8 had no effect on the TNF-induced inhibition of neutrophil 
random migration or chemotactic migration.  
 
In addition to this, the data demonstrated that the TNF response of neutrophils in relation to 



























6.0 CHAPTER 6 SELECTIVITY OF THE INHIBITORY EFFECTS OF NT8 














To gain a better understanding of how NT8 affects neutrophil functions, we took several 
approaches to elucidate aspects of the mechanisms involved.  Results from chapters 4 and 5 
focused mainly on responses to TNF.  By using other agonists, it becomes possible to not 
only characterize better the properties of NT8 but gain some insights as to how NT8 induces 
its effects since cell activation will occur through different receptors and usually involve 
different sets of intracellular signaling cascades.  Our next approach is to find out whether or 
not the inhibitory effects were selective for TNF.   A range of agonists are available to 
undertake this study and includes fMLP, LTB4, IL-8, C5a, GM-CSF and LPS-induced 
responses.  These agonists have been established previously to stimulate neutrophil functions 
by different as well as ovelapping pathways (see below) via cell surface receptors.  In 
contrast, other agonicts such as PMA which acts on intracellular PKC level, A23187 (calcium 
ionophore) have been shown to mobilize cellular calcium and arachidonic acid which causes 
neutrophil activation by diverse mechanisms (Ferrante et al., 2005).  The neutrophil 
functions to be examined here restricted to adhesion, chemotaxis and respiratory burst.  It 
was the aim of this investigation to determine as to whether or not the NT8 effects were 








6.2 Alteration of the adherence response induced by other surface receptor acting 
agonists  
 
A diverse range of agonists which act on receptors on neutrophil surfaces representing 
endogenous (LTB4, C5a, IL-8 and GM-CSF) and exogenous (fMLP and LPS) were used to try 
to extablish the selective action of NT8 for the inhibition of the TNF-induced neutrophil 
adherence response.  All experiments were performed as described in Chapter 2.11.1 for the 
different agonists.   
 
6.2.1 fMLP  
 
The synthetic bacterial peptide fMLP acts via a high and low affinity receptor on neutrophils 
and leads to the stimulation of several responses including cell adhesion (Kettritz et al., 2004; 
Bylund et al., 2003).  Treatment of cells with fMLP increased their adhesion to serum coated 
plastic surface.  Experiments were conducted in a similar manner to those in which TNF was 
used as the cell agonist (Chapter 4).  Neutrophils were pre-treated for 1 h with 0, 20 or 50 
µM of NT8.  Other cells were treated with 50 µM of either NT0 or lauric acid.  Following 
pre-treatment, the cells were challenged with 0.1 µM fMLP for 30 min and then stained to 
quantitate the amount of neutrophil adherence.   
 
The results presented in Figure 6.1 demonstrate tha, unlike the effects on the TNF-induced 
adherence, the response to fMLP was not inhibited at 20 µM NT8.  However at 50 µM, there 
was approximately an 80 % reduction in this response.  The fMLP response was not affected 




6.2.2 LTB 4 
 
LTB4 is formed from the metabolism of arachidonic acid v a the 5-lipogenease pathway 
(Ferrante et al., 2005).  Biosynthesis of leukotrienes involves the release of AA from 
membrane phospholipids by Ca2+-dependent cytosolic phospholipase A2α (cPLA2α) and its 
conversion into 5-hydroperoxyeicosatetraenoic acid and subsequently leukotriene A4, 
catalyzed by 5-lipoxygenase (Zarini et al., 2006).  LTA4 is then enzymatically converted to 
LTB4 by LTA4-hydrolase (Zarini et al., 2006).  This product is a major inflammatory 
mediator which stimulates cells by acting on its surface receptor. LTB4 has previously been 
found to cause rapid neutrophil adhesion (Dahlen et al., 1981).  
 
The effect of NT8 on the LTB4-induced neutrophil adherence response was examined.  
Neutrophils were pre-treated with 0, 20 or 50 µM of NT8, NT0, or lauric acid and then 
examined for adherence in response to LTB4.  The results showed that the LTB4-induced 
adherence was significantly inhibited at 20 and 50 µM concentration of NT8.  While NT0 
had no effect on the adherence response to LTB4, lauric acid caused significant inhibition of 




GM-CSF is a growth factor that mediates proliferation of granulocytes, macrophages, 
erythrocytes, megakaryocytes and eosinophil progenitors (Jubinsky et al., 1994).  It has been 
reported to stimulate a number of neutrophil functions including adherence and phagocyte 




The investigations on the effect of NT8 were extended further to examine its effects on the 
GM-CSF-induced neutrophil adherence response.  The neutrophils were pre-treated for 1 h 
with 0, 20, or 50 µM of NT8.  Another set of cells was treated with either NT0 or lauric acid, 
and the response to GM-CSF measured.  The results showed that the GM-CSF induced 
neutrophil adhesion was inhibited at 50 but not 20 µM NT8 (Figure 6.3).  Under these 




IL-8 is a prototypic member of the CXC subfamily of chemokines that stimulates neutrophil 
responses (Knall et al., 1996).  It exerts its effect by binding to the IL-8 receptor which is a 
seven-transmembrane spanning receptor coupled to specific G proteins (Knall et al., 1996).  
It has also been reported that IL-8 causes rapid neutrophil adhesion (Detmers et al., 1991).   
 
The effect of NT8 on IL-8 induced neutrophil adherenc  was investigated.  Results showed 
that neutrophils pre-treated with 50 µM of NT8 caused 55 % decrease in adherence in 
response to the IL-8 (Figure 6.4).  At these concentrations, NT0 and lauric acid showed no 




C5a is generated during the activation of the comple ent cascade.  This product is a 
chemotactic factor for both neutrophils and macrophages, but also stimulates the respiratory 
burst, degranulation and cell adhesion (Guo and Ward, 2005; Smith et al., 1979).   
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Using C5a as a neutrophil stimulator of adhesion, we examined the effects of NT8 on this 
response.  The neutrophils were pre-treated with 0, 20, and 50 µM of NT8 and then tested 
for their response to C5a.  Results showed that NT8 inhibited neutrophil adherence at 50 but 
not 20 µM (Figure 6.5).  At the same time, neither NT0 nor lauric acid showed any 




LPS from gram negative bacteria is known to stimulate neutrophil functions including 
adherence (Aida and Pabst, 1991; Worthen et al., 1992).  Neutrophils were pre-treated for 1 
h with 0, 20, or 50 µM of NT8, lauric acid or NT0 and measured for adherence in response to 
LPS.  The results showed that only at 50 µM did NT8 inhibit significantly neutrophil 





























Figure 6.1 Effect of NT8 on fMLP-induced neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated for 1 h with either 20 µM or 50 µM NT8, 50 µM lauric acid or 50 
µM NT0 and then stimulated by adding 20 µl of fMLP (1 µM).  Adherence was measured by 
staining the cells with Rose Bengal and reading the plates at OD 570 nm.  The data are 
expressed as % of the control responses and presented as mean ± SEM of 3 experiments, each 
conducted with neutrophils from a different donor.  The base and stimulated OD 570 nm 
values ± SEM for the non-stimulated and stimulated controls were 0.07 ± 0.00 and 0.32 ± 
0.04 respectively.  Significance of difference betwen control and 50 µM: *p<0.01 (Dunnett: 



















Figure 6.2 Effect of NT8 on LTB4-induced neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated for 1 h with either 20 or 50 µM of NT8, lauric acid or NT0 and then 
stimulated by adding 20 µl of LTB4 (0.1 µM).  Adherence was measured by staining the cells 
with Rose Bengal and reading the plates at OD 570 nm.  The data are expressed as % of the 
control responses and presented as mean ± SEM of 3 experiments, each conducted with 
neutrophils from a different donor.  The base and stimulated OD 570 nm values ± SEM for 
the controls were 0.08 ± 0.01 and 0.24 ± 0.03 respectively.  Significance of difference 
between control and 20 µM NT8, control and 50 µM NT8 and control and lauric acid (50 µM): 



















Figure 6.3 Effect of NT8 on GM-CSF- induced neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated for 1 h with either 20 µM or 50 µM NT8, 50 µM lauric acid or 50 
µM NT0 and then stimulated by adding 20 µl of GM-CSF (20 ng/ml).  Adherence was 
measured by staining the cells with Rose Bengal and rea ing the plates at OD 570 nm.  The 
data are expressed as % of the control responses and presented as mean ± SEM of 3 
experiments, each conducted with neutrophils from a different donor.  The base and 
stimulated OD 570 nm values ± SEM for the controls were 0.08 ± 0.00 and 0.21 ± 0.04 
respectively.  Significance of difference between control and NT8 (50 µM): *p<0.01 




















Figure 6.4 Effect of NT8 on IL-8-induced neutrophil adherence.  Neutrophils (5 x 106/ml) 
were pre-treated for 1 h with either 20 or 50 µM of NT8, lauric acid or NT0 and then 
stimulated by adding 20 µl of IL-8 (0.1 µM).  Adherence was measured by staining the cells 
with Rose Bengal and reading the plates at OD 570 nm.  The data are expressed as % of the 
control responses and presented as mean ± SEM of 3 experiments, each conducted with 
neutrophils from a different donor.  The base and stimulated OD 570 nm values ± SEM for 
the controls were 0.08 ± 0.00 and 0.18 ± 0.03 respectively.  Significance of difference 



















Figure 6.5 Effect of NT8 on C5a-induced neutrophil adherence.  Neutrophils (5 x 106/ml) 
were pre-treated for 1 h with either 20 µM or 50 µMNT8, 50 µM lauric acid or 50 µM NT0 
and then stimulated by adding 20 µl of C5a (0.1 µM).  Adherence was measured by staining 
the cells with Rose Bengal and reading the plates at OD 570 nm.  The data are expressed as 
% of the control responses and presented as mean ± SEM of 3 experiments, each conducted 
with neutrophils from a different donor.  The base nd stimulated OD 570 nm values ± SEM 
for the controls were 0.08 ± 0.00 and 0.33 ± 0.07 respectively.  Significance of difference 




















Figure 6.6 Effect of NT8 on LPS-induced neutrophil adherence.  Neutrophils (5 x 106/ml) 
were pre-treated for 1 h with either 20 or 50 µM of NT8, lauric acid or NT0 and then 
stimulated by adding 20 µl of LPS (10 ng/ml).  Adherence was measured by staining the 
cells with Rose Bengal and reading the plates at OD 570 nm.  The data are expressed as % of 
the control responses and presented as mean ± SEM of 3 experiments, each conducted with 
neutrophils from a different donor.  The base and stimulated OD 570 nm values ± SEM for 
the controls were 0.07 ± 0.00 and 0.24 ± 0.03 respectively.  Significance of difference 





6.3 The effect of NT8 on neutrophil chemotaxis 
 
The chemotactic response enables neutrophils to infiltrate and accumulate at sites of infection.  
The exogenous chemoattractant fMLP, which promotes th  recruitment of neutrophils from 
the blood to the inflammatory foci was used to asses th  sensitivity of this neutrophil response 
to NT8. 
 
Using the migration under agarose method, the effects of NT8 on neutrophil chemotaxis to 
fMLP was examined.  Neutrophils were treated with 0, 20, or 50 µM of NT8 for 1 h and then 
examined for migration towards fMLP.  The effects of NT8 were also compared to treatment 
with 50 µM of either NT0 or lauric acid. 
 
The results demonstrated that NT8 did not inhibit neutrophil chemotaxis at both 
concentrations and at the same time there was also no effect observed on CQ treated cells in 
the fMLP-induced chemotaxis (Figure 6.7).  This suggests that apart from being receptor 
selective, NT8 inhibits the adherence but not chemotactic response to fMLP ie. is function 
selective also.  There also was no effect on random migration.     
 
Previous studies found that CQ and its derivatives have a different effects on random 
migration and chemotaxis (Ferrante et al., 1986).  Ferrante t al., (1986) demonstrated that 
CQ inhibited random migration by 15 % at 40 µM and chemotaxis (to fMLP) only by 12 %.  
Kharazmi et al., (1983) found that chemotaxis towards casein was m rkedly inhibited by CQ, 
reaching a complete inhibition at 100 µM.  However Labro and Babin-Chevaye (1988) 
found that the inhibitory effect of CQ on either random migration or chemotaxis was 
dependent on the method used to measure these functions.  The inhibitory effects of CQ on 
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random migration, fMLP or activated serum induced migration was only observed when the 
compound was directly incorporated into the agarose but not when the cells were only 
pre-treated with the compound, even at concentration of 200 µM (Labro and Babin-Chevaye, 








































Figure 6.7 Effect of NT8 on fMLP-induced neutrophil chemotaxis.  Neutrophils (5 x 
106/ml) were pre-treated with either 20 µM, 50 µM NT8, 50 µM lauric acid or 50 µM NT0 
and then tested for migration in response to fMLP.  Data are presented as mean ± SEM of 3 








6.4 Oxygen-dependent respiratory burst 
 
Apart from the importance of the release of oxygen d rivative reactive species (ODRS) by 
neutrophils in defense against microbial pathogens, these ODRS play a role in tissue damage 
in inflammatory diseases such as rheumatoid arthritis (Hadjigogos, 2003; Mirshafiey and 
Mohsenzadegan, 2008).  Since we have an interest in developing NT8 and its derivatives as 
anti-inflammatory agents, we investigated its effects on the ability of neutrophils to produce 
ODRS.  The response was measured as lucigenin-depennt chemiluminescence which has 




The effect of NT8 on fMLP mediated lucigenin dependt respiratory burst was investigated.  
At higher concentrations than those which stimulate ch motaxis, fMLP induces a modest 
respiratory burst activity in neutrophils (Figure 6.8).  Neutrophils were pre-treated with 0, 20 
or 50 µM of NT8 and after 1 h were examined for their ability to undergo the respiratory burst 
activity induced by fMLP.  The data showed that NT8 had no effect on the basal response 
but inhibited the fMLP-induced response at 50 µM (Figure 6.8) but not at 20 µM (data not 
shown).  The kinetics of the generation of chemilumnescence in fMLP stimulated 
neutrophils is shown in Figure 6.9.  These showed that the inhibition was also reflected in 
the total amount of chemiluminescence produced (area under curve).  NT8 had no effect on 






6.4.2 LTB 4 
 
LTB4 has been found to induce a number of functional chnges in neutrophil.   Apart from 
acting as a chemotatic agent and stimulating neutrophil adherence, it also stimulates the 
oxygen-dependent respiratory burst activity (Schultz et al., 1991).  When the effect of NT8 
on LTB4 mediated enhanced chemiluminescence response was examin d, the data showed 
that NT8 at 50 µM did not inhibit the response (Figure 6.10, 6.11).  The kinetics of the 
generation of chemiluminescence in LTB4 stimulated neutrophils are shown in Figure 6.11.  
This is interesting in terms of the strong inhibitory effects of NT8 on the LTB4-induced 




GM-CSF is a neutrophil stimulator and plays an important role in the activity of neutrophil 
during inflammation (DiPersio et al., 1988; Gomez-Cambronero et al., 2003).  This includes 
the ability to stimulate ODRS production.  The effectsof NT8 on this respose induced by the 
cytokine was examined.  Cells were treated with 50 µM NT8 for 1 h and then challenged 
with GM-CSF.  The results showed that while NT8 at 50 µM inhibited the respiratory burst 












Figure 6.8 Effect of NT8 on fMLP-induced chemiluminescence. Neutrophils (5 x 106/ml) 
were pre-treated with NT8 (50 µM) for 1 h and then stimulated by adding 100 µl of fMLP 
(0.1 µM).  The resultant chemiluminescence production was measured in a luminometer.  
The data represent initial peak rates of chemiluminescence and are presented as the mean ± 
SEM of 3 experiments, each conducted with neutrophils from a different donor.  
Significance of difference between control and fMLP: **p<0.001 and between fMLP and 






















Figure 6.9 Effect of NT8 shown as kinetics of fMLP-induced change in 
chemiluminescence.  Data is a representative experiment of results shown in Figure 6.8.  
The data is presented as relative light units.  Neutrophils + diluents (■), neutrophils + fMLP 






















Figure 6.10 Effect of NT8 on LTB4-induced chemiluminescence.  Neutrophils (5 x 10
6/ml) 
were pre-treated with NT8 (50 µM) for 1 h and then stimulated by adding 100 µl of LTB4 (0.1 
µM).  The resultant chemiluminescence production wasmeasured in a luminometer.  The 
data represent initial peak rates of chemiluminescence and are presented as the mean ± SEM 
of 3 experiments, each conducted with neutrophils from a different donor.  Significance of 























Figure 6.11 Effect of NT8 shown as kinetics of LTB4-induced change in 
chemiluminescence.  Data is a representative experiment of results shown in Figure 6.10.  
The data is presented as relative light units.  Neutrophils + diluents (■), neutrophils + LTB4 























Figure 6.12 Effect of NT8 on GM-CSF-induced chemiluminescence. Neutrophils (5 x 
106/ml) were pre-treated with NT8 (50 µM) for 1 h and then stimulated by adding 100 µl of 
GM-CSF (40 ng/ml).  The resultant chemiluminescence production was measured in a 
luminometer.  The data represent initial peak rates of chemiluminescence and are presented 
as the mean ± SEM of 3 experiments, each conducted wi h neutrophils from a different donor.  










Figure 6.13 Effect of NT8 shown as kinetics of GM-CSF-induced change in 
chemiluminescence.  Data is a representative experiment of results shown in Figure 6.12.    
The data is presented as relative light units.  Neutrophils + diluents (■), neutrophils + 






6.5 Effects on arachidonic acid induced neutrophil responses. 
 
Arachidonic acid (AA) is a free fatty acid metabolized via the cycloxygenase and 
lipoxygenase pathways to produce biologically active products eicosanoids, namely 
prostaglandins, leukotrienes and lipoxins (Krischer et al., 1998).  However, it has also been 
demonstrated that AA is a strong neutrophil agonist that induces neutrophil migration 
inhibition, degranulation, adhesion and activation of the oxygen-dependent respiratory burst 
(Ferrante et al., 2005).   
 
Since AA represents an agonist with its own unique properties and is generated during cell 
activation in the inflammatory reaction, we examined whether NT8 altered the neutrophil 
stimulation by AA.  Neutrophils were pretreated with 0, 20 or 50 µM of NT8 and then 
examined for AA induced adherence.  The results showed this NT8 inhibited the AA-induced 
neutrophil adherence only at 50 µM (77 % inhibition).  The treatment with 50 µM of either 
NT0 or lauric acid had no effect on the AA response (Figure 6.14).     
 
The effect of NT8 on AA mediated neutrophil chemiluinescence was also examined. AA at 
30 µM resulted in a significant increase in chemiluminescence but the pre-treatment of 
neutrophils with NT8 (50 µM) for 1 h did not inhibit the neutrophil respiratory burst response 
(Figure 6.15, 6.16).  The results again demonstrated that NT8 has selectivity for inhibition of 






















Figure 6.14 Effect of NT8 on AA-induced neutrophil adherence.  Neutrophils (5 x 106/ml) 
were pre-treated with either 20 µM or 50 µM NT8, 50 µM lauric acid or 50 µM NT0 and then 
stimulated by adding 20 µl of AA (30 µM).  Adherence was measured by staining the cells 
with Rose Bengal and reading the plates at OD 570 nm.  The data are expressed as % of the 
control responses and presented as mean ± SEM of 3 experiments, each conducted with 
neutrophils from a different donor.  The base and stimulated OD 570 nm values ± SEM for 
the controls were 0.07 ± 0.01 and 0.31 ± 0.02 respectively.  Significance of difference 




















Figure 6.15 Effect of NT8 on AA-induced chemiluminescence. Neutrophils (5 x 106/ml) 
were pre-treated with NT8 (50 µM) for 1 h and then stimulated by adding 100 µl of AA (30 
µM).  The resultant chemiluminescence production wasmeasured in a luminometer.  The 
data represent initial peak rates of chemiluminescence and are presented as the mean ± SEM 
of 3 experiments, each conducted with neutrophils from a different donor.  Significance of 























Figure 6.16 Effect of NT8 shown as kinetics of AA-induced change in chemiluminescence.  
Data is a representative experiment of results shown in Figure 6.15.  The data is presented as 
relative light units.  Neutrophils + diluents (■), neutrophils + AA (▲), neutrophils + NT8 (Δ) 






6.6 The effect of NT8 on agonists which act at the post receptor level, PMA and 
A23187 
 
One way of gaining some understanding of the pathways t rgeted by NT8 is by using an 
agonist which acts at the post surface receptor level to stimulate the response.  In these 
investigations we have chosen two agents, PMA which a ts on PKC, and A23187 which 
mobilizes intracellular calcium.  Both of these agents have been shown to stimulate both 
neutrophil adhesion and respiratory burst responses (Davies et al., 1990; Guo and Ward, 2005; 




In these investigations, neutrophils were pretreated with either 20 or 50 µM of NT8, 50 µM 
NT0 or lauric acid.  The results presented in Figure 6.17, show that the PMA-induced 
adherence was significantly depressed at 50 µM NT8.  There was no corresponding 
inhibition either with NT0 or lauric acid.   
 
Stimulating an increase in intracellular Ca2+ has been shown to enhance neutrophil adherence, 
and calcium ionophore has been used to induce this response  (Davies et al., 1990).  
Calcium ionophore (A23187) selectively aids in the ransport of Ca2+ across the natural and 
artificial membranes so that calcium can accumulate leading to enhanced neutrophil adhesion 
(Lew et al., 1986).  In our study, neutrophils were pre-treated with either 20 or 50 µM of 
NT8 and then stimulated with A23187 to induce the cell adhesion response.  The results 
showed that NT8 caused an 80 % inhibition of A23187-induced neutrophil adherence at 50 

















Figure 6.17 Effect of NT8 on PMA-induced neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with either 20 µM or 50 µM NT8, 50 µM lauric acid or 50 µM NT0 
and then stimulated by adding 20 µl of PMA (0.1 µM).  Adherence was measured by 
staining the cells with Rose Bengal and reading the plates at OD 570 nm.  The data are 
expressed as % of the control responses and presented as mean ± SEM of 3 experiments, each 
conducted with neutrophils from a different donor.  The base and stimulated OD 570 nm 
values ± SEM for the controls were 0.07 ± 0.01 and 1.02 ± 0.09 respectively.  Significance 



















Figure 6.18 Effect of NT8 on A23187-induced neutrophil adherence.  Neutrophils (5 x 
106/ml) were pre-treated with either 20 µM or 50 µM NT8, 50 µM lauric acid or 50 µM NT0 
and the stimulated by adding 20 µl of A23187 (10 µM).  Adherence was measured by 
staining the cells with Rose Bengal and reading the plates at OD 570 nm.  The data are 
expressed as % of the control responses and presented as mean ± SEM of 3 experiments, each 
conducted with neutrophils from a different donor.  The base and stimulated OD 570 nm 
values ± SEM for the controls were 0.08 ± 0.00 and 1.08 ± 0.16 respectively.   Significance 







6.6.2 Oxygen-dependent respiratory burst 
 
PMA stimulates the neutrophil respiratory burst by acting on PKC (Allard et al., 1999).  The 
effect of NT8 on PMA mediated oxygen-dependent respi atory burst was examined by the 
lucigenin-dependent chemiluminescence assay.  The neutrophils were pre-treated with 50 
µM of NT8 and the response to PMA was examined.  The data showed that there was no 
inhibition in the response induced by this agonist (Figure 6.19).  This contrasts with the 
effects on the adherence response (Figure 6.17).  The kinetics of the generation of 
chemiluminescence in PMA stimulated neutrophils areshown in Figure 6.20.  These 
demonstrated that the total chemiluminescence produced was similarly not affected by NT8.     
 
The A23187-induced neutrophil respiratory burst was also measured in cells which had been 
pre-treated with NT8 at 50 µM.  NT8 did not cause any inhibition of the respirato y burst 
(Figure 6.21) and this was confimed in terms of asses ing the kinetics of the generation of 





























Figure 6.19 Effect of NT8 on PMA-induced chemiluminescence.  Neutrophils (5 x 106/ml) 
were pre-treated with NT8 (50 µM) for 1 h and then stimulated by adding 100 µl of PMA (0.1 
µM).  The resultant chemiluminescence production was measured in a luminometer.  The 
data represent initial peak rates of chemiluminescence and are presented as the mean ± SEM 
of 3 experiments, each conducted with neutrophils from a different donor.  Significance of 























Figure 6.20 Effect of NT8 shown as kinetics of PMA-induced change in 
chemiluminescence.  Data is a representative experiment of results shown in Figure 6.19.  
The data is presented as relative light units.  Neutrophils + diluents (■), neutrophils + PMA 






















Figure 6.21 Effect of NT8 on A23187-induced chemiluminescence.  Neutrophils (5 x 
106/ml) were pre-treated with NT8 (50 µM) for 1 h and then stimulated by adding 100 µl of 
A23187 (10 µM).  The resultant chemiluminescence production was measured in a 
luminometer.  The data represent initial peak rates of chemiluminescence and are presented 
as the mean ± SEM of 3 experiments, each conducted wi h neutrophils from a different donor.  
























Figure 6.22 Effect of NT8 shown as kinetics of A23187-induced change in 
chemiluminescence.  Data is a representative experiment of results shown in Figure 6.21.  
The data is present as relative light units.  Neutrophils + diluents (■), neutrophils + A23187 






6.7 The effects of NT8 are irreversible 
 
To gain further insights into the mechanisms of NT8 affects, we examined whether the 
inhibitory effects were reversible by washing the cells after the pretreatment.  Neutrophils 
were pre-treated with either 20 or 50 µM of NT8 and then washed three times with medium 
before stimulating them with either TNF-RM or recombinant TNF.  Cell adherence was 
measured.  The results showed that the effect was not reversible by washing (Figure 6.23).  
Similar results were obtained when recombinant TNF was used as the stimulator (Figure 
6.23). 
 
6.8 Effects of NT8 on agonist induced up regulation of CR3 expression.   
 
It is well established that neutrophil agonists increase the surface expression of the functional 
cell surface receptors such as, CR3.  This receptor plays a role in neutrophil adhesion to 
plasma coated surfaces (Schleiffenbaum et al., 1989; Powell et al., 1997).  It was therefore 
of interest to examine whether NT8 caused a reduction in the ability of TNF to induce an 
increase in expression of this receptor.  To follow the expansion of CR3 we used a 
monoclonal antibody against the CD11b peptide of this receptor and used flow cytometry 
analysis as described in Chapter 2.16 (Moghaddami et al., 2003).  When neutrophils were 
pre-treated with 50 µM of NT8 for 1 h and then stimulated with TNF-RM, there was no 
reduction in CR3 expression (Figure 6.24).  A histogram of the results obtained from a 





















Figure 6.23 Irreversible effect of NT8 on TNF-RM/TNF mediated neutrophil adherence.  
Neutrophils (5 x 106/ml) were pre-treated with 50 µM of NT8 for 1 h and prior to stimulation; 
cells were washed three times with HBSS.  Adherences in response to TNF-RM or TNF 
were then tested.  The data are expressed as % of the control responses and presented as 
mean ± SEM of 3 experiments, each conducted with neutrophils from a different donor.  The 
base and stimulated OD 570 nm values ± SEM for the controls were 0.08 ± 0.01 and 0.26 ± 
0.05 and 0.07 ± 0.03 and 0.34 ± 0.05 respectively.   Significance of difference between 
control and TNF-RM + NT8; control and TNF + NT8: *p<0.01 and **p<0.001 respectively 




















Figure 6.24 Effect of NT8 on TNF-RM-induced CD11b expression.  Neutrophils (5 x 
106/ml) pre-treated with NT8 (50 µM) for 1 h were then stimulated with TNF-RM (1 h).  The 
cells were then stained with a PE-labelled mouse anti-human CD11b antibody and CD11b 
expression analyzed by flow cytometry.  Data expressed as mean % of control ± SEM from 3 
experiments, each conducted with neutrophils from a different donor.  Significance of 























Figure 6.25 Histogram of the effects of NT8 on TNF-RM-induced increase in CD11b 










6.9 Effects on TNFR expression 
 
In consideration of the data from Chapter 4, 5, 6 and from the above data generated, 
adherence induced by TNF was highly sensitive to the action of NT8.  This response was 
inhibited at 20 µM.  At this concentration the responses to agonists which bypass the surface 
receptor, PMA and A23187 were not affected.  One possible action of NT8 on the 
TNF-induced response is to cause an alteration on the expression of TNF receptors.  This 
was therefore investigated.  Neutrophils were incubated with NT8 for 1 h and then examined 
for expression of TNFRI and TNFRII using anti-CD120a and anti-CD120b labeled 
monoclonal antibodies (Moghaddami et al., 2003).  The corresponding labeled IgG1 isotype 
antibody was used as isotype control.  The cells were then treated and analysed by flow 
cytometry. 
 
The data presented in Figure 6.26 show that NT8 significantly decreased the expression of 
TNFRII but not TNFRI.  This occurred at 20 µM, suggesting that the inhibition of the 
TNF-induced adherence response is likely to be due to a decreased in expression of this 
receptor.  Representative histograms for this data h ve been presented in Figure 6.26 and 












Figure 6.26 Effect of NT8 on neutrophil TNF receptor I and II expression.  Neutrophils 
(5 x 106/ml) in HBSS were pre-treated with various concentration of NT8 (20 and 50 µM) and 
then stained with either anti-CD120a (□) or CD120b (■) for 30 min.  An isotype control, 
mouse IgG1, was also used.  Then a goat anti-mouse FITC labeled immunoglobulin was 
added and the cells incubated for a further 30 min. The cells were washed and the levels of 
TNF receptor I and II are measured using a FACscan.  Data expressed as mean fluorescence 
intensity minus the isotype control ± SEM of 4 experiments each done in duplicate with 
neutrophils from a different donor.  Significance of difference in the CD120b group, between 
control and 20 µM and between control and 50 µM group: *p<0.05 (Tukey-Kramer multiple 
























Figure 6.27 Histogram of the effect of NT8 on TNFRI (A) and TNFRII (B).    The data is 





6.10 Effects on sphingosine pathway 
 
Since NT8 has a structure that is similar to 3-ketosphinganine (3KDS) (C18H37NO2), one of 
the substrates crucial for ceramide formation, it is possible that NT8 affects 3KDS synthesis.  
A serine palmitoyl transferase assay was performed according to Williams et al., (1984) and 
Holleran et al., (1990) to measure the final yield product 3KDS as de cribed in Chapte 2.13.3.  
A microsomal protein fraction was prepared from mouse liver.  The reaction mix, containing 
all the initiating substrates such as pyridoxal phosphate, palmitoyl CoA, [3H] serine, serine 
and microsomal protein was prepared.  A modification was made to the experiment by 
adding NBPP, ATP or Mg2+ so as to increase the yield of the final product.  NT8 (100 µM) 
was also added to the mixture to see if it inhibits the formation of 3KDS.  The reaction was 
terminated by adding ammonium hydroxide and the extraction of the final product was 
affected by the addition of sphingosine base and washing with chloroform.  The amount of 
3KDS generated was then measured in a scintillation cou ter.   
 
Due to the fact that this experiment is measuring the generation of 3KDS which depends 
highly on the availability of palmityl CoA enzyme, substrates/inhibitors such as NBPP, ATP 
and Mg2+ were incorporated into the experiment to aid in either the regeneration or the 
availability of this enzyme.  Results showed that neither NBPP or ATP resulted in an 
increase of the yield for 3KDS (Figure 6.28).  However when ATP was added along with 
Mg2+, this resulted in an increase of 3KDS was yielded and under these conditions, NT8 at 




















Figure 6.28 Effect of NT8 on serine palmitoyltransferase activity.  Assays were 
conducted under different conditions so to increase the SPS activity.  NBPP, ATP or a 
combination of ATP and Mg2+ was used along with NT8 and the resulting radioactvity was 
measured via a Beta counter.  Data expressed as activity per pmol/min/mg produced ± SEM 
from 2 experiments.  Significance of difference between control and ATP + Mg2+: *p<0.01 









It is evident from the data presented in this chapter that in comparison to several other cell 
surface receptor acting agonists NT8 preferential inhibits the neutrophil adherence response to 
TNF (Table 6.1).  Of the six other agonists examined fMLP, LTB4, GM-CSF, IL-8 C5a and 
LPS only the response to LTB4 was affected to a similar degree to the TNF response (Tabe 
6.1).   
 
The effects on the TNF response were unrelated to a post receptor binding effect.  At 20 µM 
neither the PMA nor the A23187 induced adherence response was affected.  It was evident 
that NT8 down regulated the expression of TNFRII but not TNFRI on neutrophils, most likely 
accounting for the decreased response at this concentration.  It was however interesting that 
the TNF-induced upregulation of CR3 expression was not affected by NT8.   
 
As the concentration of NT8 increased to 50 µM, the sel ctivity of the TNF responses was 
lost as we saw an effect on adherence induced by all agonists tested.  At this concentration 
substantial inhibition occurred for responses induced by PMA and A23187, suggesting that an 
effect at the post surface receptor level was a key to the mechanism of action.  Attempts to 
define this further, met with limited success.  The possibility that NT8 was affecting the 
sphingosine pathway was examined but this appeared not to be the case.   
 
In chapter 5, data was presented which showed that inhibition of the respiratory burst 
response induced by TNF was restricted to 50 µM NT8.  This also occurred for fMLP but 
not LTB4 and GM-CSF.  The results then suggest that NT8 has preference in inhibiting this 
response to TNF.  This was further supported by the fact that the responses to AA and PMA 
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were not inhibited.   
 
While TNF is not a chemoattractant for neutrophils it was of interest to see if NT8 altered 
other neutrophil functions such as chemotactic respon iveness to fMLP.  No effect was 
observed.  This again clearly supported our view that NT8 has selective effects on neutrophil 






























 NT8 (% of inhibition) 
Stimulus 5 µM 20 µM 50 µM 
TNF-RM 0 40b 85c 
TNF 0 61b 85c 
fMLP 0 0 81c 
LTB4 0 44
a 71b 
GM-CSF 0 6 76a 
IL-8 0 25 55b 
C5a 0 0 67a 
LPS 0 11 52a 
AA 0 0 77b 
PMA 0 7 67b 
A23187 0 1 79b 
The values represent the % inhibition of the adherence response caused by the indicated 
amounts of NT8 from 3 experiments.  Significance of difference from control: ap<0.05, 















7.0 CHAPTER 7 THE EFFECTS OF NT COMPOUNDS ON 















The hallmark of chronic inflammatory diseases such as RA is the intense infiltration, 
activation and proliferation of macrophages and the subsequent release of cytokines which 
regulate lymphocytes pe se or other leukocytes such as macrophages at these inflammatory 
sites.  Similarly, macrophage’s action in this disease is also mediated through the release of 
cytokines such as TNF at these inflammed sites.  These function in an in vitro setting 
provide a useful approach to assess the effects of NT8 on the lymphocyte and macrophage 
responses.    
 
CQ and HCQ have been shown to inhibited superoxide anion release from monocytes as well 
as phospholipid methylation (Hurst e  al., 1986), down-regulated monocyte FcγR expression 
and depressed IL-1β, IL-2, TNF and IL-6 production (Goldring and Nemaor ni, 1999; Jang et 
al., 2006; Landewe et al., 1995; Karres et al., 1998).  Moreover results from clinical trials 
showed that proliferation responses of lymphocytes from RA patients treated with 
chloroquine for a period of 3.6 years were inhibited compared to cells from controls (Panayi 
et al., 1973).  The presentation of Listeria antigens to T cells was also inhibited by CQ 
(Ziegler and Unanue, 1982).  The anti-malarial drug was also found to disrupt calcium 
signals in T cells, and B cells (Goldman et al., 2000).  Another cell signal which CQ 
inhibited was the activation of ERK in PBMCs (Weber et al., 2002).             
 
Furthermore, HCQ has been found to inhibit macrophage ccumulation in a peritoneal 
inflammation model (Ackerman et al., 1980) and CQ resulted in a decreased papaya 
latex-induced rat paw inflammation (Gupta et al., 1992).  The effects on mononuclear 
leukocytes were manifested both as an inhibitor of cell proliferation, cytokine production, 
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signal transduction and antigen presentation.  Since both T cells and macrophages are major 
players in the pathogenesis of chronic inflammatory diseases and CQ and HCQ have been 
found to be useful in treating conditions such as RA, we examined the effects of NT8 on T 
cell and macrophage function. It was therefore important to extent of the leukocyte inhibition 
properties of the NT compounds on mononuclear leukocyte functions. The aim of the present 
study was to exmine the effects of NT compounds on lymphocyte proliferation and cytokine 
production as well as effects on cytokine production by macrophages.   
 
7.2 Effect of NT compounds on PHA-induced lymphocyte proliferation 
 
Initial studies examined the effects of NT compounds on PHA-induced lymphocyte 
proliferation.  Human PBMCs were pre-incubated with 50 µM of an NT compound or 
chloroquine for 1 h and then challenged with PHA.  fter 48 h of culture the degree of 
proliferation was assessed.  The data presented in Table 7.1 demonstrate that none of the 13 
NT compounds examined caused inhibition of T cell proliferation.  However at the same 

















(% of control responses) 
0 92 ± 1.53 
1 90 ± 4.04 
2 95 ± 6.01 
3 97 ± 4.58 
4 87 ± 2.73 
5 88 ± 4.98 
6 89 ± 2.52 
7 99 ± 3.06 
8 95 ± 2.52 
9 95 ± 2.60 
10 88 ± 4.04 
11 93 ± 7.00 
12 109 ± 11.06 
13 96 ± 7.84 
CQ 52 ± 0.58* 
PBMCs were pre-treated with 50 µM of an NT compound or CQ for 1 h.  Data are 
expressed as the mean % of methyl-[3H]-thymidine incorporated in control group ± 
SEM from 3 experiments, each conducted with PBMCs from a different donor. 





7.3 Effect of NT8 and CQ on PHA-induced lymphocyte cytokine production  
 
Although the above results showed that NT8 did not inhibit PHA-induced 
lymphoproliferation, measuring this function does not simply imply that other functions such 
as cytokine production are not affected.  Further investigations were conducted to examine 
the effects of NT8 on the PHA-induced T cell production of IFN-γ, IL-2, LT and IL-10.   
 
In these assays the PBMCs were pre-exposed to either 20 µM or 50 µM of NT8 for 1 h and 
then challenged with PHA.  Other sets of PBMCs were treated with either lauric acid, NT0 
or CQ.  The cells were cultured for 48 h and pulsed with 3H-TdR for further 6 h.  Prior to 
harvesting the cells, cell-free culture supernatnats were collected for cytokine measurement.   
 
The results are summerized in Table 7.2.  The data showed that while CQ inhibited 
lymphoproliferation (Figure 7.1), NT8 had no effect and neither did lauric acid nor NT0.  
CQ at 50 µM significantly inhibited the production f IL-2 and IL-10 but not IFNγ and LT by 
PBMCs stimulated with PHA (Figure 7.2).  The most affected was the production of IL-10.  
In compansion, NT8 treatment of PBMCs had no effect on he production of any of the four 
cytokines examined.  The effects of CQ on lymphocyte proliferation did not follow a 
concentration related effect over 5-50 µM.  Significance was seen at 5 and 50 µM but not at 








Table 7.2 Effect of NT8 on lymphoproliferation and cytokine production in human mononuclear cell culture.  
  NT8 (µM) LA (µM) NT0 (µM) 
Stimulus Function 20 50 20 50 20 50 
PHA Proliferation 107 ± 12 109 ± 16 113 ± 21 121 ± 7 90 ± 6 102 ± 8 
 IFN-γ ND 156 ± 44 ND 92 ± 18 ND 87 ± 16 
 IL-10 ND 97 ± 10 ND 102 ± 10 ND 98 ± 10 
 IL-2 ND 177 ± 76 ND 151 ± 30 ND 180 ± 44 
 LT ND 161 ± 29 ND 124 ± 32 ND 133 ± 36 
TT Proliferation 98 ± 16 76 ± 24 88 ± 24 110 ± 22 88 ± 24 55 ± 17 
 IFN-γ ND 71 ± 17 ND 141 ± 22 ND 68 ± 16 
 IL-10 ND 53 ± 13a ND 90 ± 18 ND 40 ± 5a 
 IL-2 ND 212 ± 63 ND 96 ± 9 ND 100 ± 34 
 LT ND 66 ± 25 ND 146 ± 34 ND 75 ± 16 
S.aureus Proliferation 85 ± 25 80 ± 17 87 ± 11 122 ± 37 95 ± 12 113 ± 51 
LPS TNF-α ND 189 ± 62 ND 224 ± 5 ND 201 ± 118 
 IL-1β ND 125 ± 27 ND 174 ± 21 ND 88 ± 31 
 IL-6 ND 117 ± 6 ND 118 ± 10 ND 87 ± 12 
Data are expressed as the mean of % control values ± SEM from 3 experiments, each conducted with PBMCs from different donor. 
Significance of difference from control: ap<0.05(Tukey-Kramer multiple comparisons test). 




















Figure 7.1 Effect of CQ on PHA- induced PBMC proliferation.  PBMC (5 x 106/ml) were 
pre-treated with varying concentrations of CQ for 1 h and then stimulated by adding 100 µl of 
PHA (2 µg/ml) for 48 h 37 °C with 5 % CO2. Six hours prior to harvesting, cells were pulsed 
with 1 µCi of methyl-[3H]-thymidine and incorporated radioactivity measured. The data are 
expressed as % of the control and presented as mean ± SEM of 3 experiments, each conducted 
with PBMCs from a different donor.  The basal and stimulated DPM values ± SEM were 
1774 ± 529 and 185062 ± 73573 respectively.  Significance of difference compared to 




















Figure 7.2 Effect of CQ on PHA-induced cytokine production.  PBMCs (5 x 106/ml) 
were pre-treated with CQ (50 µM) for 1 h and then stimulated by adding 100 µl of PHA (2 
µg/ml) for 48 h at 37 °C with 5 % CO2.  Cell culture fluids were harvested and cytokine 
levels measured by cytometric bead array.  The data are expressed as % of the control and 
presented as mean ± SEM of 3 experiments, each condu ted with PBMCs from a different 
donor.    Significance of difference compared to contr l: *p<0.05 (Dunnett: compare all vs 
control).  
 
   
  CQ 
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7.4 Effect of NT8 and CQ on tetanus toxoid-induced lymphoproliferation and cytokine 
production  
 
Further properties of NT8 on lymphocytes were examined in a system in which the responses 
are driven by an antigen, tetanus toxoid (TT).  The PBMCs were pre-treated with 5, 20 or 50 
µM NT8.  The cells were then stimulated with TT and examined for lymphocyte 
proliferation and production of IFN-γ, IL-2, IL-10 and LT.  Other treatments included NT0, 
lauric acid and CQ.   
 
The results showed that as with the PHA-induced T cell responses, TT-induced 
lymphoproliferation were markedly inhibited by CQ (Table 7.2, Figure 7.3).  The response 
was inhibited by > 95 % at 50 µM CQ.  It was also evid nt that 5 µM CQ was effective in 
inhibiting the response (Figure 7.3).  A comparison of the effects of 50 µM CQ on the 
production of the four cytokines showed that it significantly inhibits all four cytokines (Figure 
7.4).  IL-2, which is required for T cell proliferation was also inhibited by CQ.  The most 
sensitive to CQ was LT and IFN-γ (Figure 7.4).  This highlights some important properties 
of CQ which are likely to have relevance to its anti-i flammatory function.   
 
In contrast to the effects of CQ, neither NT8 nor NT0 or lauric acid inhibited antigen-induced 
T cell proliferation and cytokine production (Table 7.2), although NT0 and NT8 both caused 

























Figure 7.3 Effect of CQ on tetanus toxoid-induced lymphoproliferation.  PBMCs (5 x 
106/ml) were pre-treated with varying concentrations of CQ for 1 h and then stimulated by 
adding 100 µl of TT (1 µg/ml) for 5 days at 37 °C with 5 % CO2. Six hours prior to harvesting, 
cells were pulsed with 1 µCi of methyl-[3H]-thymidine and incorporated radioactivity 
measured.  The data are expressed as % of the control a d presented as mean ± SEM of 3 
experiments, each conducted with PBMCs from a different donor.  The basal and stimulated 
DPM values ± SEM were 3855 ± 1894 and 82069 ± 16946 respectively.  Significance of 




















Figure 7.4 Effect of CQ on tetanus toxoid-induced cytokine production.  PBMCs (5 x 
106/ml) were pre-treated with CQ (50 µM) for 1 h and then stimulated by adding 100 µl of TT 
(1 µg/ml) for 5 days at 37 °C with 5 % CO2.  Cell culture fluids were harvested and cytokine 
levels measured by cytometric bead array.  The data are expressed as % of the control and 
presented as mean ± SEM of 3 experiments.  Significa ce of difference compared to control: 
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7.5 Effect of NT8 and CQ on S.aureus –induced lymphoproliferation   
 
Since NT8 has no effect on PHA mediated PBMC proliferation, the effect on S.aureus, a B 
cell mitogen, induced proliferation was examined (Forsgren et al., 1976).  PBMCs were first 
pre-treated with NT8, NT0, LA or CQ and then stimulated with S.aureus.  Cell proliferation 
was assessed by measuring the degree of 3H thymidine incorporation after 48 h of culture.   
Results showed that there was no effect on the S.aureus induced PBMC proliferation at 50 
µM by NT8, lauric acid or NT0 (Table 7.2).  However this response was significantly 
inhibited by CQ at 50 µM (Figure 7.5).   
 
7.6 Effect of NT8 and CQ on LPS-induced cytokine product in PBMCs 
 
LPS is a strong inducer of the pro-inflammatory cytokines TNF, IL-1β and IL-6 from 
macrophages (Xaus et al., 2000; West et al., 1997; Hirohashi and Morrison, 1996).  These 
play important roles in the pathogenesis of chronic inflammatory diseases (Moller and Villiger, 
2006; Feldmann and Maini, 2001).  PBMCs were pre-treated with either NT8, NT0, LA or 
CQ and then stimulated with LPS.  The results showed that NT8 had no effect on 
LPS-induced cytokine production (Table 7.2, Figure 7.6).  At the same concentration CQ 
inhibited the production of these cytokines, although significance was only reached with 
IL-1β and IL-6.  In view of the role of these cytokines in chronic inflammatory diseases such 

























Figure 7.5 Effect of CQ on S.aureus-induced lymphoproliferation.  PBMCs (5 x 106/ml) 
were pre-treated with varying concentrations of CQ for 1 h and then stimulated by adding 100 
µl of S.aureus (1 x 106/ml) for 48 h at 37 °C with 5 % CO2. Six hours prior to harvesting, cells 
were pulsed with 1 µCi of methyl-[3H]-thymidine and incorporated radioactivity measured. 
The data are expressed as % of the control and presented as mean ± SEM of 3 experiments, 
each conducted with PBMCs from a different donor.  The basal and stimulated DPM values 
± SEM were 576 ± 89 and 4161 ± 2620 respectively.  Significance of difference compared to 
























Figure 7.6 Effect of CQ on LPS-induced cytokine production.  PBMCs (5 x 106/ml) were 
pre-treated with CQ (50 µM) for 1 h and then stimulated by adding 100 µl of LPS (10 ng/ml) 
for 48 h at 37 °C with 5 % CO2.  Cell culture fluids were harvested and cytokine levels 
measured by cytometric bead array.  The data are expressed as % of the control and 
presented as mean ± SEM of 3 experiments, each condu ted with PBMCs from a different 
donor.  Significance of difference compared to contr l: *p<0.05 (Dunnett: compare all vs 









The data showed that none of the NT compounds altered the lymphoproliferation response 
induced by PHA in human PBMC cultures.  This is in contrast with their effects on 
neutrophil functions (Chapter 4). 
 
Further studies with NT8 showed that the compound did not inhibit the cytokines, IFN-γ, LT, 
IL-2 and IL-10 in response to PHA.  Similarly, very little effect was observed on the tetanus 
toxoid-induced lymphoproliferative response and cytokine production.  The response of B 
cells to S.aureus was not affected as well.  Furthermore, the respone of macrophages in the 
PBMCs to LPS was also not affected, in terms of TNF, IL-1 and IL-6 production.   
 
In contrast CQ inhibited lymphoproliferation and cytokine production induced by the 

























8.0 CHAPTER 8 EXAMINATION OF THE ANTI -INFLAMMATORY 















While we still need to characterize the properties of NT8 more extensively, it is evident that 
NT8 has a preference for inhibiting neutrophil responses (Chapters 4 to 7), particularly 
sensitive was the cell adhesion response initiated by TNF and LTB4.  Because these are key 
mediators of the inflammatory responses and indeed both are targets for pharmaceuticals, we 
were interested to see if NT8 was anti-inflammatory in vivo ie. within the complexity of an 
inflammatory reaction (Montecucco et al., 2008; Onnheim et al., 2008; Richter et al., 1995; 
Mathis et al., 2007; Schultz et al., 1991).  The upregulation of neutrophil adhesion is an 
important early step in the inflammatory process and it would thus be expected that NT8’s 
properties should be translated to the in vivo respon e. 
 
The study employed a classical animal model being used widely, LPS induced peritoneal 
inflammation. Apart from being a well established in vivo model for acute inflammation, it 
can provide us with informations such as the type of cells as well as their infiltration rate that 
can be found in the inflammed cavity. Neutrophil, TNF and LTB4 in particular, play an 
important role in this model (Canetti et al., 2003; Cunha and Tamashiro, 1992; Cunha et l., 
2008; Mercer-Jones et al., 1999; Zagryagskaya et al., 2008). The aim of the present research 
was to examine the anti-inflammatory response of NT8 in the LPS-induced peritonitis model..     
 
8.2 Effect of NT8 on LPS-induced inflammation 
 
The effect of NT8 on the LPS-induced inflammatory response was examined.  NT8 at 70 
mM/kg was injected (ip) 1 h before a 50 µg LPS challenge (ip).  The animals were sacrificed 
24 h later and the peritoneal exude cells collected.  The result showed that LPS induced a 
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significant recruitment of neutrophils to the peritoneal cavity, but not macrophages (Figure 
8.1).  Although pre-treatment of mice with NT8 befor  LPS caused a decrease in neutrophil 
influx, it did not reach significance.  Further expriments were conducted with an increase in 
NT8 pre-treatment time.   
 
In the subsequent experiments NT8 was injected 4 h prior to the LPS challenge.  After 24 h 
peritoneal exude cells were collected and cells enumerated.  While there was also a 
significant increase in neutrophil influx in the mice which received NT8 alone, there was a 
marked reduction in the number of neutrophils in the peritoneal cavity induced by LPS as a 
result of the NT8 treatment (Figure 8.2).  No effect on macrophages number was observed.     
In a second set of experiments, two doses; 40 mM and 80 mM/kg of NT8 were examined.  
The mice were treated with NT8 4 h prior to the LPS challenge.  After 24 h the peritoneal 
exudates were collected and cellular infiltrate examined.  The results showed that NT8 
caused a signifcant decrease in neutrophil influx at 40 mM/kg body weight (Figure 8.3) but 
that this was markedly increased at 80 mM/kg (Figure 8.3).  In contrast the effect of LPS on 


























Figure 8.1 Effect of short (1 h) NT8 pre-treatment time on LPS-induced peritoneal 
cavity inflammation .  Mice were injected intraperitoneally with NT8 (70 mM/kg) 1 h prior 
to PBS or LPS (50 µg) challenge.  At 24 h, the animals were euthanized an  number of 
neutrophils (□) and macrophages (■) in peritoneal cavity washouts enumerated.  Data is 
expressed as the mean number of cells/ml ± SEM of 5 animals.  Significance of difference in 
the number of neutrophils between PBS and LPS group: *p<0.001 (Tukey-Kramer multiple 






















Figure 8.2 Effect of 4 h NT8 pre-treatment time on LPS-induced peritoneal cavity 
inflammation .  Mice were injected intraperitoneally with NT8 (70 mM/kg) 4 h prior to PBS 
or LPS (50 µg) challenge.  At 24 h, the animals were euthanized and number of neutrophils 
(□) and macrophages (■) in peritoneal cavity washouts were enumerated.  Data is expressed 
as the mean number of cells/ml ± SEM of 6 animals.  Significance of difference in the 
neutrophil group: between PBS and LPS; PBS and NT8; LPS and NT8 + LPS; and in the 
macrophage group: between PBS and LPS. *p<0.05, **p<0.01 and ***p<0.001 




















Figure 8.3 Dose dependent effect of NT8 on LPS-induced neutrophils influx.  Mice were 
injected intraperitoneally with either 40 mM/kg (□) or 80 mM/kg (■).  Four hours later, 
animals were then challenged (ip) with LPS (50 µg) or PBS.  At 24 h, the animals were 
euthanized and number of neutrophils in peritoneal cavity washouts enumerated.  Data are 
expressed as mean number of neutrophils/ml ± SEM of 6 animals per group.  Significance of 
difference in 40 mM/kg group: between PBS and LPS; and 80 mM/kg group: between PBS 






















Figure 8.4 Dose dependent effect of NT8 on LPS-induced macrophages influx.  Mice 
were injected intraperitoneally with either 40 mM/kg (□) or 80 mM/kg (■).  Four hours later, 
animals were challenged (ip) with LPS (50 µg) or PBS.  At 24 h, the animals were 
euthanized and number of macrophages in peritoneal cavity washouts enumerated.  Data are 
expressed as the mean number of macrophages/ml ± SEM of 6 animals per group.  
Significance of difference in 80 mM/kg group: between PBS and LPS: *p<0.05 







At optimal pre-treatment time and in a dose related manner NT8 inhibited the influx of 
neutrophils in the peritoneal cavity of mice injected with LPS.  No effect on the number of 



















































The research in this thesis has revealed the synthesis of a new structure, following the 
conjugation of quinoline with fatty acids, which gives rise to singular immunomodulatory 
properties (Table 9.1).  These conjugates have selectivity for neutrophil responses, in 
particular adherence and cytokine production with essentially little effects on lymphocyte and 
macrophage function.  Their effects contrast to those f CQ and HCQ.  The comparative 
structures of the anti-malarials and NT8 are presented i  Figure 9.1.    
 
NT compounds: structure, physical and chemical properties 
 
The immunomodulatory properties of anti-malarial drugs have been extensively studied and 
these agents have been widely used as model examples of improving drug action by structural 
modification, usually on the side chain and not the ring structure per se.  Such modifications 
have been necessary to overcome the emergence of resistant strains of malarial parasites as 
well as the concerns in cell or organ toxicity reported in patients being given the drugs.  Past 
studies aiming to generate the modified compounds have reported that replacing the 7-chloro 
group on the ring structure by electron donor and withdrawing groups such as NH2, OCH3 or 
NO2 results in the reduction in anti-malarial activity (Egan, 2005), however, modification 
made to the side chain of 2-3 carbons or of medium chain length of 10-12 carbons still 
retained the anti-malarial property of the compound (Krogstad and Schlesinger, 1987; Ridley 
et al., 1996).  These modified compounds give rise to changes in their metabolism, efficacy 
in vivo against plasmodium falciparum and the chance of developing resistance towards the 




The ability of short, medium and long chain fatty acids to regulate inflammation has been 
well documented.  These fatty acids were successfully conjugated to the quinoline structure 
of chloroquine by adding the appropriate acid chloride (side chain of interest) to a solution of 
4-amino-7-chloroquinoline to yield the new quinoline-fatty acid conjugate.  The newly 
synthesized NT compounds were off white powders with one exception being NT6 which was 
an oil.  The solids had melting point ranges from 87-150 °C except for NT13 which was 
28-29 °C.  The overall yield was 14- 58 % with the lowest being NT2 and highest was with 
NT0.  The formation of NT2 had the lowest yield probably due to the lack of reactivity of 
the fully saturated long chain stearoyl chloride.  
 
Synthetically, these compounds differ to the conventional preparations of chloroquine-like 
analogues, which typically involve taking 4,7-dichloroquinoline with neat excess amine and 
heating the solution to reflux to effect nucleophilic aromatic substitution. In our case we 
believed it was easier to start with an aminoquinoline and generate secondary amides rather 
than using long chain amines (branched or substituted) which has been well researched for 
decades. 
 
The lead compound as determined from the biological results was NT8 (C12 carbon chain). In 
an effort to shed further light on its structure-activity relationship, its structure was energy 
minimized by use of the Spartan Computer Molecular Modeling program as shown in Figure 
9.2. The model highlights the planarity of the aromatic rings and the linearity of the alkyl 
chain. To date we are unable to delineate as to why NT8 is the lead compound based on its 
structure. Future work will be conducted in our laboratory examining further aspects of 




Abbreviations: √- inhibition observed, x- no inhibition, ND- experiment not done 
and NA-not applicable. 
 
Table 9.1 Summary effects of NT8 on neutrophil functions. 
            
                                                                                         















































TNF √ √ NA NA X √ 
fMLP X √ X X X √ 
LTB4 √ √ ND ND X X 
GM-CSF X √ NA NA X √ 
IL-8 X √ ND ND NA NA 













































































Figure 9.2  The three dimensional molecular structure of NT8 compound.  Carbons are 
represented by grey molecules, hydrogens in green, oxygen in red, nitrogens in blue and 






Modulation of TNF-induced neutrophil adhesion  
 
During inflammation, endogenously generated inflammatory mediators play diverse roles in 
bringing about the accumulation of neutophils to the site.  This includes the stimulation of 
neutrophil adhesion to the endothelium and various tissue substrates by cytokines.  Using 
both cytokine TNF rich medium and recombinant TNF to s imulate neutrophils, we have 
shown that several of the NT compounds were able to inhibit neutrophil adhesion.  There 
was no simple relationshiop between fatty acid structure and the effects on these neutrophil 
functions.  While the difference between NT1 and NT3 is that the latter has a double bond, 
both had similar inhibitory activity.  NT8, which contained lauric acid (12 carbon saturated 
fatty acid) was the most effective of the 13 compounds tested.  Both the basal compound 
NT0 and lauric acid had no effect on TNF-induced neutrophil adherence.  This suggests that 
the synthesis has generated a molecule with a new function of an anti-neutrophil effect.  This 
is somewhat suprising since previous studies have demonstrated that 6-12 carbon chain length 
fatty acids actually directly increase human neutrophil adhesion (Wanten et al., 2002; Wanten 
et al., 2000a).  
 
Under these conditions the NT8 compound did not affect neutrophil adhesion induced by a 
number of other cell surface receptors acting agonists to a similar degree as the TNF-induced 
response.  Thus at 20 µM concentration of NT8, there was significant inhibition of the 
TNF-induced response but not adhesion induced by fMLP, GM-CSF, IL-8, C5a, and AA.  
The only exception was LTB4-induced adherence.  Interestingly this concentration of NT8 
caused a significant reduction in the expression of TNFRII.  There was no significant effect 
on TNFRI expression.  It is therefore likely that the effects that we are seeing at this 
concentration relates to a decrease in the expression of this receptor.  The selectivity for 
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TNFRII was further strengthened by the finding that the TNF-induced increase of CR3 was 
not affected. It is however interesting that the response to LTB4 was also affected.   
 
From our results it is evident that TNFRII is essential for the neutrophil adhesion response to 
TNF.  TNFRII has been reported to act as a ligand handling step for TNFRI (Tartaglia et al., 
1993; Porteu et al., 1991) but others have suggested that TNFRII initiates signalling events 
responsible for effector function (Bigda et al., 1994; Montecucco et al., 2008; Weiss et al., 
1997).  Our results suggested that TNF-induced adherenc  is likely to be regulated by 
TNFRII.  The same concentration of NT8 which inhibited the TNF-induced adhesion, was 
unable to prevent adherence induced by PMA and A23187.  Both of these agonists act at a 
post receptor binding level. Thus the data suggest an effect upstream of PKC and intracellular 
calcium mobilisation. 
 
Furthermore our studies revealed that NT8 is unique n its action.  Firstly it stimulated the 
cell directly to cause a decrease in TNFRII.  Previously it has been reported that a range of 
endogenous and exogenous mediators cause the down-regulation of TNFR expression on 
neutrophils (Ferrante t al., 1994; Moghaddami et al., 2003; Schleiffenbaum and Fehr, 1990).  
This includes LPS, fMLP, C5a, LTB4, PAF, GM-CSF, opsonised microbial pathogens and n-3 
polyunsaturated fatty acids (Moghaddami et al., 2007) but in these cases, both TNFR were 
decreased on neutrophils.  It has been reported that the decreased expression of the TNFR is 
due to the enzymatic cleavage of these (Dri et al., 2000).  The view is that a 
membrane-bound, non-matrix metalloproteinase, possibly ADAM-17 is involved for TNFRI 
(Walcheck et al., 2006; Dri et al., 2000) and a metalloproteinase and the serine protease, 
elastase for TNFRII (Dri et al., 2000; Gasparini et al., 2003).  Unlike the above agents, NT8 
did not appear to be a neutrophil stimulator.  Whether or not NT8 affects these enzymes 
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differently to give rise to the selective action on TNFRII remain to be established and indeed 
is a challenging question.   
 
We also found that the expression of CR3 on neutrophils was not decreased by treating 
neutrophils with NT8, possibly supporting some previous reports which suggested that 
upregulation of CR3 does not play a major role in mediating neutrophil adhesion 
(Schleiffenbaum et al., 1989; Vedder and Harlan, 1988) and the finding that neutrophil from 
patients with a defect in CR3 can still adhere (Dobrina et al., 1989).   
 
The significance of the effects of NT8 on neutrophil adherence was suggested by in vivo 
studies in mice.  Adherence to the endothelium of bl od vessels is an essential step in the 
ability of neutrophil to move from the blood stream to be recruited in tissues.  We found that 
the injection of NT8 in the peritoneum of mice caused a decreased accumulation of 
neutrophils in response to LPS.  LPS is a strong inducer of TNF and it is likely to be an 
important cytokine in promoting neutrophil adhesion t  the endothelium during inflammation.   
 
Inhibition of neutrophil cytokine production 
 
Interestingly the TNF-induced neutrophil production f IL-1β and IL-8 was significantly 
inhibited by NT8.  This response was as sensitive to NT8 inhibition as was neutrophil 
adhesion.  The data suggests also that the TNFRII is likely to play a critical role in the 
production of IL-1β and IL-8 in response to TNF.  Expression of TNFRI alone seemed 
inadequate for this response.   
Since a role for these cytokines in neutrophil activation and accumulation has been previously 
extablished, it is likey that NT8 wll inhibit the inflammatory response.  In view of the 
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importance of neutrophils and these cytokines in inflammatory disorders such as rheumatoid 
arthritis (Feldmann and Maini, 2001) and chronic obstructive lung disease (Taggart e  al., 
2005; Carroll et al., 2005), a therapeutic based on NT8 may be useful.   
 
Effects on TNF-induced cell migration inhibition and superoxide production 
 
TNF has been recognised to cause the inhibition of neutrophil random migration and 
chemotactic migration (Ferrante et al., 1988).  However our studies demonstrated that NT8
treatment of neutrophils could not prevent the migrat on inhibition induced by TNF.  
Similarly there was no effect of NT8 on the TNF-induced oxygen radical production at the 20 
µM concentration.   
 
The findings indicated that the TNF-induced migration inhibition and the induction of the 
respiratory burst does not require TNFRII as both were not inhibited at concentrations of NT8 
which significantly decreased the expression of TNFRII.  This shows that NT8 selectively 
targets the adhesion response and cytokine productin induced by TNF and highlights the 
importance of TNFRII in ths response.  The results indicated that TNFRI is involved in 
stimulating neutrophil migration inhibition and superoxide production independent of 









Effects on the responses induced by other surface membrane receptor agonists 
 
Of several other surface receptors acting agonists studied, only the adherence response to 
LTB4 was similarly affected.  AT 20 µM NT8, there was significant inhibition of adherence 
induced by LTB4.  Again we cannot explain this at a level of PKC or intracellular calcium 
mobilisation since at this concentration NT8 failed to inhibit either the PMA or A23187 
response, suggesting an upstream effect, possibly at the level of the LTB4 receptor.  In 
comparison, the LTB4-induced oxygen-dependent respiratory burst was not affected by NT8 
even at 50 µM.  This further illustrates the relative selectivity of the effects of the compound 
for some neutrophil responses.  Of the two LTB4 receptors BLT1 and BLT2, the former plays 
an important role in neutrophil adhesion (Kim et al., 2006; Mathis et al., 2007; Schultz et al., 
1991).  This in view of the effects of NT8, it is likely that the compound affects this LTB4 
receptor type.   
 
Most interesting was the finding that a number of other surface receptor acting agonists had 
no effect at 20 µM of NT8 in relation to all neutrophil response measured.  The agonist 
examined were fMLP, GM-CSF, IL-8 and C5a.  At 50 µM NT8, all agonists significantly 
inhibited the adherence response (Table 9.1).  Since the response induced by either PMA or 
A23187 was also inhibited at this concentration, it is likely that the effects are due to post 
surface receptor binding at this concentration of NT8.  Interestingly, and in contrast to 
adherence, fMLP-induced chemotaxis was not affected a  this concentration.  This appears to 
dissociate pathways involved in neutrophil adhesion to those involved in chemotaxis and to 
some extend this is not surprisingly, as the two functions are promoted by quite different 
concentrations of fMLP (Hii et al., 2004).  The findings from our study showed that the
fMLP-induced respiratory burst was inhibited by 50 µM NT8.  We have previously 
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demonstrated that different signalling molecules are involved between the two different fMLP 
concentrations (Hii et al., 2004), related to the low and high affinity fMLP receptors.   
The selectivity of the action of NT8 on the neutrophil response was evident from the 
respiratory burst response of neutrophils induced by LTB4, AA, PMA and A23187.  The 
response to these agonists was not inhibited by NT8, thus apart from selectivity targeting 
specific neutrophil responses based on the concentration, we see selectivity at the 50 µM 
concentration.   
 
Probing further into the mechanism of action of NT8 we were unable to demonstrate that the 
effects of the compound were due to the alteration in the synthesis of 3KDS, one of the 
substrates for ceramide formation (Hannun and Luberto, 2000; Williams et al., 1984).  This 
was suspected as the structure of NT8 is similar to 3KDS.   
 
Comparison with effects of NT0 and lauric acid 
 
In most of the experiments, the effects of NT8 were compared with any effects due to the base 
compounds NT0 and lauric acid.  It was evident in all cases that at equivalent concentrations, 
these components had no effect on any of the neutrophil functions stimulated by any of the 
agonists.  This illustrates that the synthesis has given rise to a novel structure in terms of its 
biological characteristics.  Previous studies with medium chain fatty acids showed 
enhancement of neutrophil functions but this was attained at very high (mM) concentration 






Effects on lymphocyte and macrophage functions 
 
Lymphocyte response in human PBMCs was examined by using the T cell mitogen, PHA and 
the B cell mitogen S.aureus.  In terms of lymphoproliferation, there was no effect by 
exposing the lymphocytes to NT8.  This was also reflected in the ability of the cells to 
produce the cytokines, IFN-γ, IL-2, LT and IL-10.  Similarly there was no effect when the 
lymphoyctes were stimulated with antigen, TT.   
 
To examine the effects on monocyte function, PBMCs were stimulated with LPS which 
induces TNF, IL-1 and IL-6 production.  The results al o demonstrated that NT8 did not 
affect the production of these cytokines.  Hence this stands in contrast to the findings with 
neutrophils which were inhibited in their ability to be stimulated in key responses and further 
highlights the selectivity of NT8 for neutrophil functions. 
 
Comparison with CQ 
 
Although there have been previous reports that CQ and HCQ inhibited neutrophil functions 
(Ferrante et al., 1986; French et al., 1987; Labro and Babin-Chevaye, 1988; Raghoebar t l., 
1988; Hurst et al., 1987, 1988), these effects were seen at high concentrations of the 
anti-malarials.  When CQ and HCQ were examined in parallel with NT8, there was no effect 
on neutrophil functions at concentrations up to 50 µM.  This was evident with adherence, 
chemotaxis and respiratory burst response which higlights the uniqueness of the compounds 





The difference between NT8 and CQ/HCQ was also evident at the level of lymphocyte and 
macrophage function.  CQ inhibited PHA-induced proliferation at 5-50 µM with a 
corresponding decrease in IL-2 and IL-10 but not LT.  he decrease in IL-2 may explain the 
decrease in lymphoproliferation.  The response to TT was even more sensitive to CQ.  At 5 
µM CQ there was an 80 % inhibition of the lymphoproliferative response.  This marked 
inhibition was also seen in relation to cytokine production.   
 
The B cell response was less sensitive and the inhibition of S.aureus induced proliferation was 
only evident at 50 µM of CQ.  At 50 µM, monoycte production of cytokines was also 
inhibited by the anti-malarial but only about by 40 %, illustrating the preferrential effect on T 
cell function.  Such effects on T cells are likely to contribute to the anti-inflammatory 
properties of CQ and its derivative HCQ.   
 
It is interesting that while CQ and HCQ inhibited lymphocyte function and macrophage 
function, the NT0 did not have this property.  This suggests that the additional groups on the 
side chain give rise to the anti-inflammatory effects (Figure 9.1). 
 
Other studies in progress in our laboratory have ben xamining the effects of these NT 
compounds on P. falciparum intraerythrocytic forms.  It is interesting that these have 
retained the anti-malarial activity to a similar degr e as shown by CQ.  Like CQ, NT8 is a 
weak base which would give the compound the ability to accumulate down the pH gradient to 
increase its concentration in the parasite compared to the red cell.  The ability to accumulate 





Effects of NT8 on experimental inflammation 
 
Evidence of anti-inflammatory properties of NT8 was extended to an in vivo settings.  Mice 
given single injections of NT8 showed reduced inflammatory reactions using a classical 
inflammatory model.  In an LPS-induced peritonitis model, the neutrophil influx was 
significantly reduced by NT8.  There was an indication that NT8 also affected the number of 
macrophages in the peritoneal cavity.  LPS causes th  apoptosis of peritoneal macrophages 
(Albina et al., 1993).  This response did not appear to be affected by treatment of mice with 
NT8.  The ability of the compound to inhibit neutrophil accumulation was dependent on the 
period of exposure of mice to NT8 prior to the LPS challenge.  When the injection was 4 h 
before challenge, a significant effect on neutrophil levels was seen but not with a 1 h 
pre-exposure time.  This may be due to the time requi d for NT8 to be incorporated into 
neutrophils and prior to TNFR being engaged.  LPS-induced influx of neutrophils and 
macrophages in the peritoneal cavity was found previously to be dependent on TNF (Yang et 
al., 2002; Calkins et al., 2001; Skerrett et al., 1999; Mercer-Jones et al., 1999) .   
 
This finding would be consistant with the ability of NT8 to inhibit TNF-induced neutrophil 
adhesion.  However, effects of the LTB4 responses are also likely to be relevant since 
LTB4-induced neutrophil adhesion occurred at the lower concentration in the in vitro studies 








Significance of the findings and concluding remarks 
 
In the course of conducting the research covered by this thesis, novel immunomodulators 
were identified which have the potential to be develop d into immunosuppressive agents.  In 
particular the compound NT8, quinoline-CO(CH2)10CH3 was identified as a potential lead 
compound.  By conjugating the quinoline to lauric acid, a structure was created which had 
unique immunosuppressive properties not present in ei her the quinolines or the fatty acids.   
 
The compound showed selective inhibition of neutrophil function but not lymphocyte or 
macrophage responses.  Indeed it was also selective with respect to the type of neutrophil 
function and the type of neutrophil agonist used.  Neutrophil adherence was highly sensitive 
to the effects of NT8 and particularly interesting was the finding that its effects were mainly 
evident when TNF was used as the agonist, most likey related to its ability to cause selective 
decrease in expression of TNFRII.  The work also highlighted some important biological 
function for TNFRII, perhaps not appreciated previously.   
 
The inhibitory effects of NT8 were less evident with other neutrophil agonists, apart from 
LTB4.  This suggested that NT8 has an action on selective receptors which are key targets of 
anti-inflammatory agents.  This was supported by proof of concept in a murine inflammatory 
model in which neutrophils, TNF and LTB4 play important roles.  Apart from the potential 
use of NT8 to treat acute inflammatory diseases, its usefulness in chronic inflammatory 
diseases is also likely to be of importance since neutrophils are known to play a role during 





The relationship between the anti-malarial/anti-inflammatory agent CQ/HCQ and NT8 was 
also extensively examined.  It was interesting that in contrast to CQ, NT8 inhibited 
neutrophil function but not lymphocyte and monocyte function.  Interesting was the finding 
that T cell responses were most sensitive to CQ. 
 
There are several areas in this thesis which requir fu ther investigations.  Firstly, the 
selective action on neutrophil resposes versus macrophage responses should be more 
appropriately compared by examining the same functio s eg. adherece and superoxide  
production.  Another area of further studies relates to the finding that TNFRII may play key 
roles in neutrophil adhesion and cytokine production.  The fact that NT8 down-regulates 
TNFRII and not TNFRI is also a very important findig.  This may be related to the 
compound activating proteases that cleave the former receptor.  Further investigation is 
likely to significantly increase our knowledge on how TNF receptor expression is regulated.  
The selective effects of NT8 on responses induced by a restricted number of agonists could be 
further examined.  In this regard, its effect on the LTB4 response and as to whether this 
relates to altering LTB4 receptor expression needs further clarification.  Embarking on the 
examination of the anti-inflammatory properties of NT8 in more complex inflammatory 
models relevant to specific diseases would verify the usefulness of the new compound.  
While we have learned aspects of the basis for its effects on neutrophil functions, there has 
been inadequate time to study these mechanisms of action in depth.  Because of the 
interesting actions described above, further studies on the mechanisms by which NT8 alters 
the cellular functions and inflammatory response may lead to new approaches in targeting 
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